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Part I
Introduction and Methods
Chapter 1
Introduction
1.1 DNA and Cancer
Cancerous cells divide without control, growing also in the absence of the proper
signals and ignoring the pressure from neighboring cells. The search of a cure against
cancer progression is one of the big challenges in medicine, mainly because of two
relevant issues [1]. The first is that several factors appear to be related with (and be
the cause of) the disease. These include:
• The alteration in the DNA sequence of cancer-related genes [1]: i) tumour sup-
pressor genes (e.g. p53, RB and APC), which encode for proteins restraining
cells’ ability to survive and divide; ii) oncogenes (e.g. BRAF, c-fos, cerbb3),
whose mutation causes oncoproteins to become hyperactive prompting the cell
to grow ignoring stopping signals.
• The inactivation of one or more genes encoding for proteins that synthesize or
repair the DNA [2]. This leads to the introduction of a high number of random
mutations during cellular replication, which remain unrepaired and accumulate,
and eventually hit cancer-related genes short-circuiting apoptotic mechanisms.
• The silencing of “master” genes regulating cell division [3], which endowes
daughter cells with mangled chromosomes (wrong in number, cut, mixed or
containing extra segments).1 These aneuploid cells can accumulate chromoso-
mal aberrations with generations, finally altering the relative amounts of thou-
sands of genes and eventually the normal dosage of tumor suppressor and on-
1It is worth to point out that the search for a restricted set of oncogenes, tumour suppressor genes,
or “master genes” has failed so far. For example, in the 2003, 116 oncogenes and 15 tumour suppressor
genes were already identified, inducing scientist to not exclude a priori the idea that each tumour is
unique in the pattern of its genetic disarray.
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coproteins. It is not clear if aneuploidy is related to mutations in genes or it is
itself a cause of cancer [4].
• The epigenetic modifications, such as DNA methylation and histone-modifica-
tions [1, 5].
The second and most life-threating reason is that primary tumours often evolve in
metastases, for which no effective cure exists (they are cause of nine of every ten
deaths from cancer). Metastatic cells are in fact able to enter blood and limphatic
vessels, spreading out the malignancy in different parts of the body. This renders
uneffective the treatment of the primary tumour.
The most common strategies for the cure of cancer are surgery, chemotherapy, ra-
diotherapy, immunotherapy and others. The choice depends on the type and the stage
of cancer and on the status of the patient. Obviously only localized tumours can be ef-
ficaciously removed by surgical procedures (known examples are breast and prostate
cancer), which besides need to be extremely precise to avoid recurrence phenom-
ena. The preferred alternative to surgery has become today chemotherapy [6, 7, 8],
not only for the treatment of leukaemias and lymphomas, which are spread in the
body and thus untractable by surgery and radiotherapy, but for the cure of almost all
kinds of cancers. In addition, chemotherapy is often used after surgical intervention
to lower the risk of recurrence.
Most chemotherapeutics in use today rely on a cytotoxic action, which is a direct
consequence of their reversible or covalent binding to cellular DNA [9,7,10,11]. This
affects the propensity of DNA to interact with proteins [12, 13], eventually inhibiting
vital processes such as replication, transcription, repairing enzymes action, and it may
lead ultimately to cell apoptosis (Figure 1.1) [12, 14, 15, 16, 17]. Figure 1.2 reports a
(partial) list of of drugs that have been assayed for their propensity to interact with
transcription factor/DNA systems [12]. Although effective against virtually all kinds
of tumours, genotoxic chemotherapeutics approved so far in the clinics act indiscrim-
inately on wealth and malignant cells. Thus, understanding at a molecular level the
mechanism of action of these drugs is a key step in the design new and more effective
pharmaceuticals.
1.2 Structural determinants of drug/DNA adducts
Most drugs exert their action by binding to DNA. Therefore their rational design
requires a detailed understanding of which interactions are responsible for affinity,
reactivity and selectivity towards nucleic acids, as well as the comprehension of the
molecular recognition events. Such a knowledge is the prerequisite for the inves-
tigation of molecular routes triggering cellular responses to genotoxic agents (like
ATM/p53 activation – Figure 1.1). For these purposes, structural information on
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Figure 1.1: Responses provoked by replication- and transcription-blocking DNA lesions.
Replication-blocking DNA lesions are repaired by global genomic repair (GGR), which is part
of the Nucleotide Excision Repair (NER). If not repaired, they block DNA replication during
S phase, which can lead to collapse of the replication fork and the formation of lethal Dou-
ble Strand Breaks (DSBs). Bulky DNA lesions can also block transcription. Transcription-
blocking lesions are repaired by Transcription-Coupled Repair (TCR), which also is part of
NER. If not repaired, proteins required for survival might not be transcribed and the cell will
undergo apoptosis (adapted from Ref. 17).
drug/DNA adducts is firstly required. To date∼ 1500 ligand/oligonucleotide X-ray or
NMR structures have been reported on Nucleic Acids and Protein DataBases (NDB
and PDB respectively, Table 1.1).2 Ligands can bind DNA both covalently (to nucle-
obases or to phospate sugar-backbone) or non covalently. They can be accomodated
in the minor or in the major groove, with or without intercalating between base pairs.
Most compounds lie in the minor groove, where they form favorable packing interac-
tions with the walls of the DNA. Organic covalent binders usually alkylates purines
in the minor groove. The structures of about 35 adducts between DNA and minor
groove ligands have been solved (Table 1.2), of which 6 are DNA anticancer alky-
lating agents [9, 12]. The dominance of non-covalent binders is mainly due to the
difficulties in obtaining pure crystallographic quantities of adducts. This contrasts
with the simple mixing procedures used for non covalent complex formation [18,19].
Molecular modeling of drug/DNA adducts
Computer simulations have become an essential tool for investigating the behavior
of biological systems, unraveling the subtle relationship involving structural and dy-
namical features and activity of biomolecules at an atomic level of detail. However,
2For a short summary of DNA structure see Appendix A.
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Figure 1.2: DNA-binding targets: mode of interactions and their region and sequence speci-
ficity (taken from Ref. 12). 1 Sequence preference. 2 A series of related drugs with di-
stamycin A moiety and a polyamine tail, which interacts in the major groove and exhibits
preference to GC. 3 Methyl-derivative of aryltetrasaccharide moiety of calicheamycin. The
drug lacks the enedyne component, hence, it does not cleave DNA. 4 In some studies, anthra-
cycline antibiotics covalently bound to DNA in the presence of dithiothreitol and Fe (III) ions
or formaldehyde was assayed. 5 Interactions in the minor groove. 6 A cross-linking agent
related to mitomycin C. 7 Preferential binding to A.
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Biomolecule contains Number of hits
DNA 2567
DNA and ligands 1477
Proteins 45946
Proteins and ligands 11045
DNA and proteins 1350
Table 1.1: Number of hits corresponding to structures containing DNA, proteins and lig-
ands. The search has been performed on the PDB database over a total of 47805 structures
(december 2007), after removal of sequences with similarity larger than 95%.
the development of models (force fields) for the simulation of DNA has revealed itself
much more challenging than for proteins, because of several factors. These include:
i) the polyanionic nature of oligonucleotides, which requires a very accurate treat-
ment of the balance between the oligonucleotides’ conformational energies and their
interactions with the aqueous solvent [20] (i.e. a very accurate tuning of bonded vs
non bonded force field terms); ii) the relatively low potential energy barrier associ-
ated to the torsion angles governing the conformation of the DNA phosphate-sugar
backbone [21, 22, 23]. Reliable force fields for the simulation of oligonucleotides in
acqueous solvent have been developed since the mid 1990s [24,25,26,27,28,29,30],
and are under continuous development (pathologies still exist which are being cured
nowadays [31]). Despite these difficulties, molecular modeling allowed to study
structural, kinetic and thermodynamic aspects of oligonucleotides alone or interacting
with proteins and ligands [32, 33, 34, 35, 36, 37, 38]. Among the biologically relevant
issues which have been addressed there are:
• Conformational properties of DNA duplexes: the structural stability and flexi-
bility of A, B, Z-DNA in solution [39, 40, 41, 42], the transitions between dif-
ferent oligonucleotide conformations [43,44,45]; sequence effects on the struc-
ture [46,47,48], the population of different conformational substates [49,50,51,
52]; the opening of base-pairs [53, 54, 55, 56, 57], the unwinding and stretching
of DNA duplexes [58, 59], the minor groove deformability [60]; the ion and
water distribution around DNA [61, 62].
• Electrostatic properties of DNA [63, 64, 65, 35].
• Protein/DNA interactions and molecular recognition [66, 67, 68, 69].
• Interactions, selectivity and binding of small ligands to DNA [70,71,72,19,73,
74, 75, 76].
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Such studies facilitate interpretation of experimental data and allow for information
not readily accessible to experimental methods to be obtained [20, 35, 34].
1.3 Motivation of the work
The first and largest part of my thesis focuses on ligands which bind to DNA, in
particular alkylating agents. Despite the latest methodological advances and the phar-
macological relevance of alkylating drugs [77, 78, 79, 80, 81], their interaction with
DNA has been less characterized compared to non covalent binders. Only few re-
cent theoretical studies have appeared in the literature (including some from our
group)3 concerning the structure, the thermodynamics, the kinetics and the molec-
ular recognition of minor groove alkylating binders [82, 83, 84, 85, 86, 71]. This con-
trasts with the relatively large number of studies on non covalent ligands (see e.g.
Refs. 87, 76, 88, 37, 75, 89, 74, 90, 91, 92, 93, 94, 70, 95, 96, 97). More importantly,
many issues are still not fully understood, such as the contributions of different inter-
actions and structural features to DNA sequence selectivity, the routes of molecular
recognition by ligands and proteins and the catalytic role of nucleic acids in bond
covalent modification. This information is essential for structural biology and drug
design, as the latter relies on the assumption that beneficial effects of drugs origin
from the interaction with its target.
My project during this PhD is thigtly placed within the scenario depicted above.
I firstly characterized the structure and the energetics of adducts between the anti-
cancer covalent binder anthramycin [98] and DNA, for which x-ray structure is avail-
able [99]. This study follows the spirit of previous investigations performed in the
group on other two anticancer compounds (the major groove binder cisplatin [100,
101, 102, 103, 104] and the minor groove alkylating agent duocarmycin [105, 106,
107, 83]). Subsequently, I extended my investigation to the molecular recognition
events involving both the latter compound as well as anthramycin. Comparison has
also been made with the prototype of non covalent minor groove binders, distamy-
cin A [108, 109, 110, 111]. The focus has been on the calculation of free energies,
the evaluation of enthalpic vs entropic contributions and the role of the solvent, the
estmation of the weigths of various interactions. This information has provided in-
sights on similarities and differences in the molecular recognition process between
the different kind of DNA ligands.
The second part of the thesis focused on the hydrolysis of two ruthenium-based
compounds, ICR [112] and NAMI-A [113,114,115]. These are very promising for the
treatment of primary tumours and metastases, respectively [116,117]. The identifica-
tion of most stable hydrolytic products is important as they would likely interact with
3I do not include in this list MD simulations performed to refine NMR structures
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Compound bond type total number
duocarmycin
covalent, minor groove 9
anthramycin
mitomycin
bizelesin
esperamycin
calicheamicin
tamoxifen (anti-estrogen)
epidoxorubicin (also intercalator)
psolaren (also intercalator)
netropsin
non covalent, minor groove 29
distamycin
lexitropsins (3)
polyamides (6)
hoechst33258
hoechst33342
proamine
bis-benzimidazole
tris-benzimidazole
propamidine
pentamidine
furamidine
chromomycin
mithramycin
DAPI
AR-1-144
DB819
DB884
DB921
SN6999
SN7167
UCH9
cisplatin
metal-containing 3oxaliplatin
bisplatin
Table 1.2: Minor groove covalent and non covalent binders, and metal-based DNA drugs for
which the structure of an adduct with DNA has been resolved (from PDB databank, updated
december 2007).
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biological targets. This work has started thanks to the collaboration here in Trieste
with E. Alessio and G. Sava’s labs, who discovered NAMI-A in the mid 1990s.
1.4 Outline of the Thesis
The outline of the thesis is the following:
• Chapter 2 introduces the theoretical background needed to understand molecu-
lar simulations and free energy calculations, which are the main tools used in
the work exposed here.
• Chapters 3 to 5 constitute the first part of my thesis.
– Chapter 3 focuses on the interaction between the anticancer alkylating
drug anthramycin and DNA. Following the spirit of previous works here
in SISSA, I characterized both the covalent complex and the non-covalent
adducts between two supposed reactive forms of the drug and the DNA by
performing classical MD. Then I used Car-Parrinello quantum MD to gain
insigths on the reactivity of the two forms and to investigate the catalytic
role of DNA for the reaction.
– Chapter 4 addresses the problem of molecular recognition. This is a
complex phenomenon, that goes beyond the simple formation of a sta-
ble adduct. In fact, small molecules exploit not only binding, yet sliding
into and unbinding from the minor groove until they reach a preferred se-
quence on DNA. In this Chapter is reported the evaluation of free energy
profiles associated to the sliding of anthramycin and duocarmycin into the
minor groove of their non covalent complexes with DNA. The drugs are
different in size, selectivity and affinity, which reflects in two significantly
different profiles associated to the process. A dissection of the profiles is
also undertaken, which allows for a understanding of the sources of simi-
larities and differences in the mechanisms of the two drugs.
– Chapter 5 describes the mechanism of unbinding from DNA of anthra-
mycin and distamycin A, again starting from the non covalent complexes.
The behaviors are compared between a covalent binder, whose specificity
to guanines is due to covalent linkage, and a non covalent ligand that
achieves its high selectivity towards AT-tracts through specific h-bonds.
The routes of detachment turn out to be very different. Indeed unbinding
of distamycin goes through the formation of a relatively stable intermedi-
ate. In contrast, the detachment of anthramycin appears as a monophasic
process triggered by local DNA structural changes and involving a role of
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waters. For both the compounds, the last contacts with DNA are formed
by the hydrophilic tails, and the main cost of detachment arise from the
disruption of hydrophobic packing interactions.
• Chapter 6 concerns the second Part of my thesis. It is a quantum mechanical
study on the hydrolysis of NAMI-A and ICR. Despite the structural similarity,
ICR is active mainly on the primary tumours, while NAMI-A is only active
against metastases. Significant differences are seen in the hydrolysis paths of
these two drugs, which could be relevant to understand the reason of their di-
verse pharmacological activity.
• In the last Part I draw some conclusions of these works and I outline future
perspectives.
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Chapter 2
Methods
The role of molecular modeling for life sciences has had a boomy increase over the
past few decades thanks to the constant expansion in computer performances and the
development of fast and robust simulation algorithms. In particular, computer simu-
lations has been more and more being employed to investigate features not directly
accessible to experiments. Among these are multiple conformations of ligand-DNA
complexes [75], multi nanosecond dynamics at atomistic level [62, 31], and discov-
ery of unpredicted conformations of chemical compounds [118]. The bridge between
molecular simulations and macroscopic world has deep bases in statistical mechan-
ics. Indeed, thermodynamic quantities are determined in computer simulations as en-
semble averages over a large number of microscopic configurations assumed by the
system under study. Common techniques to sample the configurations assumed by a
system at equilibrium are Molecular Dynamics (MD), Monte Carlo (MC) sampling
and Stochastic/Brownian dynamics. The work described in this thesis mainly benefit
of MD techniques, with both a quantum and classical description of the system under
study. As the use of MD in Statistical Biology is based on the ergodic hypothesis and
the existence of shadow orbits, I will start briefly recalling these assumptions. Then, I
will describe how to approach the many-body problem within Schrödinger and New-
ton system-evolution representations. Finally, I will describe methods I used for the
calculations of free energies and for the evaluation of its various contributions.
2.1 Statistical foundations of MD: Ergodic hypothesis
and shadow orbits
The idea behind MD simulations echoes the way real-life experiments are performed.
The equilibrium behavior of a complex system is studied by following its time evolu-
tion in the absence of external impulses and thermodynamic properties are calculated
from averages over a sufficient long trajectory. Such a procedure is well founded only
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for the so-called ergodic systems, which are assumed to fully sample the accessible
phase space (hyper)volume during the “observation” (i.e. “simulation”) time. This
is equivalent to assume that time averages are independent from MD initial condi-
tions. Let consider a system of N particles in a volume V and denote Ω(N, V,E)
the number of microstates with energy E. Within the ergodic hypothesis, if we per-
form a number #{r0, p0} of MD simulations starting from different initial conditions
(r0, p0) in the space of coordinates and momenta (phase space), the time average of
any properties f(r, p; t′) over a time interval t can be expressed as:
f(r, p) = lim
t→∞
1
t
∫ t
0
dt′ f(r, p; t′) =
∑
{r0,p0} limt→∞
1
t
∫ t
0
dt′ f(r, p; r0, p0; t′)
#{r0, p0} (2.1)
The last term in eq. 2.1 can be rewritten as:
lim
t→∞
1
t
∫ t
0
dt′
∑
{r0,p0}
f(r, p; r0, p0; t′)
#{r0, p0} (2.2)
Considering the limiting case in which we sum a function g(r0, p0) over all the
possible initial conditions, we obtain the ensemble average:∑
{r0,p0} g(r
0, p0)
#{r0, p0} −→
∫
E
drdp g(r0, p0)
Ω(N, V,E)
= 〈g(r0, p0)〉NV E (2.3)
where Ω(N, V,E) = c
∫
E
drdp g(r0, p0) and c is a constant.1
Thus, we have:
f(r, p) = lim
t→∞
1
t
∫ t
o
dt′ 〈f(r, p; r0, p0, t′)〉NV E = 〈f(r, p)〉NV E (2.4)
where the last equality comes from the independence of ensemble averages on
time [119]. It is generally assumed that complex systems, such as the majority of
those biologically relevant, are ergodic. Although this is a plausible assumption, it
should be pointed out that the ergodic hypothesis is not always true (for some ex-
ample see e.g. Ref. [119]). A further drawback affecting (in principle) all kinds of
MD simulations is the so-called Liapunov instability [120, 119]. For chaotic sys-
tems, like almost all those simulated by MD, the trajectory is extremely sensitive to
initial conditions. This implies that any error in the integration of the equation of mo-
tion, no matter how small, will always cause the simulated (numerical) trajectory to
diverge exponentially from the “true” trajectory starting from the same initial condi-
tions. However, for the purpose of MD simulations, what is needed is the equivalence
1We assume here c = 1, that is correct for quantum systems. In the classical limit, c = 1/h3N and
c = 1/N ! h3N for distinguishable and indistinguishable particles respectively [119].
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of the numerical and “true” trajectories in a statistical rather than deterministic sense.
Thus, even if the numerical trajectory diverges from the true one, as long it conserves
the total energy E within a given accuracy ∆E, the sampled configurations will be-
long to a constant energy hypersurface E∗ for which |E∗ − E| < ∆E. This means
that the numerical trajectory will be, within the error ∆E, representative of some true
trajectory in the phase space, although it is not known a priori which one. The true
trajectory, to which the numerical one overlaps for a certain period of time, is called
shadow orbit. At the time the Liapunov instability raises up, the numerical trajectory
will get far from that specific shadow orbit, but there always will be another one of
these to which it is superimposed.
2.2 MD in various Statistical Ensembles
2.2.1 NVE Ensemble
In the last section we introduced the ergodic hypothesis for a system described by
the microcanonical distribution NV E. The dynamics of such system follows the
Hamiltonan (or the equivalent Newtonian) laws of motion:
r˙i =
pi
mi
, (2.5)
p˙i = Fi . (2.6)
However, the conditions of constant volume V , number of particles N and total en-
ergy E do not fit those in which experiments are usually made. Thus, it is necessary
to define schemes allowing for the evolution of systems under conditions of constant
volume and temperature (NV T ), or constant pressure and temperature (NPT ), cor-
responding to typical real-life situations. In order to devise MD schemes for these
ensembles, two main strategies have been developed [119], one based on the ex-
tended Lagrangian formalism, the other on mixing MD with some MC moves which
transport the system between different shells of constant energy. Here I describe the
Nosé-Hoover thermostat [121, 122] and the Andersen barostat [123], which are im-
plemented in the MD codes I used and belong to the extended Lagrangian picture.
2.2.2 NVT: Nosé-Hoover thermostat
A way to sample the NV T ensemble within the framework of MD was introduced
about twenty years ago by Nosé [121] and reformulated by Hoover [122], who modify
Newton equation of motion by adding two non physical variables, thus introducing
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the following non-Hamiltonian dynamical system:
r˙i =
pi
mi
, (2.7)
p˙i = Fi − pη
Q
pi , (2.8)
η˙ =
pη
Q
, (2.9)
p˙η =
N∑
i=1
pi
2
mi
− LkT . (2.10)
where {ri}, {pi} are coordinates and and momenta of the N particles with masses
mi, the forces Fi are derived from the N -particle potential and L is a parameter to
be determined. The two nonphysical variables η and pη in eq. 2.7 regulate the fluctu-
ations in the total kinetic energy of the physical variables, and can be thus regarded
as an effective "thermostat" for the physical system. The parameter Q controls the
strength of the coupling to the thermostat: high values result into a low coupling and
viceversa. These equations of motion conserve the following quantity:
C = H(p, r) +
p2η
2Q
+ LkTη (2.11)
where H(p, r) is the physical Hamiltonian. Assuming that C is the only constant of
motion, the microcanonical partition function at temperature T can be written as:
ΩT (N, V,C) =
∫
dNp dNr dpη dη e
3Nηδ
(
H(p, r) +
p2η
2Q
+ LkTη − C
)
=
e3NC/LkT
LkT
∫
dpηe
−3Np2η/2QLkT
∫
dNp dNr e−3NH(p,r)/LkT
(2.12)
that, with L = 3N , is proportional to the canonical partition function for the physical
system. Thus, the Nosé “extended” scheme gives conformations of the physical sys-
tems that belong to the canonical ensemble. In eq. 2.12, the metric e3Nη has been used
as dNp dNr dpη dη e
3Nη is the phase-space conserved measure for this set of equation
of motion (see Appendix B).
Nosé-Hoover chains
When there is more than one constant of motion a single Nosé-Hoover thermostat is
unable to get the correct canonical sampling for the physical system [119]. It has been
indeed shown that this is the case for small or stiff systems [124], where a single Nosé-
Hoover thermostat can give rise to high oscillations in the temperature. Examples of
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pathological systems are a catalytic site of a protein or a drug-nucleobase adduct in
quantum MD simulations. To allow the simulation of more general systems Martyna
et al. [125] devised a scheme in which additional dynamical variables are inserted in
the Lagrangian. This corresponds to couple the first thermostat to another one, and
so on, generating a whole chain of thermostats (here the name Nosé-Hoover chains).
In fact, as the momentum of the extended variable entering in the first Nosé-Hoover
thermostat is distributed canonically, it can also be thermostated. The chains take
into account for additional conservation laws, and generates the correct canonical
distribution. The equations of motion for a system coupled to Nc thermostats are:
r˙i =
p˙i
mi
, (2.13)
p˙i = Fi − pη1
Q1
pi , (2.14)
η˙k =
pηk
Qk
, k = 1, ..., Nc, (2.15)
p˙η1 =
(
N∑
i=1
p2i
mi
− LkT
)
− pη2
Q2
pη1 , (2.16)
p˙ηk =
(
p2ηk−1
Qk−1
− kT
)
− pηk+1
Qk+1
pηk , (2.17)
p˙ηNc =
(
p2ηNc−1
QNc−1
− kT
)
. (2.18)
The dynamics generated by these equations conserves the following "energy":
HNHC = H(p, r) +
Nc∑
k=1
p2ηk
2Qk
+ LkTη1 +
Nc∑
k=2
kTηk (2.19)
2.2.3 NPH: Andersen barostat
At constant pressure, the volume V of the system fluctuates and has to be treated as
a dynamical variable. Andersen introduced a dynamical scheme in which the time-
average of any property is equal to the isoenthalpic-isobaric (NPH) ensemble aver-
age [123]. Subsequently, Parrinello and Rahaman [126] generalized the algorithm to
allow the simulation of solids under stress, where different pressures can be applied
along the three box edges. The Andersen algorithm considers a physical system of N
particles, with coordinates {ri} and momenta {pi}, and introduces a new variable Q
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and a set of scaled coordinates {ρi} which enter in the following Lagrangian:
LAnd(ρN , ρ˙N , Q, Q˙) = 1
2
mQ2/3
N∑
i=1
ρ˙i · ρ˙i−
N∑
i<j=1
φ(Q1/3ρij)+
1
2
MQ˙2−αQ , (2.20)
wherem is the mass of the (identical)N particles, φ is the potential. α a parameter
having the value of the pressure P of the system to be simulated, and M is the mass
of the “piston” coupled to it. The corresponding Hamiltonian is:
HAnd(ρN , πN , Q,Π) = (2mQ2/3)−1
N∑
i=1
πi · πi +
N∑
i<j=1
φ(Q1/3ρij) +
Π2
2M
+ αQ ,
(2.21)
where πi = mQ2/3ρ˙i and Π = MQ˙ are the momenta conjugate to ρi and Q,
respectively. A trajectory generated by this Hamiltonian has the property that the
time average of a function of the original system variables F (rN ,pN ;V ) is equal,
except for a negligible error, to the isoenthalpic-isobaric ensemble average of F , at
pressure P = α:
F¯ = FNPH(N,P,H) =
∫
dNr dNp dV δ
(H(rN ,pN ;V ) + PV −H)F (rN ,pN ;V )
N ! Γ(N,P,H)
,
(2.22)
where H(rN ,pN ;V ) is the original system Hamiltonian, and
Γ(N,P,H) =
1
N !
∫
dNr dNp dV δ
(H(rN ,pN ;V ) + PV −H) (2.23)
The above relation is true providing that the following correspondences between
the original and scaled dynamical variables are defined:
V (t) = Q(t) , (2.24)
ri(t) = Q
1/3ρi(t) , (2.25)
pi(t) = Q
−1/3πi(t) . (2.26)
This mapping identifies the instantaneous value of the volume of the system with
the introduced variable Q and allows to express HAnd in terms of H.
HAnd(ρN , πN , Q,Π) = H(Q1/3ρN , Q−1/3πN ;Q) + Π
2M
+ αV . (2.27)
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Now, expressing F through the scaled coordinates as
F (rN ,pN ;V ) = F (Q1/3ρN , Q−1/3πN ;Q) ≡ G(ρN , πN , Q,Π) , (2.28)
it follows that the average of F is equivalent to the average of G in the micro-
canonical ensemble NE corresponding to HAnd:
F¯ = G¯ =
∫
1
dρN
∫
dπN
∫
dQ
∫
dΠ δ
(HAnd(ρN , πN , Q,Π)− E) G(ρN , πN , Q,Π)
=
∫
1
dρN
∫
dπN
∫
dQ
∫
dΠ δ
(HAnd(ρN , πN , Q,Π)− E) F (Q1/3ρN , Q−1/3πN ;Q)
(2.29)
The integration in ρN is done over a unitary volume, since the coordinates are
scaled. Returning to the variables rN ,pN , and V one obtains:
F¯ =
∫
dΠ
∫
dNr dNp dV δ
(
H(rN ,pN ;V ) + Π2
2M
+ αV − E
)
F (rN ,pN ;V )∫
dΠ
∫
dNr dNp dV δ
(H(rN ,pN ;V ) + Π2
2M
+ αV − E)
(2.30)
which resembles FNPH , except for the integration in Π. Thus, we can write:
F¯ =
∫
dΠ Γ(N,α,E − Π2
2M
)FNPH(N,α,E − Π22M )∫
dΠ Γ(N,α,E − Π2
2M
)
, (2.31)
and expanding the ensemble average FNPH in the numerator as a power series of
Π2/2M up to the first order one finds:
F¯ ≈ FNPH(N,α,E − Π2/2M) . (2.32)
As the momentum Π appears inHAnd only as quadratic term, the average Π2/2M
is equal to kT/2, where T is the temperature of the scaled system (at fixed N and E).
The equations of motion for the original system are obtained from those of the scaled
one (derived from HAnd) by using the correspondence rules 2.24:
r˙i =
p˙i
mi
+
1
3
ri
d lnV
dt
, (2.33)
p˙i = Fi − 1
3
pi
d lnV
dt
, (2.34)
Md2V
dt2
= −α +
(
2
3
N∑
i=1
pi
2
2m
− 1
3
N∑
i<j=1
rij
dφ(rij)
drij
)
/V . (2.35)
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Summarizing, when the trajectory of the physical system is being determined by
that of the scaled system through the correspondence rules 2.24, the time average of
any property F coincides with its NPH ensemble average.
2.3 Force calculation
Once the equations of motion have been devised to sample the different statistical
ensembles, all we need is to calculate the forces acting on each “particle” (i.e. the
constitutive entity in the system). At the first level of approximation after the neglec-
tion of the subnuclear particles, these particles are identified as nuclei and electrons,
which are rigorously described by quantum mechanics.2 However, for most of the
purposes of biological simulations, the quantum nature of nuclei can be neglected,
leading to the so-called semi-classical description of matter. In this framework, we
describe the Born-Oppeheimer and Car-Parrinello MD schemes. The next level of
approximation consist in integrating out the electronic degrees of freedom, describ-
ing the interaction among atoms though mean-average force fields. These are used to
evolve systems through classical MD.
2.3.1 The semi-classical approximation
In the non-relativistic limit, the time evolution of a system of M atoms and N elec-
trons are described by the time dependent Schrödinger equation [127]:
i~
∂
∂t
Ψ = HΨ , (2.36)
where the wavefunction Ψ depends (in the space representation) on the 3(M+N)
coordinates, the nuclear and electronic spin states and on time. In absence of external
2 For the sake of clarity, in the following we will often restrict to closed-shell systems, for which
the sum over spins can be factorized out. Only when no additional complexity is added the discussion
will be taken as most as general considering explicitly spin-orbitals instead of spatial orbitals.
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fields, the Hamiltonian H reads:
H =T + V = Te + TN + VeN + Vee + VNN
=−
M∑
i=1
~
2
2me
∇2i −
N∑
I=1
~
2
2MI
∇2I +
∑
I,i
ZIe
2
|RI − ri|
+
M∑
i<j
e2
|ri − rj| +
N∑
I<J
ZIZJe
2
|RI −RJ |
=−
M∑
i=1
~
2
2MI
∇2I +He({ri}, {RI})
(2.37)
At room temperature the thermal wavelength λ is about 0.1 Å, while typical in-
teratomic distances, in liquids and solids, are of the order of 1 Å. Thus, a good ap-
proximation is to neglect quantum correlations between wave functions of different
nuclei, i.e to consider the nuclear wavefunction as an incoherent superimposition of
individual nuclear wave packets. In addition, nuclear masses are large enough that
such individual wave packets are usually well localized. These two observations lead
to the conclusion that the quantum nature of nuclei can be safely neglected in many
circumstances. In fact the majority of the so-called first-principle or ab initio meth-
ods consider the nuclei as classical particles moving in a (effective) potential due to
electrons. To achieve a classical description of nuclei, it is first necessary to separate
electronic from nuclear degrees of freedom. Formally, this can be done by writing the
wavefunction as product of terms depending only on electronic or nuclear positions
("one-determinant" Ansatz [128]):
Φ({ri}, {RI}; t) ≈ Ψ({ri}; t)χ({RI}; t) exp
[
i
~
∫ t
t0
dt′ 〈He(t′)〉
]
(2.38)
This separation leads to a set of self-consistent equations for the electronic and
nuclear wavefunctions, in which each system move in the average field of the other
class of degrees of freedom:
i~
∂Ψ
∂t
= −
M∑
i=1
~
2
2me
∇2iΨ +
{∫
dRχ∗({RI}; t)VeN({ri}, {RI})χ({RI}; t)
}
Ψ
(2.39)
i~
∂χ
∂t
= −
N∑
I=1
~
2
2MI
∇2Iχ+
{∫
drΨ∗({ri}; t)He({ri}, {RI}) Ψ({ri}; t)
}
χ
(2.40)
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Eqs. 2.39 and 2.40 define the Time-Dependent Self-Consistent Method (TDSCF),
first introduced by Dirac in 1930. A classical description of nuclei dynamics is achie-
ved by expressing χ in exponential form [129],
χ({RI}; t) = A({RI}; t) exp [iS({RI}; t)/~] , (2.41)
where A and S are real and A > 0. Substituting this expression in eq. 2.40 gives,
in the classical limit ~ → 0, the following set of equations:
∂S
∂t
+
N∑
I=1
(∇IS)2
2MI
+
∫
drΨ∗He Ψ = 0 (2.42)
∂A2
∂t
+
N∑
I=1
∇ ·
(
A2
∇IS
MI
)
= 0 . (2.43)
Using the connection PI ≡ ∇IS eq. 2.42 is isomorphic to the Hamilton-Jacobi
equation of classical motion for action S and HamiltonianH = T ({PI})+V ({RI}),
while eq. 2.43 is a continuity equation for the density probability A2 = |χ|2 of nuclei,
which move with classical velocities ∇IS/MI = pI/MI . Thus, the motion of nuclei
can be described using Newton’s law:
dPI
dt
= −∇I
∫
drΨ∗He Ψ = −∇IV E({RI(t)}) . (2.44)
In particular, nuclei are driven by a mean-field potential due to electrons (and
containing also a contribution from their kinetic energy) and depending on nuclear
configuration at time t. To get off the nuclear wavefuntion also from eq. 2.39 one
replaces the nuclear density |χ({RI}; t)|2 by a product of delta functions
∏
Iδ(RI −
RI(t)) (i.e. incoherent wave packets extremely localized) [128]. Summarizing, in
the semi-classical picture the nuclei evolve classically, and the only requirement is
to solve the Schrödinger equation for the electrons, whose wave function depends on
time only parametrically on nuclear positions at time t:
i~
∂Ψ
∂t
= −
M∑
i=1
~
2
2me
∇2iΨ + VΨ = HeΨ (2.45)
MIR¨(t) = −∇I
∫
drΨ∗He Ψ . (2.46)
The set of equations 2.45 and 2.46 describe the so called "Ehrenfest molecular
dynamics" scheme. It is clear now that the motion of the nuclei is dictated by the
HamiltonianHe, which basically contains the quantistic information on the electronic
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system. Thus, the major task of quantum mechanics concerns the solution of the
Schrödinger equation for the electrons, whose solution allow to know the dynamical
behaviour of the system.
2.3.2 Empirical force-fields and Classical MD
The large computational costs in the implementation of ab-initio molecular dynamics
end up into two major limitations: i) the relatively small size of the systems that can be
simulated (hundreds of atoms) and ii) the relatively short simulation timescale (tenths
of picoseconds). As many relevant biological processes usually involve large systems
(thousands of atoms or more), and occur in relatively long timescales (nanoseconds
or more), it is necessary to develop effective parametrized potentials, which are faster
to integrate, albeit less accurate, in order to study this kind of systems. Force-fields
based simulations originate from the assumption that the Born-Oppenheimer potential
energy surface can be approximated by additive parametrized many-body terms that
can be obtained by fitting experimental and high-level quantum chemical data into
simple functional forms. The term “force field” indicates a functional form for this
approximation, which relates the configuration of the system ({Ri} , i = 1, ..., N )
to its internal energy U, along with the set of parameters used in that function. In
this work, the AMBER parm94 force field [24] for description of macromolecules
in solution has been used, which is particularly well-suited for nucleic acids model-
ing. Namely, two sligthly modified versions of the original Cornell et al. force field
have been employed. The first, called parm99 [25], was introduced by Cheatham
et al. in 1999 to better reproduce the equilibrium between C2’-endo and C3’-endo
sugar puckers and the helical repeat of DNA, which is slightly underestimated by the
parm94 force field. The second was introduced this year by Perez et al. to improve
the description of α/γ conformers [31]. It is important to remind that changes in a
force field do not guarantee a systematic improvement over the original version. For
example, one drawback of parm99 with respect to parm94 is its slowness in convert-
ing the DNA from A to B form, which could hamper effective sampling in short MD
runs. The AMBER force fields belong to the so-called ClassI, whose the functional
form is the following:
U =
∑
bonds
Kr(r − req)2 +
∑
angles
Kϑ(ϑ− ϑeq)2 +
∑
dihedrals
Vn
2
[1 + cos (nφ− γ)]
+
∑
i<j
[
4εij
(
σij
rij
)12
−
(
σij
rij
)6
+
qiqj
εrij
]
(2.47)
Atom bond stretching and angle bending are represented as harmonic terms, while
dihedrals or torsionals are described by a sinusoidal term. Non-bonded interactions
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comprise two terms, the first is a Lennard-Jones 6-12 which describes atom-atom re-
pulsion and dispersion interactions, the second is the Coulomb electrostatic term. In
eq. 2.47, r and ϑ are respectively the bond length and valence angle; φ is the dihedral
or torsion angle and rij is the distance between atoms i and j. Parameters include the
bond force constant and equilibrium distance, Kr and req, respectively; the valence
angle force constant and equilibrium angle, Kϑ, and ϑeq, respectively; the dihedral
force constant, multiplicity and phase angle, Vn, n, and γ, respectively. The functional
form used for out-of-plane distorsions (e.g. in planar groups) is different in different
force fields [130]. For instance, in the AMBER force field [24, 25, 131] this term has
the same form as that used for proper dihedrals, while in CHARMM [132, 133] an
harmonic term is used. Collectively, these parameters represent the internal or in-
tramolecular ones. Nonbonded parameters between atoms i and j include the partial
atomic charges, qi, along with the LJ well-depth, εij , and σij , the (finite) distance at
which the interparticle potential is zero. These terms are also referred to as the inter-
action or external parameters. Typically, εii and σii are obtained for individual atom
types and then combined to yield εij and σij for the interacting atoms via combining
rules. The dielectric constant ε is typically set to 1 (corresponding to the permittiv-
ity of vacuum) in calculations that incorporate explicit solvent representations [130].
Van der Waals and electrostatic interactions are calculated between atoms belonging
to different molecules or for atoms in the same molecules separated by at least three
bonds.
Force-field optimization. Force field parameters are fitted to reproduce chemical-
physical properties of a class of model compounds representative of the biomolecules
of interest. To this end quantum mechanics geometry optimizations are used to obtain
bond and valence angle equilibrium constants and the dihedral phase and multiplic-
ity, whereas vibrational spectra calculations are used to adjust force constants [130].
Lennard-Jones parameters are fitted to reproduce observable such as enthalpies of
vaporization, free energies of solvation and densities of molecular liquids. Atomic
charges are optimized to reproduce the QM-determined electrostatic potential (ESP)
on a grid surrounding the molecule. As ESP charges tend to be undetermined, a
widely used approach is to use restraints during fitting (usually to Hirshfeld charges),
a method referred as Restrained ESP (RESP) [134]. Of course gas-phase calculations
do no properly represent some of the condensed phase properties, thus a further refine-
ment based on available experimental data is necessary. ESP charges are calculated,
in most the cases, at the HF/6-31G(d) level as this is known to overestimate dipole
moments and interaction energies [24]. This overestimation leads to partial charges
that include the implicit polarization proper for condensed phase simulations.
2.3 Force calculation 29
2.3.3 Long-range interactions
In simulations of biological systems it is highly desiderable to avoid the calculation of
all non-bonded pair interactions, since the computational cost would be proportional
to the square of the number of atoms. These interactions primarily dictates the dy-
namics of biomolecules, and cannot be merely truncated beyond a given cutoff [119]
when long-ranged. An interaction can be roughly defined long-range if the associated
energy falls off slower than r−d, where d is the dimensionality of the system. Thus,
Coulomb (∼ φ−1) and dipole-dipole (∼ φ−3) should be considered long-range when
dealing with three dimensional systems. Indeed, cutting the interaction on a sphere of
radius rc makes it is easy to see that the tail correction, proportional to
∫ ∞
rc
φ(r) 4πr2
diverges if the potential function goes to zero with r → ∞ faster than r−3. 3 For-
tunately efficient methods to handle the evaluation of long-range interactions were
developed. Among these, the most used are reaction field methods and lattice meth-
ods [135]. The first class assumes that beyond a given distance the interaction can
be treated using an “average field” approach, derived from macroscopic electrostatic.
The second class of methods, much widely used, is represented by the Ewald sum-
mation algorithm [136], which efficiently handles long-range interaction in periodic
systems (and thus require Periodic Boundary Conditions - PBC - to be used for the
system being simulated).
Ewald sums
Within PBC each particle interacts with all the other N-1 particles into the simulation
box and with all the N particle images in an infinite 3D array of periodic cells. The
electrostatic potential energy UCoul of the infinite system, therefore, takes the form:
UCoul =
1
2
∑
n=0
′
N∑
ij
qiqj
|rij + nL| (2.48)
where L is the length of the periodic box (assumed cubic for simplicity), N is
the total number of atoms, and n are the direct lattice vectors. The prime on the
summation indicates that the sum is over all the images n, and i 6= j if n = 0. The
convergence of this series is extremely slow, and thus a very large number of images
is required to achieve a reliable estimate of UCoul. A simple recipe to cope with this
problem consist in splitting the electrostatic energy in two parts, a short-range and a
3 The LJ interactions, instead, can be cut at a given cutoff (tipically 10-12 Å), since they decay
very rapidly. Methods have been developed that treat the region beyond the cutoff radius rc as being
homogeneous (i.e. with LJ parameters averaged over all the LJ atom types) [119]. These interactions
are thus effectively treated as short-range interaction, with the addition of a constant correction term.
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long-range term. This means to find some function β such that the Coulomb potential
can be rewritten (x ≡ |rij + nL|):
1
x
=
β(x)
x
+
1− β(x)
x
(2.49)
If β is properly chosen, the first term will be negligible beyond a given cutoff
xc, and the latter will be a slowly varying function of x, that can be expressed as
Fourier Series with a low number of k points. Ewald [136] made for β(x) the natural
choice of the complementary error function erfc(x) = (2/
√
(π))
∫ ∞
x
exp(−u2)du,
such that 1 − β(x) = 1 − erfc(x) = erf(x). Thus, in eq. 2.49 the term erfc(x)
is evaluated cutting the interactions at a given cut-off, while the long-range term is
Fourier transformed in the reciprocal space, where it becomes short-ranged and can
be thus accurately estimated by summing over a limited number of reciprocal vectors
(both the sums in real and reciprocal space becomes in fact exponentially converging).
The parameter α tunes the relative weights of real and reciprocal sums, although the
final result is independent of it. An optimal choice makes the Ewald sum converge
as N3/2, which can be further improved to N lnN with the use of Particle-Mesh
methods (as the Particle-Mesh Ewald, PME [137] or the Particle-Particle Particle-
Mesh, PPPM [138]), making advantage of the Fast Fourier Transform (FFT) [139]
algorithm. For a detailed derivation of the electrostatic energy in the Ewald method
and a brief discussion on Particle-Mesh Approaches see Appendix C.
2.4 The electronic structure problem
In the previous section I described the recipes that are used to evaluate interactions
in dynamical systems. Concerning the force fields, once a proper parametrization is
available, nothing more is requested that solving classical Newton equation of motion.
Within the semi-classical approximation, the knowledge of the electronic structure is
needed to calculate forces acting on the nuclei. In the following, I describe the main
methods used for solving the electronic structure problem.
2.4.1 Time-space separation
Within the TDSCF scheme derived in the previous section, it is relevant noticing that
He depends on time only parametrically through the positions of nuclei. Whenever
the Hamiltonian does not depend explicitly on time, it is possible to formally separate
the variables and reduce to a time-independent eigenvalue problem. In fact, we can
cast the electronic wavefunction Ψ as simple product:
Ψ({ri}; {RI}, t) = ψ({ri}; {RI}) f(t) , (2.50)
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where RI are instantaneous positions at time t, and ψ and f satisfy the following
set of equations (obtained substituting the above expression in eq. 2.45):
i~
d
dtf(t) = Ef(t) , (2.51)
Heψ({ri}; {RI}) = Eψ({ri}; {RI}) . (2.52)
A particular solution of the Time-Dependent Schrödinger Equation (TDSE) is
thus the product of a sinusoidal wave in time and a function satisfying the eigenvalue
equation 2.52, which is called time-independent Schrödinger equation (TISE):
Ψ({ri}; {RI}, t) = ψ({ri}; {RI})
[
f e−iEt/~
]
. (2.53)
where E = 〈He〉 is the energy of the electronic system in the nuclear configura-
tion {RI}. At this point we have a whole series of solutions because generally there
will be multiple values of E for which eq. 2.52 has solutions for ψ. As the time-
dependent Schrodinger equation is linear in time, the general solution will be simply
given by a linear combination of the various independent solutions:
Ψ =
∞∑
k=0
fk(t)ψk({ri}, {RI}) , (2.54)
where fk(t) ≡ fk e−iEk t/~ and ψk is the eigenfunction corresponding to energy
Ek. Thus, system time evolution is entirely described by the set of coefficients
fk(t). In fact, the occupation of eigenstates at any time is given by |fk(t)|2 (with∑
k |fk(t)|2 = 1), while transitions are described via the cross-terms fkfl 6=k.
2.4.2 Methods for solving Time Independent Schrödinger Equa-
tion
Eq. 2.52, describing the behaviour of the electronic subsystem, is still too compli-
cated, thus approximations have to be introduced to tackle it. A common approach
consist in writing the total electronic wavefunction as a product (symmetrized or not)
of single-particle wavefunctions. The work presented in this thesis has profited from
Density Functional Theory [140] (DFT) and Hartree-Fock (HF) with Møller-Plesset
(MP) 2nd order corrections. Both of these methods include electronic correlation
effects, and allows treatment of relatively large systems with a reasonable computa-
tional cost.
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Hartree-Fock Methods
The Hartree-Fock method takes into account the Pauli principle for electrons writing
the total electronic wavefunction as single (antisymmetric) Slater determinant of the
spin-orbitals ψi(x) = φi(r)σ(s) [141], where σ(s) = α(s) or β(s):
ΨHF =
1√
(N !)
∣∣∣∣∣∣∣∣∣
ψ1(x1) ψ2(x1) · · · ψN(x1)
ψ1(x2) ψ2(x2) · · · ψN(x2)
.
.
.
.
.
.
.
.
.
ψ1(xN) ψ2(xN) · · · ψN(xN)
∣∣∣∣∣∣∣∣∣
. (2.55)
Minimizing the expectation value of the Hamiltonian He with respect to the set
{ψi} subject to the orthonormalization conditions 〈ψi|ψj〉 =
∫
dx, ψ∗i (x)ψj(x) = δij
gives, after diagonalization through a unitary operator U, the canonical Hartree-Fock
system of equations:
Fiφi = ǫiφi , (2.56)
with
Fi = −∇
2
i
2
+
∑
I
ZIe
|ri −RI|︸ ︷︷ ︸
hi
+
N∑
j=1
(Jj −Kj) . (2.57)
The so-called Fock operator Fi is an effective one-electron operator describing
the kinetic energy of an electron, the attraction to all the nuclei, and the repulsion
between electrons, through the Coulomb and exchange operators:
Jj(x1)φi(x1) ≡
N∑
k=1
∫
dx2φ
∗
k(x2)φk(x2)g12 φi(x1) , (2.58)
Kj(x1)φi(x1) ≡
N∑
k=1
∫
dx2φ
∗
k(x2)φi(x2)g12 φk(x1) , (2.59)
with
gij ≡ 1|ri − rj| . (2.60)
The exchange operator has a non-local character, and is the term that accounts for
the exclusion principle of Pauli. The expectation value of the Fock operator
εl = 〈φl|Fl|φl〉 (2.61)
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can be interpreted as the energy of the l-th MO, which in the limit of frozen
orbitals is equal to minus the ionization energy Il of the l-th electron (Koopmans’
theorem [142]). The total energy
E =
N∑
i=1
εi − 1
2
N∑
ij=1
(Jij −Kij) + Vnn (2.62)
is not simply the sum of MO energies, because the Fock operator contains terms
describing the repulsion of each MO to all other electrons, and thus the sum over εi
counts the electron-electron repulsion twice, which have to be corrected by the second
term. Moreover, this total energy cannot be exact, as the electron-electron repulsion is
only accounted for in an average fashion, due to the approximation of a single Slater
determinant as the trial wave function. The absence of correlation among electrons
can be included within a perturbative scheme, like the one of Møller-Plesset.
Møller-Plesset perturbation theory
In the Møller-Plesset scheme [143, 144] the unperturbed Hamiltonian H0 is taken
to be a sum over Fock operators. As this sum counts twice the (average) electron-
electron repulsion, the perturbation H1 becomes the exact Vee operator minus twice
〈Vee〉 (also called fluctuation potential:
H0 =
N∑
i=1
Fi =
N∑
i=1
(
hi +
N∑
j=1
(Jj −Kj)
)
=
N∑
i=1
hi + 2 〈Vee〉 (2.63)
H1 = Vee − 2 〈Vee〉 (2.64)
The zero-order wave function is the HF determinant, while the first (MP1) order
correction to the energy is given by the average electron-electron repulsion changed
in sign. Electron correlation enters at the MP2 level, and involves only a sum over
doubly excited determinants (if canonical HF orbitals are used) [144]:
EMP2 =
occ∑
i<j
vir∑
a<b
∫∫
dr1dr2φi(r1)φj(r2)g12 [φa(r1)φb(r2)− φb(r1)φa(r2)]
εi + εj − εa − εb . (2.65)
The MP2 correction typically recovers 80-90% of the correlation energy, at a
cost roughly twice as that for solving HF equations in practical calculations (this be-
cause only two-electron integrals corresponding to two combination of two occupied
and two virtual MOs are required in eq. 2.65). Moreover, for “well-behaved” sys-
tems, MP2 usually gives better results than MP3 [144]. Including higher terms in
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the perturbation is not very common, as other methods become competitive [144],
like Configuration Interaction (CI), which has the advantage of being intrinsically
multi-reference.
Density Functional Theory
Density Functional Theory (DFT) is a rigorous method to find the ground state of
many particle system [140]. The main idea lies in assumption that the ground-state
properties of a quantum system of N particles can be described starting from its
density ρ(r)
ρ(r) = N
∫
|Ψ(r1, r2, ...rN)|2 dr2dr3...drN . (2.66)
This has two main advantages over the other techniques:
• density is an observable that can be easily measured and visualized.
• the dimensionality of the problem is reduced from 3N to 3, as the density is a
function of space.
The Hohenberg-Kohn theorems. The use of the density as fundamental quantity
is based on the two Hohenberg-Kohn theorems, enunciated in the early sixties [140].
The first theorem demonstrates that, given a Hamiltonian characterized by a general
external potential Vext, the ground-state density ρ(r) associated to it is unique. As
Vext univocally determines the Hamiltonian of the system, it follows that the ground
state wavefunction, and thus all the observables are functionals of the density ρ. The
second theorem provides a variational principle for the ground state density: given
any trial density ρ¯ > 0 for which
∫
ρ¯(r)dr = N , it follows that E[ρ¯] ≥ E[ρ]. From
this result, one can get a variational equation to obtain the ground-state energy. Let
apply the Hohenberg-Kohn theorem to a system of N electrons in which the external
potential is due to the nuclei. The energy in terms of the electronic density reads:
E[ρ] = Te[ρ] + Vee[ρ] + VeN [ρ] + VNN = F [ρ] +
∫
drρ(r)Vext (2.67)
where F [ρ] = Te[ρ] +Vee[ρ] = 〈ψ |Te + Vee|ψ〉 is a universal functional indepen-
dent from the external potential Vext[ρ] = VeN [ρ] + VNN .
Applying to ρ the stationary principle
δ
{
E[ρ]− µ
[∫
ρ(r)dr−N
]}
= 0, (2.68)
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we obtain the Euler-Lagrange equation for the multiplier µ:
µ = Vext(r) +
∂F [ρ]
∂ρ
(2.69)
Although DFT is formally a rigorous method, the application of the variational
principle requires in practice an explicit form of the functional F . Kohn and Sham
suggested to decompose it in parts whose only the most important need to be treated
exactly [145].
Kohn-Sham equations. The main idea of the Kohn-Sham method lies in the
possibility of mapping a system of N interacting particles into an equivalent one of
non-interacting bodies, characterized by the same ground state density [145]. For
such systems, the density can be written as a summation over single-particle contri-
butions:
ρ(r) =
N∑
i=1
∣∣ϕKSi (r)∣∣2 (2.70)
and the kinetic energy functional has an analytical expression:
T0[ρ] =
N∑
i=1
〈
ϕKSi
∣∣∣∣−12∇2
∣∣∣∣ϕKSi
〉
(2.71)
The functional F [ρ] can be rewritten as:
F [ρ] = T0[ρ] + VH [ρ] + Exc[ρ] (2.72)
where VH = 12
∫
dr′ ρ(r)ρ(r
′)
|r−r′| is the classical part of the particle-particle interaction,
and the ‘exchange-correlation’ functional Exc is defined as:
Exc[ρ] = T [ρ]− T0[ρ] + Vee[ρ]− VH [ρ] (2.73)
Thus all the unknowns of the problem are put intoExc, which sums the corrections
in the kinetic energy and of the non-classical part of the particle-particle interaction.
The echange-correlation term describes the lowering in energy gained by a system of
interacting electrons with respect to the Fermi gas, and has therefore a negative sign.
Formally Exc can be written in terms of an exchange-correlation energy per particle
εxc, which is itself functional of the total density:
Exc[ρ] =
∫
drρ(r)εxc[ρ] (2.74)
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Equation 2.69, turns out to be:
µ = V KS(r) +
∂T0[ρ]
∂ρ
(2.75)
with
V KS = Vext(r) +
∫
dr′
ρ(r′)
|r− r′| + Vxc[ρ] (2.76)
where we have defined the exchange correlation potential
Vxc(r) =
δExc[ρ]
δρ
(2.77)
Eq. 2.75 says that we can solve the original problem by finding the ground state
energy for a system of non-interacting electrons in a effective potential. The single-
particle orbitals describing these electrons solve the self-consistent Kohn-Sham (KS)
equations:
[
1
2
∇2 + VKS(r)]ϕKSi = εiϕKSi i = 1, ..., N (2.78)
The total energy of the system is not the sum of KS eigenvalues, but can be ex-
pressed as
E =
N∑
i=1
εi − 1
2
∫
drdr′
ρ(r)ρ(r′)
|r− r′| + Exc[ρ]−
∫
drVxc(r) ρ(r) (2.79)
The method of Kohn and Sham shifts the complexity of the problem on finding
a suitable analytical formulation of the exchange-correlation functional. In practice
this is not possible, so once again approximated expressions have been derived for
Exc.
Exchange-Correlation functionals
Local Density Approximation. An approximation for the exchange-correlation
functional has been proposed already in the original paper by Hohenberg and Kohn [140,
141]. They recover the idea beyond Thomas-Fermi approximation of the kinetic en-
ergy for an homogeneous electron gas, and apply it to the evaluation of Exc[ρ]. The
exchange-correlation energy density in r is assumed to be local, i.e. only depends
on the value of ρ in r itself (here the name Local Density Approximation, LDA):
εxc[ρ] = εxc(ρ(r)). In addition, εxc is approximated by that of an homogeneous gas
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of electrons of density ρhom = ρ(r) (in a uniform background of positive charge).
Thus
εLDAxc [ρ] = ε
hom
xc (ρ(r)) (2.80)
The simplification introduced by LDA becomes clear if one divides εxc into ex-
change and correlation contributions εx and εc. In fact, for a homogeneous electron
gas εx is known exactly [140,141,146], and is proportional to the cubic square of the
density:
εLDAx [ρ] = −
3
4
(
3
π
)1/3
ρ1/3(r) (2.81)
The situation is more complicated for the correlation term, which has been de-
termined analytically in the high and low density limit [147, 148], and by Quantum
Monte Carlo calculations for intermediate states [149]. Suitable (approximate) an-
alytical formulas have been derived by Vosko, Wilk and Nusair (VWN correlation
functional) [150] and by Perdew and Wang (PW) [151]. The main reason behind suc-
cess of LDA is most probably a partial cancellation of errors. In fact, LDA typically
underestimates Ec but overestimates Ex, resulting in unexpectedly good values of
Exc. However, for molecular systems εx is underestimated by a factor of 10, leading
to errors larger than the whole correlation energy (overestimated by a factor 2), and
bond energies up to 25 kcal/mol larger than experimental values [144]. In addition,
LDA exhibits heavy deficiencies in describing hydrogen-bonds, which are crucial for
studies on biologically relevant systems [152, 153].
Generalized Gradient Approximation. The General Gradient Approximation
(GGA) successfully improves the accuracy of DFT by introducing the gradient4 of
the density in the functional form of Exc:
EGGAxc [ρ] =
∫
d(r)f(ρ(r),∇ρ(r)) (2.82)
Quite generally, GGAs functionals give good results for all the main bond types
(covalent, ionic, metallic and hydrogen bonds) (see for example [146] and Refs.
therein). For Van der Waals interactions, however, common GGAs and LDA fail. To
treat these weak interactions more specialized approaches have been developed [154,
155] but I will not treat them in detail here. The GGA functionals used in biochem-
istry typically are derived by fitting parameters on the properties of sets of molecules.
4 Notice here the difference from the gradient-expansion-approximation (GEA), where one tries
to systematically calculate gradient-corrections to LDA of the form |∇ρ|, ∇2ρ, |∇ρ|2. In contrast
to GGA, GEA shown no improvement with respect to LDA, because of the loss of some important
properties of the exchange-correlation hole [144].
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Nowadays the most popular and reliable GGA functional used in biochemistry is
BLYP, which also has been used in the work exposed in this thesis. The acronym
BLYP denotes the combination of Becke’s exchange functional B88 [156], and the
correlation functional of Lee, Yang and Parr (LYP) [157], both introduced in 1988.
Becke exchange functional. This correction was introduced by Becke [156] to
reproduce the exact asymptotic behaviour of the exchange energy. The analytical
formula reads:
Ex[ρ]
B88 = ELDAxc + ∆E
B88
x (2.83)
where
∆EB88x = −β
∫
drρ
4
3 (r) x
2
1+6β sinh−1 x
(2.84)
x = |∇ρ|
ρ
4
3
(2.85)
x gives a measure of the local inhomogeneity of the system, and the parameter
β has been fixed to 0.0042 a.u. by a fit on known Hartree-Fock data for the rare gas
atoms.
Lee-Yang-Parr correlation functional. The LYP functional [157] for the corre-
lation energy was derived from the Colle-Salvetti formula, and computes correlation
energies from HF second order density matrices. Its expression is the following:
ELY Pc [ρ] = −a
∫
dr
1
1 + dρ−
1
3
{
ρ+ bρ−
2
3
[
CFρ
5
3 − 2tW +
(
1
9
tW +
1
18
∇2ρ
)]
e−cρ
− 13
}
(2.86)
where CF = 310(3π
2)
2
3 , tW =
1
8
|∇ρ|2
ρ
− 1
8
∇2ρ. The parameters a=0.04918,
b=0.132, c=2533 and d=0.349 are obtained by fitting the functional formula on HF
calculations for the Helium atom.
Hybrid functionals. The main problem in DFT practical implementations arise
from the approximation inherent in the exchange-correlation potential introduces a
Self Interaction Error (SIE) that does not conveniently cancels as in HF theory [144].
This leads to serious drawbacks in calculations of thermochemistry of molecules us-
ing the LDA or GGA standard functionals. Relative energies of states with differ-
ent spin multiplicity are often poorly described, radicals or atom transfer transition
structures are predicted to be too stable, and activation barriers are severely underes-
timated [83,158]. These considerations have pushed Becke to include exact exchange
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into the functional form of Exc. Theoretical instrument for this proposal is the adia-
batic connection method [159], that gives a link between the non-interacting reference
system and the real fully interacting system:
Exc =
∫ 1
0
dEλxc
dλ
dλ (2.87)
Here λ is an inter-electronic coupling strength parameter taking the system from
no Coulomb interaction at λ = 0 to full correlation at λ = 1. In the limit λ = 0 we
have only exchange energy, exactly the one given by the HF theory 5. Following this
idea people tried to decompose Exc as a combination of LDA, exact exchange and a
gradient correction term [160]. Coefficients have been both calculated by fitting of
some properties [161, 162] or derived from requirements on the correct behaviour of
Vxc [163]. Among these hybrid functionals the B3LYP [161], employed in the work
exposed here, is probably the most used in biological calculations:
EB3LY Pxc = (1− a)ELDAxc + aEexactx + b∆EB88x + (1− c)ELDAc + cELY Pc (2.88)
The a, b and c parameters are determined by fitting to experimental data and de-
pend on the chosen forms for EGGAx and EGGAc , with typical values being a ∼ 0.2,
b ∼ 0.7 and c ∼ 0.8. Hybrid functionals represent today the better choice in terms of
performance vs accuracy.
2.4.3 Basis Set approximation
In actual implementations of (Post)HF or DFT-Kohn-Sham schemes, the MOs are
usually expanded in terms of Mb basis functions of well-known behavior
ϕi =
Mb∑
α
ciαχα (2.89)
The mathematical problem is thus transformed into that of solving a secular ma-
trix equation, in which the matrix elements are calculated from arrays of integrals
evaluated for the given basis functions. Taking HF equations 2.56 as example, and
expanding the eigenfunctions as above, one obtain the famous Roothaan-Hall equa-
tions (for a closed shell system) [144]:
FC = SCε (2.90)
5This energy would be equal to that calculated with HF wavefunction methods if the the KS orbitals
were identical to the HF ones.
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where S is the matrix describing basis set functions overlap (Sαβ = 〈χα|χβ〉) and
the matrix elements of the Fock operator are written as sum of one-electron integrals
and products of a density matrix with two-electron integrals
Fαβ = 〈χα|F|χβ〉 = hαβ +
∑
γδ
GαβγδDγδ (2.91)
hαβ = 〈χα|h|χβ〉 =
∫
dr1χα(1)
−∇2
2
χβ(1) +
N∑
a
∫
dr1χα(1)
Za
|Ra−r1|χβ(1)
(2.92)
Gαβγδ = 〈χα(1)χβ(2)|g12|χγ(1)χδ(2)〉 =
∫
dr1χα(1)χβ(2)
1
|r1−r2|χβ(1)χδ(2)
(2.93)
Dγδ =
occ.MO∑
j
cγjcδj (2.94)
Essentially two philosophies exist for the construction of a basis set, one using
localized atomic orbitals (AO), the other delocalized plane-waves (PW) for the ex-
pansion of MOs.
Localized basis sets
The basis sets are composed by localized and usually atomic-centered functions 6,
firstly introduced by Slater, that resemble hydrogen-like eigenfunctions [164]
χζ,n,l,m(r, θ, ϕ) = NYl,m(θ, ϕ)r
n−1e−ζr (2.95)
Slater Type Orbitals (STO) are certainly the best suited for electronic structure cal-
culations. However, the evaluation of especially three and four center two-electrons
integrals is very expensive using such an exponential functions. So, for practical pur-
poses STO are almost universally replaced by Gaussian Type Orbitals (GTO) [165]
χζ,n,l,m(r, θ, ϕ) = NYl,m(θ, ϕ)r
2n−2−le−ζr
2 (2.96)
In fact, the product of two Gaussians located at different centers have the (nice)
property of being a Gaussian centered at the intermediate position, that greatly im-
proves the efficiency in calculating two-electrons integrals. Obviously a single GTO
does not reproduce as well as an STO the proper behavior of the wavefunction (in
particular near to the nucleus and for large r), so three times as many GTOs as STOs
6For a recent and exhaustive description of AO type basis sets see e.g. the book by Jensen [144].
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are roughly required to reach a given accuracy. This theoretical disadvantage is more
than compensated by the overall gain in computational time. The quality of a calcu-
lation depends obviously on the number of functions used in the expansion. A double
zeta basis (DZ) set, in which the number of basis functions is twice what is needed
to contain all the electrons of neutral atoms, is considered “good” for organic mole-
cules. Most often only valence orbitals are doubled, while core states are described
with the smallest number of functions possible (minimum basis set), which gives the
double zeta valence split basis (VDZ). Often polarization and diffuse functions are
added to the basis set to improve the description of electronic correlation and polar-
ization, and systems with loosely bound electrons (see Ref. [144] for further details).
MOs are thus expanded as linear combination of a given number of GTOs with dif-
ferent exponents ζ (primitives, PGTO). As these are determined by an energy-based
variational procedure, most of them are “well-tuned” on core-states, which are en-
ergetically but not chemically relevant. To improve efficiency contracted basis sets
have been introduced. The idea is to combine a given set of primitives into a smaller
set of (contracted, CGTO) orbitals, each one being a linear combination of a given
number of PGTO with fixed coefficients. The acronyms DZ, VDZ, etc. always refer
to the number of contracted basis functions. Calculations reported in this thesis have
been performed using the VDZ Pople-style k-nlmG basis set described in the next
paragraph.
Pople-style k-nlmG basis sets. In this basis set the k indicates the number of PGTOs
used for representing the core orbitals, while nlm indicates both how many functions
the valence orbitals are split into, and how many PGTOs are used for their represen-
tation. Two values (nl) indicate a split valence, three (nlm) a triple split valence.
Polarization functions are specified after the G. The most used basis set of this kind
is the 6-31G one [166], in which the core orbitals are a contraction of six PGTOs, the
inner part of valence orbitals is contraction of three, and the outer part is represented
by one PGTO.
Plane waves
Following the Bloch theorem [167] for periodic systems, a one-particle wave-function
can be written as Fourier’s series:
ϕk(r) =
1√
V
eik·r
∑
g
ckj (g)e
ig·r (2.97)
where V is the volume of the cell, k vectors belong to the first Brillouin zone, g
is a reciprocal lattice vector, c is the first Fourier component of the plane waves ex-
pansion, and the summation is extended to infinite lattice vectors In the treatment of
42 Methods
isolated clusters with a low symmetry, such as, organic molecules or the active sites of
enzymes, the Γ-point approximation (k=0) still guarantees a good accuracy, leading
to a relevant reduction of the computational cost. The simulation of isolated clus-
ters within a periodic boundary condition scheme needs some care, as self-interaction
among replicas has to be cancelled. In our calculations, we have used the procedure
developed by Martyna and Tuckerman [168], which linked the expression of the elec-
trostatic potential energy of a cluster to that of a infinitely periodic system, allowing
thus to take advantage of the Ewald method (see Section 2.3.3 and Appendix C) for
isolated systems treated with a plane-wave orbital expansion. The algorithm is based
on the assumption that the electrostatic potential Φ can be written as the sum of a
short and long-range contributions:
Φ(r) = φlong(r) + φshort(r)
In a plane-wave expansion, the potential energy due to Φ can be expressed as
U =
1
2V
∑
g
|ρ¯(g)|2 Φ¯(−g) = 1
2V
∑
g
|ρ¯(g)|2 [φ¯short(−g) + φ¯long(−g)] (2.98)
where ρ¯(g) and Φ¯(−g) are the finite Fourier series of the density and the potential,
respectively, the finite Fourier series of f(r) being:
f¯(r) =
∫
V
dre−ig·rf(r) (2.99)
Requiring φshort(r) to vanish exponentially quickly at large distances from the
center of the cluster (d ∼ 2ds, where ds is the typical system size), we can express
this function as a Fourier transform plus an (exponentially vanishing) error term:
φ¯short(g) =
∫
V
dre−ig·rφshort(r)
=
∫
all space
dre−ig·rφshort(r) + ε(g)
= φ˜short(g) + ε(g)
(2.100)
where φ˜short(g) is the Fourier transform of φshort(r). Thus, neglecting the error
term:
φ¯(g) = φ˜short(g) + φ¯long(g)
= φ˜short(g) + φ¯long(g) + φ˜long(g)− φ˜long(g)
= φ˜(g) + φ˜screen(g)
(2.101)
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The function
φ˜screen(g) = φ¯long(g)− φ˜long(g) (2.102)
screens the interaction of the cluster with an infinite array of periodic images,
realizing the link between isolated and replicated systems (its value is zero in this
latter case). Thus, the potential energy can be written as:
U =
1
2V
∑
g
|ρ¯(g)|2
[
Φ˜(−g) + φ˜screen(−g)
]
(2.103)
In this expression φ˜long(g) is supposed to be known, while φ¯long(g) can be eval-
uated efficiently over a grid using Fast Fourier Transform [139], which scales as O
(N lnN ).
Pseudopotentials. The greatest drawback in using a plane-wave basis-set comes
from the impossibility, from a practical point of view, of describing core electrons
within a reasonable computational expense. Indeed, the sharp spatial oscillations of
their wave-functions near to the nuclei would require an extremely high number of
plane-waves for an accurate characterization. On the other hand, the core levels are
well separated in energy from valence electrons, and, at a first level of approxima-
tion, do not play any role in the chemical properties of molecular systems. Thus, the
core electron orbitals can be frozen in the KS equations and only the valence elec-
trons are described explicitly. The core-valence electron interactions are implicitly
included into the nuclear potential, which becomes an “effective-potential” or “pseu-
dopotential”. Pseudopotentials are usually derived from all electron (AE) atomic cal-
culations, and several recipes have been proposed to date. In the work presented
in this thesis "norm-conserving" pseudopotentials derived from the Martins-Troullier
method [169] have been used. Pseudopotentials have to satisfy the following condi-
tions:
• The valence pseudo-wave-function should not contain any radial nodes.
• The valence AE and pseudopotential eigenvalues from the radial KS equations
must be the same:
εPPℓ = ε
AE
ℓ (2.104)
where ℓ is the angular momentum.
• The pseudo and AE atomic radial wave-functions must be equal for r greater
than a chosen cut-off distance rcut.
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These three conditions ensure that the pseudo-atom behaves like the real one in
the region of interaction with other atoms while forming chemical bonds. Other con-
ditions are the following:
• The integrated electron density within the cut-off radius for the two wave-
functions must be the same. This requirement guarantees the transferability
and the norm conserving rule of the MT pseudopotential.
• At r = rcut, the pseudo wave-function and its first four derivatives should be
continuous.
• The pseudopotentials should have zero curvature at the origin.
With these conditions, the general form for a pseudopotential wave-function is:
ϕPPℓ (r) =
{
ϕAEℓ (r) ; r > rcut
rℓep(r); r ≤ rcut (2.105)
where p(r) = c0 +
∑6
i=1 cir
2i
, and the coefficients are obtained by imposing the
first three conditions.
The functional form of the pseudopotential is
Vpseudo = Vval(r) +
∑
m,l
|Yl,m〉Vl(r) 〈Yl,m| (2.106)
where |Yl,m〉 are spherical harmonics. The "semilocality" of this functional form
(local in the radial coordinate, non local in the angular ones), implies an increase
in the computational cost. This difficulty can be overcome by using the method of
Kleinman-Bylander [170], which implies addition and subtraction of an "ad-hoc" ra-
dial function VL(r) to the pseudopotential, leading to a new functional form, where
the local and non-local parts can be completely separated.
2.5 Born-Oppenheimer approximation
We have seen that the Ehrenfest molecular dynamics scheme, eqs. 2.45 and 2.46, al-
lows to propagate the electronic system by solving the time-dependent Schrödinger
equation "on the fly", as the nuclear configuration changes under the force ∇I 〈He〉.
Unfortunately there is a major problem with practical implementation of the Ehren-
fest scheme: the time scale and thus the time step used to integrate eqs. 2.45 and 2.46
simultaneously is dictated by the intrinsic dynamics of electrons. Now, typical vibra-
tional and angular frequencies in biological systems rise up to 3000−4000 cm−1 (for
example bond frequencies in water are ∼3500 cm−1 [171]), which correspond to a
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timescale of τN ∼ 10−14. This time interval is two order of magnitude larger than the
maximum time step ∆tmaxe necessary to integrate correctly electron dynamics. Thus,
there is a bottleneck limiting the efficient implementation of such a simultaneous
evolution of electronic and nuclear systems. A solution to this problem is the Born-
Oppenheimer (BO) approximation, which was proposed in the early days of quantum
mechanics (1927) [172]. In the BO scheme the strong dynamical separation between
electronic and nuclear motions is exploited to increase the maximum time step used
to propagate the nuclei. Since atoms are about three orders of magnitude heavier
than electrons, the latter are supposed to follow instantaneously the motion of the
nuclei, staying always in the same stationary state of the Hamiltonian. This station-
ary state will vary with the configuration of nuclei because of the Coulomb coupling
between the two sets of degrees of freedom, but non-radiative transitions like those
from phonon-electron interactions are negligible. This is obviously true only if the
energy separation between the ground and the first excited state is larger than typi-
cal phonon energies. In this case, one can solve the time-independent Schrödinger
equation at fixed positions of the nuclei, move them under the action of the effective
electronic potential, and iterate the process. The equations describing the so-called
Born-Oppenheimer approximation (for the ground state) are then 7.
HeΨ0 = E0Ψ0 (2.107)
MIR¨(t) = −∇I minΨ {〈Ψ0|He|Ψ0〉} (2.108)
At opposite to Ehrenfest dynamics, now time dependence of the electronic struc-
ture is only implicit through the motion of nuclei. This allows for time steps ∆tmaxN ∼
τN/10. However, the bottleneck of Born-Oppenheimer dynamics is that at each MD
step the electronic wavefunction needs to be relaxed.
2.6 Car-Parrinello molecular dynamics
The drawbacks of both Ehrenfest and Born-Oppenheimer molecular dynamics schemes
stimulated the search for new algorithms that could overcome their limitations. In
1985 Car and Parrinello developed a new scheme, based on the extended Lagrangian
formalism and avoiding the optimization of the electronic wavefunction by introduc-
ing a second order fictious dynamics on the electrons. These latter are kept suffi-
ciently close to the adiabatic surface, allowing for an increase of the time step by a
factor ∼ 10 with respect to Ehrenfest dynamics. The method is based on the obser-
vation that 〈Ψ0|H|Ψ0〉 can be viewed not only as a function of {RI}, but also as a
7Note that Born-Oppenheimer approximation slightly differs from the so-called "adiabatic" one for
presence in the latter of a diagonal correction term containing the expectation value of the nuclear
kinetic energy operator on the electronic wavefunction [144].
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functional of the wavefunction Ψ0, and thus of the set of one-electron orbitals {ψi}
used to build it. In this case, the force acting on these orbitals can be obtained from a
functional derivative of a suitable Lagrangian containing 〈Ψ0|H|Ψ0〉, like in classical
mechanics for the nuclear motion. The Lagrangian L proposed by Car and Parrinello
has the form
L =
M∑
i=1
1
2
MIR˙
2
I +
N∑
i=1
1
2
µi
〈
ψ˙i
∣∣∣ψ˙i〉− 〈Ψ0|He|Ψ0〉+ constraints (2.109)
where the first term is the kinetic energy of nuclei, and µi = µ are the "fictious
masses" assigned to orbitals; the second term represents the fictious kinetic energy
associated to them (the sum is on the occupied orbital only). The (holonomic) con-
straints act in general on both the orbitals (e.g. to guarantee orthonormality) and on
the nuclei (e.g. if one would perform molecular dynamics with geometric restraints).
The dynamics is described by the Euler-Lagrange equations associated to L
d
dt
∂L
∂R˙I
= MIR¨I =
∂L
∂RI
= − ∂
∂RI
〈Ψ0|He|Ψ0〉+ ∂
∂RI
{constraints} (2.110)
d
dt
∂L
∂ψ˙∗i
= µiψ¨
∗
i =
∂L
∂ψ∗i
= − ∂
∂ψ∗i
〈Ψ0|He|Ψ0〉+ ∂
∂ψ∗i
{constraints} (2.111)
Note that if |µψ¨i| → 0 eq. 2.111 reduces to a stationary problem, and the elec-
tronic system will stay on the Born-Oppenheimer surface (no forces acting on or-
bitals), corresponding to the true equilibrium dynamics. Higher is the fictious kinetic
energy Te =
∑N
i=1
1
2
µi
〈
ψ˙i
∣∣∣ψ˙i〉, more the electrons will be far from the minimum
energy configuration. In particular, a ground state wavefunction optimized at time t0
will stay close to its ground state if it is kept at sufficiently low temperature. The only
quantity one can change to ensure this condition is µ, often called "adiabacity param-
eter" [128]. If µ and τ are chosen consistently the energy flow between electronic
and nuclear subsystems is slow enough to cause no drift in Te 8, thus conserving the
"physical" energy Ephys:
Ephys = Etot − Te = TI + Ve =
M∑
i=1
1
2
MIR˙
2
I + 〈Ψ0|He|Ψ0〉 (2.112)
8 Te actually performs two-frequency bound oscillations around a constant value. The first fre-
quency is associated to the drag exerted by the nuclei, and it is in anti-phase with Ve oscillations, while
the second is a small-amplitude high-frequency oscillation intrinsic to the fictious electronic dynam-
ics. Note that having a nonvanishing masses, also the electrons dampen nuclear motion, causing a
renormalization of the nuclear masses which can be important in the case of light atoms.
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The choice of a reasonable fictious mass µ meets two opposite requirements. In
fact, considering a simple harmonic model for the electronic system around the BO
surface, (discrete) excitations frequencies are given by
ωeij =
√
2(ε∗i − εj)
µ
(2.113)
where ε∗ and ε are energy levels of unoccupied and occupied orbitals, respec-
tively. If ωnmax is the maximum vibrational frequency of the nuclear system, in order
to perform adiabatic dynamics it must be ωegap >> ωnmax. As the only tunable param-
eter is µ, one could decrease it arbitrarily to increase the frequency of the gap ωemin.
However, decreasing µ stretches the entire spectrum {ωeij} and in particular increases
ωemax, which is inversely proportional to the maximum time step. Typical values of
µ are in the range 500 − 1500 a.u., which allow for a time step of about 5 − 10 a.u.
(0.12−0.24 fs). For calculations discussed here we used µ = 600 a.u. and a time step
of 5 a.u.
2.7 Hybrid Models
Pure Quantum calculations are today restricted to the treatment of at most a few hun-
dreds of atoms. Classical Molecular Mechanics, on the other hand, can deal with
systems containing 105− 106 atoms, but cannot take into account the quantum nature
of chemical bonds. Since most of times the relevant chemistry of a biological pro-
cess is restricted to a small subset of atoms, hybrid schemes have been developed that
model different parts of the system at a different level of modeling [173,174,175,176].
These schemes allow to evaluate the effect of the biological environment on chemical
processes, and represents thus an improvement over a quantum calculation in vacuo.
In particular a widely adopted approach is to partition the system into two regions
and to treat one at Quantum Mechanics and the other at Molecular Mechanics levels.
Such approach, as implemented in the CPMD code [177], has been used in the works
reported in this thesis, and is based on a single hybrid Hamiltonian:
H = HQM +HMM +HQM/MM (2.114)
whereHQM is the quantum Hamiltonian,HMM is the Molecular Mechanics Hamil-
tonian and HQM/MM is the Hamiltonian describing the interaction between the two
subsystems. For the purpose of describing each term in eq. 2.114, let start by con-
sidering the total system (QM+MM) as described uniformly at quantum level and by
(artificially) partitioning the system in the QM and MM regions. According to the
Hohenberg-Kohn theorem, the total energy of the system is given by the following
48 Methods
functional:
E[ρ] = T [ρ]+
∫
Ω
V ext(r)ρ(r)dr+
1
2
∫ ∫
ρ(r1)ρ(r2)
r12
dr1dr2 +
1
2
∑
I,J
ZIZJ
RIJ
+Exc[ρ]
(2.115)
where T and Exc are the kinetic and exchange-correlation energy functionals,
respectively; V ext is the electrostatic potential of the nuclei, r12 and RIJ the inter-
electronic and internuclear distances and ZI and ZJ the nuclear charge of atom I and
J , respectively. By partitioning the total electronic density into the two contributions,
ρQM+MM = ρQM + ρMM , the total energy can be rewritten as:
E[ρQM+MM ] = E[ρQM ] + E[ρMM ] +
∫ ∫
ρQM(r1) ρMM(r2)
r12
dr1dr2
+
∑
I ∈ QM
J ∈MM
ZIZJ
RIJ
+ ENLxc + T
NL (2.116)
where ENLxc = Exc[ρQM + ρMM ]− Exc[ρQM ]− Exc[ρMM ] and TNL = T [ρQM +
ρMM ]−T [ρQM ]−T [ρMM ] arise from the nonlinearity of the kinetic and exchange and
correlation functionals. In eq. 2.116, the term E[ρQM ] is treated at the quantum level,
while each contribution to E[ρMM ] is approximated by using a force field, function of
the nuclear coordinates only. In particular, as force fields are parametrized at a fixed
value of the electronic density, the kinetic energy functional is an additive constant
which can be neglected. In this context, the energy Exc is approximated by a Lennard-
Jones pair-additive potential:
Exc ≈
∑
I,J∈MM
4ǫIJ
((
σIJ
RIJ
)12
−
(
σIJ
RIJ
)6)
. (2.117)
The remaining three term of eq. 2.115 describe the nuclear-electronic, electronic-
electronic, and nuclear-nuclear charge densities electrostatic energies. In the force-
field spirit, the total contribution to the energy is represented by the interaction energy
among effective point charges located at the nuclear positions:
∫
Ω
V ext(r)ρ(r)dr +
1
2
∫ ∫
ρ(r1)ρ(r2)
r12
dr1dr2 +
1
2
∑
I,J∈MM
ZIZJ
RIJ
≈ 1
2
∑
I,J∈MM
qIqJ
RIJ
(2.118)
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The chemical bonding cannot be described by solely Lennard-Jones and point
charges electrostatic interaction energy, thus bonded terms as in eq. 2.47 have to be
added to the MM energy. The most interesting part of eq. 2.116 concerns the interac-
tion between the two subsystems. Using for TNL and ENLxc the same approximation
as above, we can express the interaction energy as:
E[ρQM/MM ] =
∑
I∈MM
∫
Ω
qI
|RI − r|ρ
el+nuc
QM (r)dr
+
∑
I ∈ QM
J ∈MM
4ǫIJ
((
σIJ
RIJ
)12
−
(
σIJ
RIJ
)6)
+
∑
bonds
Kr(r − req)2 +
∑
angles
Kϑ(ϑ− ϑeq)2
+
∑
dihedrals
Vn
2
[1 + cos (nφ− γ)]
(2.119)
where bonds, angles and dihedrals involve at least one QM atom. Notice that in
eq. 2.119 the term TNL has been neglected while for ENLxc the force-field approxi-
mation has been used. In this formulation the electrostatic potential provided by the
effective classical point charges polarizes the QM electronic charge density. It should
be noted that the presence of a discontinuous QM/MM interface introduces a series
of artifacts. One of the most serious is the so-called link atom problem. When a
chemical bond involves atoms on the two subsets, the QM system will contain by
construction unsaturated valencies and has to be made chemically inert. Two ap-
proaches are mainly used to deal with this problem. The first consists of the use of a
monovalent pseudopotential situated at the position of the MM involved in the bond
crossing the QM/MM interface. In the CPMD code an analytical non-local pseudopo-
tential of the Goedecker type [178] is used. The second approach introduces capping
atoms (usually hydrogens) to saturate chemical bonds at the interface. It should be
pointed out that the latter strategy introduces additional artifacts and a correction for
the interactions between the “ghost” atoms and the classical environment is required.
Furthermore the approximation of ENLxc by a purley classical term, i.e. not involving
QM electronic degrees of freedom, results in the so-called electron spill out problem.
Due to the fact that the MM region contains no electrons, those of the QM part are
no longer repelled by closed-shell cores of the atoms belonging to the MM region.
The effect of the missing Pauli repulsion is to artificially localize electrons on MM
positive point charges. In order to avoid this artifact a pseudopotential-like approach
can be applied by replacing the classical point charges Coulomb potential with a suit-
able function vI(|r−RI|), which ensures the correct 1/r behaviour for large r and
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goes to a finite value for r → 0. The first term of eq. 2.119 is thus replaced by the
following quantity:
EelecQM/MM =
∑
I∈MM
qI
∫
Ω
ρel+nucQM (r)vI(|r−RI|)dr . (2.120)
In particular an appropriate form for vI(|r−RI|) is:
vI(|r−RI|) = r
4
cI − r4
r5cI − r5
, (2.121)
where rcI is the covalent radius of atom I . This functional form resembles that ob-
tained by smearing the MM point charges into Gaussian charge distributions of finite
width. In the context of plane-waves, the QM/MM scheme devised above cannot be
used for practical purposes without an additional approximation. Indeed, the quantum
charge distribution is distributed on a grid of Nr ∼ 1003 points, so that an exact evalu-
ation ofEelecQM/MM would involveNr×NMM operations, withNMM ≥ 105. Therefore,
this interaction term is split into a short and a long-range part, in a way reminishent
of the Ewald method [136]. The direct evaluation of the integral in eq. 2.120 is done
only for a subset (NN) of MM atoms. The latter is defined in such a way as to include
all non neutral atoms belonging to charge groups with at least one atom inside a shell
of thickness Rc around any QM atom. The rest of MM atoms belong to the second
shell. For those, the electrostatic interaction with the QM system is calculated using
for the charge density of the QM system a multipolar expansion around the geometri-
cal center of the quantum system r¯α = 1/NQM
∑
I rI up to the quadrupole order. In
particular, the electrostatic interaction Hamiltonian can be expressed as:
Helec =
∑
j∈NN
qj
∫
drρ(r)vj(|r− rj|) +Hlr (2.122)
where Hlr is defined as:
Hlr = C
∑
j /∈NN
qj
τj
+
∑
α
Dα
∑
j /∈NN
qj
τ 3j
ταj +
1
2
∑
αβ
Qαβ
∑
j /∈NN
qj
τ 5j
ταj τ
β
j (2.123)
with ταj = rαj − r¯α; C, Dα and Qαβ are the total charge, the dipole and the
quadrupole of the electronic charge distribution, respectively. The potential entering
into the Khon-Sham Hamiltonian is given by the functional derivative of Helec with
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respect to the density ρel:
V (r) =
δHelec
δρel
=
∑
j /∈NN
qj
τj
+
∑
α
(rα − r¯α)
∑
j /∈NN
qj
τ 3j
ταj
+
1
2
∑
αβ
[
3(rα − r¯α)(rβ − r¯β)− δαβ |r− r¯|2] ∑
j /∈NN
qj
τ 5j
ταj τ
β
j
(2.124)
The forces on the atom arising from Helec are obtained by taking the derivatives
with respect to the atomic positions. These are for the QM , NN and classical atoms
not belonging to the NN set:
F γj =
1
NQM
[
−5
2
∑
αβ
Qαβ
∑
k/∈NN
qk
τ 7k
ταk τ
β
k τ
γ
k +
∑
α
Qαγ
∑
k/∈NN
qk
τ 5k
ταk
]
,
for j ∈ QM (2.125)
F γj = qj
∫
drρ(r)gj(|r− rj|)
rγ − rγj
|r− rj| ,
for j ∈ NN (2.126)
F γj = −qj
[(
−C
τ 3j
− 3
τ 5j
∑
α
Dαταj −
5
2τ 7j
∑
αβ
Qαβταj τ
β
j
)
τ γj +
Dγ
τ 3j
+
1
τ 5j
∑
α
Qαγταj
]
for j /∈ NN,QM (2.127)
where gj(r) = dvj/dr. This two level coupling scheme can also be refined in-
troducing an intermediate third layer in which the charge density of the QM system
is replaced by variational D-RESP charges [179]. In the work exposed in the thesis I
have used the implementation of QM/MM realized in the code CPMD [177], which
has been interfaced to the AMBER [24, 25, 131] force field. The code is available for
free with the CPMD package (www.cpmd.org).
2.8 Free Energy calculations
The calculation of free energies and the molecular-level description of rare events are
probably the fields where biomolecular simulation has most demonstrated its power,
often giving insights which are not directly accessible to experiments [72, 180, 181].
A number of elegant and powerful methods [182, 183, 184, 185, 186, 187, 188, 189,
180] have been developed allowing to characterize the thermodynamics of processes
like chemical reactions [104, 190, 191, 192], ligand binding [193, 194, 195, 196, 197,
198], “alchemical” mutations [70, 76, 199, 200] and conformational changes between
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relevant states of biomolecules (e.g. B and Z conformations of DNA [201, 202]). It
is well-known that thermodynamics is intimately related to Statistical Mechanics: the
achievement of a reliable estimate of the free energy change accompanying a process
depends on how well the phase-space is sampled in a computer simulation. Thus,
enhancing the sampling of thermodynamically unlikely states is the primary scope of
methods for the calculation of free energies. This represent a particular challenge in
biology, due to the ruggedness of free energy profiles of complex macromolecules.
In the following I review the methodologies used here to calculate the free energies
of drug sliding within the minor groove and unbinding from oligonucleotides. These
schemes rely on the definition of few coordinates {sj}, called collective variables
(CVs) or reaction coordinates, which are believed to be relevant for the process under
study. This means that they are slow, i.e. change very little during the course of a
standard MD or MC run. Thus, enhancing their sampling will allow to simulate the
rare event and to accurately calculate the associated free energy ∆F as a function of
the CVs, which takes the name of Potential of Mean Force (PMF) [203]. Among the
various ways to enhance the exploration of the phase space, one consist in adding to
the original potential energy function U(x) a biasing term in the CVs space, which
forces the system to visit interesting configurations. The following scheme depicts
the passage from the absolute to this reduced representation:
x ≡ {xi} , i = 1, ..., 3N ←→ F = − 1β lnZ
↓ ↓
s ≡ {sj} , j = 1, ..., NCV ←→ F (s) = − 1β lnP (s)
where β = kBT , N is the number of particles, NCV is the number of collective
variables, Z is the canonical configuration partition function, and P is the probability
to find the system in a state corresponding to a given value s of the reaction coordi-
nates. For ergodic systems, this is equal to the distribution function along s:
P (s) = lim
t→∞
1
t
∫ t
0
dt δ (s− s(t)) ≡ ρ(s) =
∫
dxδ (s− s(x)) e−βU(x)
Z (2.128)
where the dependence of s on the coordinates x has been explicited. At this point
it is important to say that also in the case s is a “good” reaction coordinate, estimating
∆F as a PMF is an intrinsically ill-defined approximation. Indeed, considering a
reversible change of variable s → q, the PMF as a function of these two CVs will
not be the same. In fact, due to the invariance property of the probability distribution,
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whose integral is indipendent from the chosen coordinate9:
P (s)ds = P (q)dq ⇒ F (q) = F (s) + 1
β
ln
(
dq
ds
)
(2.129)
This relation confirms that the choice of the CVs is fundamental in all the pro-
cesses being studied within a PMF approach.
2.8.1 Umbrella Sampling
The Umbrella Sampling method [183] realizes a non-Boltzmann sampling in the
phase space by introducing a modified distribution function. In general, the free en-
ergy difference between two systems, the “interesting” and “reference” one, with
internal energies U(x), U0(x) and inverse temperatures β and β0, can be written
as [183, 135]:
∆F ∗ = βF − β0F0 = − ln
∫
dx
[
e−βU(x)+β0U0(x)
]
e−β0U0(x)
Z0 = − ln
〈
e−∆U
∗(x)
〉
0
(2.130)
where the subscript 0 means that the average is on the reference system, and
F ∗ = βF and U∗(x) = βU are the reduced free and internal energies, respectively.
Now, ∆U∗ will be large (and e−∆U∗ small) for the configurations corresponding to
the interesting system (i.e. those for which the reduced internal energy is close to
U∗), unless this is very similar to the reference one. Indeed, the average ensemble is
performed on this latter, which very rarely will sample configurations of the interest-
ing system. Thus, we are lacking almost one half of the sampling needed to obtain a
reliable estimate of F ∗. This can be better understood if one rewrites 2.130 as:
∆F ∗ = − ln
∫ ∞
−∞
d∆U∗ ρ0 (∆U∗) e−∆U
∗ (2.131)
with ρ0 (∆U∗) being the probability density of ∆U∗ in the reference system. By
definition, ρ0 will be peaked at a value of ∆U∗ given by the difference between the
average energies of the two systems, 〈U∗〉 − 〈U∗0 〉0, and will decay to zero for small
∆U∗. However, the exponential in Eq. 2.131 will give the largest contributions just
for small ∆U∗. Therefore, the most important contribution to the integral will be
poorly evaluated in every finite-length simulation, rendering the estimation of ∆F ∗
9 This equation can be derived from the expression of F (s) using the relation
δ (q(s′)− q(s(x))) = δ (s
′ − s(x))
|dq/ds|
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inaccurate. Torrie and Valleau [183] introduced a bias to sample configurations in a
wider ∆U∗ range, through a new non-Boltzmann probability function:
ρw(x) =
w(x)e−β0U0(x)∫
dxw(x)e−β0U0(x)
(2.132)
w(x) = w(∆U∗) is a weighting function chosen to sample configurations corre-
sponding to significative values ∆U∗ in the integral 2.131. Notice that all of these
significative values should be sampled, corresponding to both the reference and inter-
esting systems. In other words, the requirement for the weighting function is to flatten
the profile of the distribution function in order to cover the range between them like
an umbrella (hence the name). The unbiased average of any observable O can be
easily recovered from the biased ensemble:
〈O〉 =
∫
dx [O(x)/w(x)]w(x)e−β0U0(x)∫
dx [1/w(x)]w(x)e−β0U0(x)
=
〈O/w〉w
〈1/w〉w
(2.133)
where 〈 〉w indicates averaging over the distribution ρw. From the biased sampling
one can also recover the unbiased probability density
ρ0(∆U
∗) =
ρw(∆U
∗)/w(∆U∗)
〈1/w(∆U∗)〉w
(2.134)
The improved ρ0, evaluated through eq. 2.133 in a wider range than from a Boltz-
mann sampling, can be used to calculate with a greater accuracy the reduced free
energy difference ∆F ∗. As rule of thumb ρw should extend the range of energies
sampled by at least three times.
In terms of PMF, the enhanced sampling of the configuration space can be obtained
by adding to U(x) a biasing potential Uw(s(x)) that depends on x only through the
CVs.
The unbiased probability distribution ρ(s) can be derived from ρw(s) through the
following relation:
ρw(s) =
∫
dx δ (s− s(x)) e−βUw(s(x))e−βU(x)
Zw
= e−βUw(s)
∫
dx δ (s− s(x)) e−βU(x)
Z
Z
Zw
= ρ(s)e−βUw(s)efw
(2.135)
where
fw =
1
β
ln
Z
Zw
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Thus, the unbiased PMF F (s) is given by:
F (s) = − 1
β
ln [ρw(s)]− Uw(s(x))− fw (2.136)
Note that fw is a constant independent of s, which can be safely neglected when
calculating free energy differences.
Error evaluation
We derive an expression for the standard deviation of F (s) and ρw(s) in a finite-length
simulation (considering a one-dimensional profile for simplicity). In an umbrella
sampling simulation ρw(s) is estimated after discretization of the CVs space as:
ρw(s) ∼ 1
m∆s
m∑
k=1
χs(sk) (2.137)
where s1, ..., sm are the values assumed by the collective variable, and χs = 1
if sk ∈ [s, s + ∆s] and zero otherwise. Assuming that the sk are uncorrelated, if
p = ρw(s)∆s is the probability that sk ∈ [s, s + ∆s], the probability to observe i
out of m entries within the interval [s, s + ∆s] is given by the Poisson distribution
(m→∞):
Pp,m (i) = ν
ie−ν
i!
(2.138)
with ν = pm. For this distribution, we have
〈
i
m
〉
= p and
〈
i2
m2
〉
= p2 + p
m
10
,
hence the variance on ρw(s) is:
σ2(ρw(s)) =
ρw(s)
m∆s
=
1
m2∆s
m∑
k=1
χs(sk) (2.139)
A constant variance is obtained if ρw(s) itself is a constant, which implies (eq. 2.136)
Uw(s) = −F (s) for each value of the CVs (up to a constant). The variance on the
free energy will be:
σ2(F (s)) =
1
β2
σ2(ρw(s))
(ρw(s))2
=
1
β2
1
(m∆s)2 σ2(ρw(s))
(2.140)
10 For example〈
i
m
〉
=
m∑
i=1
i
m
νie−ν
i!
=
e−ν
m
m∑
i=1
ν
νi−1
(i− 1)!
m→∞−−−−→ e
−ν
m
ν [eν ] = p
and a similar derivation can be made for
〈(
i
m
)2〉
.
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which is also independent on s if one requires σ2(ρw(s)) to be constant.
2.8.2 Weighted Histogram Analysis Method
A single biased simulation is usually not enough to obtain a reliable F (s) over the
required range of s. Indeed, we have seen that to have a flat σ2(F (s)) we would know
the free energy itself, and this can be only be done approximatively or iteratively
within a limited interval. To cope with this problem, a number Nw of simulations
can be performed each with different bias potentials, covering adjacent windows in
the CVs space. The results from each window then need to be unbiased and glued
together into a single PMF. Among the various algorithms proposed, the Weighted
Hystogram Analysis Method (WHAM) [184,185] has proven to be very efficient and
almost free of information-loss. The main idea, which goes back to the hystogram
method developed by Ferrenberg and Swensden [204, 205], consist in constructing
ρ(s) as weighted sum of the unbiased distribution functions extracted from each win-
dow
ρ(s) = A
Nw∑
i=1
πi(s)ρi(s) . (2.141)
The weigths are functions of s, and are chosen as to minimize σ2(ρ(s)), subject
to normalization
∑
i πi(s) = 1. Thus they are determined using the Lagrange λ
multiplier method:
δ
δπj(s)
[
σ2(ρ(s))− λ
(∑
i
πi(s)− 1
)]
=
δ
δπj(s)
[
A2
∑
i
π2i (s)σ
2(ρi(s))− λ
(∑
i
πi(s)− 1
)]
= 2A2πj(s)σ
2(ρj(s))− λ = 0
(2.142)
which, after writing λ/2A2 = 1/
∑
i [σ
2(ρi(s))]
−1 (from normalization), gives:
πj(s) =
[σ2(ρj(s))]
−1∑
i [σ
2(ρi(s))]
−1 (2.143)
Thus, the most accurate ρj will have the largest weigth when composing the total
distribution function. In a real simulation is clearly useful to express the weigths in
terms of the known biasing potentials Uwi. From eq. 2.135, one has
σ2(ρi(s)) =
[
eβ[Uwi(s)−fwi]
]2
σ2(ρwi(s)) , (2.144)
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which by insertion of eq. 2.139 gives:
πj(s) =
mje
−β[Uwj(s)−fwj ]∑
imie
−β[Uwi(s)−fwi] (2.145)
where mj is the number of sampled points in the j-th window. Thus, the weigths
depends on the parameters fwj , that in turn are function of the πj:
e−βfwj =
Zwj
Z =
∫
ds ρj(s)e
−βUwj(s)
= A
∫
ds e−βUwj(s)
Nw∑
k=1
πk(s)ρk(s)
= A
∫
ds e−βUwj(s)
∑Nw
k=1 mkρwk(s)∑
imie
−β[Uwi(s)−fwi]
(2.146)
Thus, eqs. 2.145 and 2.146 have to be solved with a self-consistent procedure.
The variance of the free energy can be obtained straigthforwardly from eq. 2.140:
σ2(F (s)) =
1
β2
∑
i π
2
i (s)σ
2(ρi(s))
[
∑
i πi(s)ρi(s)]
=
1
β2
1∑
imiρwi(s)
(2.147)
Notably, the error on the free energy can be made as constant as the cumulative
histogram in the denominator of eq. 2.147 is uniform, and it is independent on the
form of the biasing potential (no approximate knowledge of the free energy on the
explored range is required). The only need is to have ρwi(s)’s from adjacent windows
whose tails are overimposed in order to get a uniform histogram: this can be always
done by adjusting the sampling on a given window or introducing a new one to fill a
hole in the overall probability distribution.
2.8.3 Metadynamics
The main idea behind metadynamics [189] is to drive the evolution in the space of
CVs by adding to the thermodynamic force, coming from the free energy F (s), a
force due to a history-dependent biasing potential FG(s, t). The bias potential is con-
structed as a sum of Gaussians deposed along the trajectory of the CVs up to time t.
The method can be seen as the finite temperature extension of the Wang and Landau
algorithm [206], and is related in the spirit to taboo search [207], local elevation [208]
and adaptive bias force [187]. The most important property of metadynamics is that
the biased trajectory proceeds by filling valleys in the free energy surface [189], so
that the system tends to escape from every stable state. After a long enough time t
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the sum of the Gaussians deposed along the trajectory will counterbalance the free
energy landscape, allowing to estimate the free energy itself:
lim
t→∞
FG(s, t) = F (s) (2.148)
It can be shown that the above relation is true under rather general assump-
tions [209]. In real cases, the time needed for considering eq. 2.148 to be valid can
be estimated by visual inspection of the trajectory of the CVs: when the FG(s, t)
counterbalances the free energy F (s), the CVs have a diffusive behaviour. If one uses
simultaneously 2 or more CVs is not necessary to know a priori the reaction path in
metadynamics. The force due to the history-dependent potential naturally drives the
system through the Lowest Free Energy Path (LFEP), i.e. the most likely reaction
path [210]; after the crossing of a barrier the system naturally goes towards a new
and possibly unpredicted metastable state. For this reason the method has found a
large use not only for predicting free energies, but also for accelerating rare events
and investigating molecular mechanism of biological processes. Obviously, as for all
the methods based on dimensional reduction, the chosen CVs must describe some-
what the process of interest. Nevertheless, many application have shown that choos-
ing general and flexible CVs allows discovering unknown stable states and reaction
mechanisms [211, 212]. The work exposed in this thesis has been done choosing as
CVs the distance between the centers of mass of molecular groups and coordination
numbers. Here I first describe the “discrete” version of the algorithm, which has been
introduced by Laio and Parrinello in 2002 [189], along with some of the modifica-
tions introduced later to enhance its efficiency and accuracy [213,209]. The so-called
“continuous” version, which has been used in the work exposed in this thesis, can be
simply derived from the discrete one by discarding the evaluation of the thermody-
namic force (speeding-up the algorithm).
In discrete metadynamics the CVs are evolved step by step. A multidimensional
Gaussian of width δs = (δs1, ..., δsNCV) and height w is deposed at position s(x, t)
every time metastep τG. Thus, at time t the free energy underlying the dynamics of
the CVs is given by:
F˜ (s(x), t) = F (s(x)) + FG(s(x), t) = F (s(x)) + w
ntG∑
j=1
NCV∏
i=1
e
−
»
si(x)−si(x(jτG))√
2δsi
–2
(2.149)
where the number ntG of Gaussians deposed at time t is given by the integer clos-
est to t/τG. In order to simplify matter the CVs space can be rendered approximately
spherical by rescaling all the CVs si to their thermal fluctuations
√
(si − 〈si〉)2,
which can be evaluated at the starting minimum through an unbiased dynamics. In
this way spherical Gaussians can be used, for which the width is the same in all the
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directions, δsi = δs, ∀ i. From eq. 2.149 it can be seen that the dynamics of the CVs
is driven by two forces:
• the thermodynamic force, evaluated at st = s(x(t)):
f thi
∣∣
t
= − ∂
∂sti
F (s) . (2.150)
Following Sprik and Ciccotti [214], these forces are estimated through the Con-
strained Reaction Coordinate Dynamics (CRCD) algorithm, adding to the nor-
mal Lagrangian of the system a restraining term
∑NCV
i=1 λi(si − si(x(t)). By
averaging over the time, in the absence of inertial terms, the components of
the thermodynamic force are given by f thi = 〈λi〉. Thermodynamic forces are
evaluated in the time between two subsequent hill depositions.
• the history-dependent force at time t, whose components are:
fGi
∣∣
t
= − ∂
∂sti
w
ntG∑
j=1
NCV∏
i=1
e
−
»
si(x)−si(x(jτG))√
2δsi
–2
(2.151)
which discourage the system to visit the same region in the CVs phase space.
The metadynamics of the walker in the CVs space thus is regulated by the follow-
ing discrete equation of motion (I removed the superscript t for simplicity):
s(t+ τG) = s(t) + δs · f˜∣∣∣f˜ ∣∣∣ (2.152)
f˜ = f th + fG (2.153)
Equation 2.152 was introduced firstly in Ref. [189]. Subsequently, three correc-
tions were applied in order to enhance accuracy and reduce sistematic errors:
1. To improve efficiency, the Gaussians are shifted with respect to the position of
the walker. In fact, if the thermodynamic force at time t is evaluated at the same
point where the Gaussian is placed, the total force felt by the walker will be the
same as in the previous metastep. In order to compensate the thermodynamic
force is better to depose the Gaussian at a distance δs from s(t) in the direction
of the thermodynamic force.
2. To reduce the correlation induced by depositions with constant step, at every
iteration the metastep is chosen randomly from a uniform distribution with two
limiting values (e.g. δs and 1.5 δs).
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3. When the metadynamics is terminated FG will present a bump in the region
around the last hill; the spread of this bump depends on the correlation time
of the metadynamics. In order to reduce these spatial correlations in the free
energy the contributions of the Gaussians placed at the end of the dynamics
are weighted less. In Ref. [213] each term of the sum in eq. 2.149 has been
multiplied by tanh
(
(ntG−j)τG
τc
)
, where τc is larger than the typical time required
to sweep the “filled” CVs space, j is the metastep number and ntG is the total
number of metasteps at time t.
With the modification listed above, eqs. 2.152, 2.153 and 2.149 become:
s(t+ τG) = s(t) + ∆s · f˜∣∣∣f˜ ∣∣∣ , ∆s ∈ [δs, αδs], α > 1 (2.154)
f˜i = f
th
i −
∂
∂sti
w
ntG∑
j=1
NCV∏
i=1
e
−
˛˛
˛˛˛
˛˛
si(x)−si(x(jτG))−δsi
f˜i
|f˜ |√
2δsi
˛˛
˛˛˛
˛˛
2
(2.155)
F˜ (s(x), t) = F (s(x)) + w
ntG∑
j=1
NCV∏
i=1
tanh
(
(ntG − j)τG
τc
)
e
−
˛˛
˛˛
˛˛
˛
si(x)−si(x(jτG))−δsi
f˜i
|f˜ |√
2δsi
˛˛
˛˛
˛˛
˛
2
(2.156)
In the continuous version of metadynamics the system is not constrained between
two successive metasteps in order to evaluate thermodynamic forces; these latter in-
deed are not calculated at all. This is equivalent [209] to evolve the CVs continuosly
(at every MD step, altough this is not done in practice for reasons of efficiency).
The system evolve under the action of the history-dependent forces only, which act
directly on the cartesian coordinates:
fG(t) = − ∂
∂x
w
τG
∫ t
0
dt′
NCV∏
i=1
e
−
»
si(x)−si(x(t′))√
2δsi
–2
(2.157)
where the parameter w
τG
controls the Gaussians deposition rate and x(t) is the
trajectory of the system. It has been shown [209] that the reconstructed Free Energy
does not vary for constant ratios w
τG
along a quite large interval for τG (in classical
MD the invariance has been demonstrated up to τG = 5 ps). The reconstructed free
energy is given by:
FG(s, t) =
w
τG
∫ t
0
dt′
NCV∏
i=1
e
−
»
si−si(x(t′))√
2δsi
–2
(2.158)
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and it is an approximation of the F (s) in the CVs region explored up to time t.
Efficiency and Accuracy. It can be demonstrated [209] that the error on the cal-
culated F (s) is proportional to the height barrier w; furthermore, with the improve-
ments achieved with eqs. 2.154,2.155,2.156, a single metadynamics run has shown
to already give a very good estimate of the profile, with an error approximately con-
stant in the region where the number of accumulated Gaussians is significant (con-
ventionally this means that F (s)/w ≥ 5. Obviously the width of the Gaussian also
influences the efficiency and the accuracy of the method. In particular, using hills of
width larger than typical thermal fluctuations can lead to “bury” some thermodynamic
state corresponding to narrow minima. Finally, the accuracy in the evaluation of the
thermodynamic force enters in the overall error.
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Part II
Drug/DNA interactions and molecular
recognition
Chapter 3
Characterization of
Anthramycin/DNA adducts
3.1 Introduction
Pyrrol[1,4]benzodiazepines (PBD’s) cytotoxins [215] exert a powerful antitumoral
activity [98, 216] by covalently binding to the minor groove of B-DNA. All PBD’s
share a condensed three ring moiety featuring a right-handed twist between the phenol
and pyrrol rings (rings A and C in Chart I), which allows them to snugly fit into
the backbone of B-DNA. In spite of their low molecular weight, PBD’s are quite
sequence-selective, recognizing codes 3 ÷ 7 base pairs (bps) long [217, 218]. Drug
binding is believed to proceed by formation of a non-covalent complex (Step I) [219]:
DNA+ PBD
KB
⇋ (DNA • PBD)noncov
followed by a covalent linkage (Step II):
(DNA • PBD)noncov kr→ (DNA− PBD)cov
The molecular recognition process is supposed to be driven by (non-specific) non-
bonded interactions and sequence-specific structural features, rather than by specific
H-bond patterns [18]. However, the molecular details of this process are not yet
fully understood. A PBD derivative, anthramycin [99] (Chart I), is one of the very
few organic minor groove covalent binders for which the X-ray structure of the co-
valent complex with an oligonucleotide is available. This drug covalently binds to
the exocyclic amino group of guanine through the C11 carbon [99, 220], showing a
modest sequence selectivity for guanines embedded in Pu-G-Pu sequences (namely
AGA-5’>AGG-5’≈GGA-5’>GGG-5’) [217, 219, 218, 221]. The investigation of
DNA/PBD complexes may provide useful insights on the factors affecting both re-
activity and binding of minor groove covalent binders. In fact, although anthramycin
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is cardiotoxic [98,222], a number of its derivatives have shown improved antitumoral
activity. In particular, the dimer SJG-136 [223, 224] is currently in Phase I clinical
trials in both UK and USA. In addition, PBD’s have also being used as components of
a gene targeting strategy [225,15] aiming at designing molecules able to target a spe-
cific cancer-related gene. Prompted by the biological and pharmacological relevance
of PBD’s, we performed molecular dynamics (MD) simulations on both the hydroxy
and anhydro putative reactive forms of anthramycin (Chart I) in complex with DNA.
Previous computational studies on PBDs have been performed without inclusion of
explicit waters and counter-ions [222, 226, 227, 228], which are very important to
accurately simulate nucleic acids and their complexes [36, 38, 35], as well as their
reactivity [229]. The main aim of our investigation is to obtain insights on Step I of
the reaction. The drugs are initially positioned in front of the reactive guanine G∗ of
d[GCCAACGTTG∗GC]d[GCCAACGTTGGC], based on the X-ray structure of the
covalent complex [99]. Our simulations show that both the drugs, docked in front
of the reactive site, induce structural deformations on the DNA frame at its central
region, while for the covalent adduct the most significant distortions are seen at the
binding region. Interestingly, anhydro-anthramycin slides by one base pair step to-
wards the centre of the oligonucleotide after ∼ 10ns, where it is stable for the rest of
the simulation; this process causes both an energetic and structural relaxation of the
complex. Instead, the hydroxy form oscillates around the reactive site for the whole
dynamics. Our MD simulations are complemented by a quantum chemistry investiga-
tion of environmental effects on the reactivity of the drug and G10 in the two adducts.
By using a hybrid QM/MM method [176], we show that the DNA frame influence
significantly the electronic distribution on the reactants; in particular, it appears to
polarize the anhydro form of the drug in a way favourable to the alkylation reaction.
3.2 Systems and Methods
3.2.1 Classical MD simulations
The following system have been investigated in aqueous solution:
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Covalent complex: We built our model (ANT-DNA hereafter) starting from the X-
ray structure of two anthramycin molecules covalently linked to the oligonucleotide
d[CCAACGTTG∗G]2 [99]. To asses the structural impact of binding, we remove one
of the two drugs present in the experimental structure. To limit artifacts associated to
terminal effects, we added one CG base pair (bp) at each end.
Non-covalent complexes: Hydroxy-anthramycin•d[GCCAACGTTG∗GC]d[GCC-
AACGTTGGC] (ANT•DNA) and anhydro-anthramycin•d[GCCAACGTTG∗GC]-
d[GCCAACGTTGGC] (IMI•DNA) complexes were built: i) cutting the bond be-
tween the C11 of the drug and the N2 of deoxyguanine, and manually pulling out
the drug perpendicularly to the minor groove, until distance N2-C11 was ∼ 3.5 ; ii)
adding the OH group on C11 in the case of ANT•DNA, or removing an H atom
from N10 in the case of IMI•DNA (see Chart I); iii) optimizing in vacuo the geome-
tries of the drugs at the B3LYP-6-31G(d) [156, 161, 157] level of calculations with
Gaussian [230].
Reference systems: i) DNA, which is the 12-mer d[GCCAACGTTGGC]d[GCCA-
ACGTTGGC] in the B conformation, and was constructed with the nucgen module
of the AMBER package [231], ii) hydroxy-anthramycin (ANT) and iii) anhydro-
anthramycin (IMI). Because we observed a sliding of IMI along the oligonucleotide
(see Results), we constructed an additional complex between IMI and the 14-mer
d[CAACGTTG∗GCCAAC]d[GTTGGCCAACGTTG] (IMI•DNAc). This latter has
been built taking IMI•DNA as template (so that the mode of binding of the drug is
the same as in IMI•DNA), removing the first two d[GC]d[GC] bps and adding the
d[CAAC]d[GTTG] duplex at the end near to the drug. The simulation of IMI•DNAc
allowed us to check whether such a sliding occurs also if the ligand is located in the
central part of the oligonucleotide.
The DNA-containing systems were neutralized by adding sodium counter-ions.
All the systems were immersed in water boxes allowing for a solvent shell extending
for at least 12 Å around each solute atom (see Table 3.1 for detailed information).
The oligonucleotide (except for the nucleoside G∗ in ANT-DNA) was parametri-
zed using the refined Cornell et al. force field [24, 25, 131], while TIP3P [232] and
Aaqvist [233] models were used to represent water and sodium ions respectively. The
ANT-DNA ANT•DNA IMI•DNA IMI•DNA(c) DNA ANT IMI
box (Å3) 58×72×58 60×62×66 64×59×66 66×67×78 56×55×56 45×36×35 47×47×46
waters 6000 7700 8000 8900 5500 1900 2900
Na+ 22 22 22 26 22 - -
time (ns) 21 19 19 20 21 6 10s
Table 3.1: Box dimensions, number of waters, number of counterions, and simulated time
for the various system.
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structural parameters of the drugs were taken from the gaff [234] database, or con-
structed with the parmcal module of the AMBER package [231], while RESP [134]
charges were obtained using the resp utility of AMBER after minimization of the elec-
tronic structure with Gaussian [230]. The nucleoside G∗ in ANT-DNA was parametri-
zed using the same scheme. Periodic boundary conditions were used, and the electro-
static interactions were calculated with the particle-mesh Ewald method (PME) [137],
using a 12 Å cutoff for the real part, as for the van der Waals interactions. NPT sim-
ulations at 300K and 1 atm were performed using the Nosé-Hoover [121, 122] ther-
mostat and the Andersen-Parrinello-Rahman [123,126] pressure-coupling scheme. A
time step of 1.5 fs was set for all the simulations. H-bond lengths were constrained
using the lincs algorithm [235], and the translational and rotational motions of the
center of mass of the solute were removed every 25 MD steps.
Before starting the dynamics, all the systems underwent geometry optimization in
two steps: the first with an harmonic restraint of k = 150 kcal/mol imposed to the
solute; the second without any restraint. Then, the systems were heated up linearly
to 300K in 100 ps of NVT MD (namely the temperature was increased by 15K each
5 ps), and, as a last step preceeding the productive dynamics, 200 ps of NPT runs
were carried out. Multi-ns trajectories were finally collected (Table 3.1), for a total
of ∼ 140ns. Although it has been show that the sampling of counter-ions motion
requires very long times [52], according to recent publications [236, 62, 34] the time
intervals spanned in our simulations provide good statistic on DNA conformational
and helicoidal parameters.
All the simulations were performed using the GROMACS package [237, 238].
The structural parameters of DNA were calculated with the program Curves [239,
239]. The minor groove widths were defined as the distances between sugar C4′
atoms, subtracted by two carbon van der Waals radii [99]. A propeller twist and a
buckle angle between the pyrrol and the phenol rings of the drug were also defined,
according to Ref. [99]. The relative energies of non-bonded interactions were esti-
mated using the terms in the AMBER force field [231, 25, 131]. The molecular Sol-
vent Accessible Surface Area (SASA) [240] of various molecules was calculated with
GROMACS [238], using a probe radius of 1.4 Å. The variation in the hydrophobic
SASA, which is proportional to the non-polar free energy of solvation, was evaluated
as ∆SASA = SASAcomplex − SASADNA − SASAdrug. All contributions to the bind-
ing are calculated limitedly to the bps G7 − C18. . .G11 − C14, directly involved in
the binding and covering the sliding path of anhydro-anthramycin (a test calculation
shown that the interaction of the drug with the rest of the oligonucleotide amounts to
less than 5% of the total - data not shown).
3.2 Systems and Methods 69
3.2.2 QM/MM simulations
The QM/MM scheme allows to investigate at a quantum level the reactive site of
the system, taking into account the electrostatic effects of the biomolecular frame,
and to dissect between various sources of polarization. In this work we used the
scheme developed by Rothlisberger and co-workers [176], implemented in the pro-
gram CPMD [177]. The drug/DNA adducts were partitioned in quantum and classi-
cal regions. The first (QM hereafter) comprised the drug and the nucleoside of the
reactive guanine G10 (56 ÷ 59 atoms), and was treated at the DFT level [241, 242],
using the BLYP [243, 157] exchange-correlation functional. The guanine was cut at
the C1′ carbon, and the valence of this atom was saturated with two capping hydro-
gens [244]. The remaining part of the system (MM hereafter) was treated using the
AMBER [231, 25, 131] effective potential.
The QM part is contained within a rectangular box of 6000 ÷ 7000 Å3, and was
treated as an isolated system [245]. Quantum calculations were performed using
plane waves decomposition of up to a kinetic energy of 70Ry, along with pseudo-
potentials of the Martins-Trouillers type [169]. The electrostatic interactions between
QM and MM atoms were calculated using a hierarchical scheme [176]. In this ap-
proach, the short range electrostatic interactions between the QM and MM part were
taken explicitly into account within a sphere of radius 5.3 Å around every QM atom
using an appropriately modified Coulomb potential that ensures that no electron spill-
out occurs. Beyond this first shell and within 10.6 Å, the electrostatic interactions
were calculated using the D-RESP charges for the QM atoms. In the outermost re-
gion, a multipole expansion scheme was employed. This hierarchical method is fully
Hamiltonian and ensures high accuracy in the core region and efficient computation
in the region further away from the QM part.
The starting structures were taken from the last MD snapshots, and then slowly
quenched to reach a temperature close to 0K, in order to relax the constraints on
QM atoms. Subsequently, the systems were slowly heated up to 300K, and NVT
simulations were carried out for 3 ps, coupling the systems to a Nosé-Hoover ther-
mostat [121, 122]. A time step of 5 au (∼ 0.12 fs) and a fictitious electronic mass
of 600 au were used. To estimate the amount of polarization within the QM region,
Boys orbitals [246] (BO’s) were calculated during the QM/MM simulations, and,
based on their position, we estimated the ionicity of selected bonds. To this aim, fol-
lowing [247], we defined a bond ionicity of the A-B bond as BIAB = |
−→
dA| cos θ
|−−→dAB| , where−→
dA is the position vector of the BO along A-B with respect to A,
−−→
dAB is the position
vector of B with respect to A, and θ is the angle between the two position vectors.
With this definition, BI’s identify electron lone pairs and can be used to visualize the
polarization of selected bonds. For example, a value of BIAB much lower than 0.5
indicates a strong polarization of the electronic charge towards A.
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3.3 Results and Discussion
3.3.1 MD simulations
Covalent complex
We summarize here our results from a 20ns MD simulation of the ANT-DNA cova-
lent complex in aqueous solution, and compare its features with those of the X-ray
structure [99] in order to validate our computational setup. The RMSD between the
average structure of the 10-mer d[CCAACGTTG∗G]d[CCAACGTTGG] and the X-
ray structure is 3.3 Å. The average RMSD of the whole DNA frame with respect to
DNA is 1.6 Å: consistently, binding by the drug does not induce any appreciable bend-
ing of the DNA axis (Figure 3.1), in agreement with experimental findings [99, 220].
The structural determinants (Figures. 3.2, 3.3) and the B-factors of the complex agree
well with the experimental ones, except around the region C24-G1....T20-A5, from
where we removed a second drug bonded to G22 in the X-ray structure (See Meth-
ods). It turns out that the bonding by the drug affects the DNA frame essentially in
the binding region. The H-bond pattern between the drug and the oligonucleotide
however differs significantly with respect the experiment. In MD simulation, one to
four direct H-bonds are formed and broken during the dynamics (average number
1.7), involving mostly the OHAnt group, that interacts with both NHG11 and OC15,
and the acrylamid tail of the drug (Figure 3.8 and Table 3.2). In addition, one to
three water-mediated H-bonds are established between HN15Ant and O2T9, O4′G10,
N3A17. These waters push the drug tail towards the strand containing A17. As a con-
sequence, HN15Ant links to NA17 and looses the contact with O2T9 and O4′G10. Note
that these bridging waters are not present in the X-ray structure. Three of these direct
H-bonds are also present in the X-ray structure, that exhibits six H-bonds (Table 3.3).
This discrepancy might be due to the effect of packing forces in the crystallographic
structure, which are particularly important at the ends of the oligonucleotide [18]. Ac-
cording to our results the role of the H-bond pattern connecting the drug and the DNA
IMI•DNA 1 IMI•DNA 2 ANT•DNA ANT-DNA DNA IMI ANT
drug 3
3.6± 1.0
2
2.2± 0.8
3
4.3± 1.1
4
3.6± 0.9 −
6
2.3± 1.1
9
5.4± 1.3
DNA 9
8.6± 1.5
8
7.5± 1.4
13
8.8± 1.7
8
5.6± 1.1
14
11.4± 1.6 − −
Table 3.2: Total number of persistent H-bonds (present for more than 10% of the simulation
time) formed by the drug and the five bps d(G7T8T9G10G11)d(C18A17A16C15C14) involved
in the binding. Averages and standard deviations of the total number of H-bonds are also
reported in the second row of each entry.
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Figure 3.1: Superimposition between the MD-averaged structure of DNA (red) and those of
ANT•DNA (blue), IMI•DNA 2 (orange), IMI•DNA 1 (green) and ANT-DNA (magenta).
The details show the sugar flips that arise upon non-covalent binding.
have a minor role in stabilization, as compared to Ref. [99]. However, the aqueous
solvent, not detected by the X-ray experiment, might assist significantly the forma-
tion of water-mediated H-bonds. We conclude that the MD structure of ANT-DNA
reproduces most of the experimental data, apart from the drug-DNA H-bond pattern,
which may differ mostly from the X-ray structure because of environment effects.
N3G11..O9AnO2C15..O9AnO2C15..N10AnN3G11..N10AnO2T9..N15AnO4
′
G10..N15An
X− ray
MD
3.9
4.0± 0.3
3.1
2.9± 0.3
3.4
2.9± 0.2
3.7
3.3± 0.2
2.9
5.3± 0.4
3.3
4.9± 0.9
Table 3.3: Comparison between X-ray and calculated acceptor-donor distances involving
drug and DNA.
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Figure 3.2: Average values of the minor groove width of DNA (red), ANT•DNA (blue),
IMI•DNA 1 (green) , IMI•DNA 2 (orange), ANT-DNA (magenta), calculated between C4’
sugars.
Non-covalent complexes
In this section, we provide insights on aspects of the molecular recognition process
between anthramycin and DNA, through MD simulations of the non-covalent com-
plexes IMI•DNA and ANT•DNA, and we compare them with the isolated reactants
in water solution (ANT, IMI, and DNA), as well as that of the covalent adduct ANT-
DNA, discussed above.
Structural analysis and sliding of anhydro-anthramycin. The structural stability
of the systems has been firstly analyzed in terms of deviations from their averages,
as well as from those of canonical B-DNA and A-DNA. Figure 3.4 shows that the
RMSD of the oligonucleotides assumes two different values for several ns in the
non-covalent complexes, while it is almost constant in DNA and ANT-DNA. Consis-
tently, while for DNA and ANT-DNA the RMSD is 4 Å with respect to B-DNA and
5 Å with respect to A-DNA for the whole simulation, the non-covalent complexes as-
sume for several ns conformations having lower RMSD relative to A-DNA than to
B-DNA. The most interesting event observed is a sliding of the drug in IMI•DNA
along the minor groove, towards the central part of the oligonucleotide (from site 1 -
configuration IMI•DNA 1 - to 2 - configuration IMI•DNA 2 - in Figure 3.5), which
occurs after 10ns. Interestingly, shuffling and translocation have been observed ex-
perimentally for other DNA-binding drugs [248, 249]. The drug moves by one base
pair (bp) step, so that C11Ant is located in the vicinity of T9 in IMI•DNA 2, and
keeps the new position for the rest of the simulation. In contrast, in ANT•DNA the
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Figure 3.3: Average values of selected helical parameters (a: twist, b: rise) of DNA (red),
ANT•DNA (blue), IMI•DNA 1 (green), IMI•DNA 2 (orange), ANT-DNA (magenta).
drug is stable around its binding site for the entire dynamics ( 20ns). It is interesting
to test whether ANT would move back if initially located in the “slipped” position
of IMI. To this aim, we performed MD simulations in which ANT is docked in the
non-reactive site (with the reactive carbon between bases T8 and T9). Two slightly
different configurations were chosen. Both MD simulations, carried out for 2.5ns,
show that the drug does not move back to the reactive site: in one MD, the average
distance between C11ANT and N2G10 passes from 6.3 Å to 5.6±0.3 Å (average value
over the last 2ns), in the other from 7.4 Å to 7.6± 0.3 Å.
These results suggest that movement of ANT from one “site” to another are
most probably not kinetically driven. A key issue to be addressed is on whether
the sliding process is due (totally or in part) to the choice of the model, i.e. by
having positioned the drug near to the end of the oligonucleotide rather than in its
center: in fact, nucleobases and ligands in such positions might be subjected to dif-
ferent electrostatic and dynamical stresses. To quantify the relevance of end-effects
on the properties of the biomolecular frame, we have compared features of DNA,
i.e. the oligonucleotide in aqueous solution, in its central (d[ACGT]2) and termi-
nal (d[TGGC]2) parts. The RMSD’s with respect to the average structure turns out
to be very similar (1.4 ± 0.3 Å vs 1.3 ± 0.3 Å), and the flexibilities, measured as
RMSF’s, are identical (0.9 ± 0.3 Å). The differences in electrostatic forces acting
on the base atoms are very small, within 15%. Furthermore, we have construct
two more models other than IMI•DNA. In the first, the system is the same, but
the initial conditions (in particular the docking of the drug, done manually) are dif-
ferent; 20ns MD simulation of the model in aqueous solution show that a slid-
ing of the drug occurs after 10ns (note that this is quite long time in MD sim-
ulations with explicit solvent and counter-ions [250, 236, 35, 34]). In the second,
which also has been simulated for 20ns, IMI is docked in the centre of the 14-mer
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Figure 3.4: Mass weighted RMSDs of the oligonucleotides in ANT•DNA, IMI•DNA,
ANT-DNA, and DNA, calculated for heavy atoms after least square (LSQ) fit to the aver-
age structures in solvent. Running averages are reported as bold lines. The inset reports the
distance between reactive atoms N2G11 and C11Ant in the non-covalent complexes.
d[CAACGTTG∗GCCAAC]d[GTTGGCCAACGTTG] (IMI•DNAc). In this case the
same sliding process occurs after 15ns; in addition, flexibility, minor groove width
and electrostatic field acting on the drug, turn out to be very similar to those of
IMI•DNA (Table 3.4 and Figure 3.6). Based on results from the structural analy-
sis of DNA and from three independent simulations, we suggest that the sliding of the
drug is caused by a stabilisation of the drug in a position other than the “reactive” one,
and we proceed to a structural and energetic analysis of the process. Structurally, the
sliding of the drug is accompanied by a significant rearrangement of the DNA frame
(mirrored by a decrease of 8 kcal/mol of the internal energy): in fact, the average
structure of the complex before the sliding (IMI•DNA 1) shows large deformations
with respect to those of DNA and ANT-DNA, in particular at the central region (Fig-
system\step C12-C15 G11-C16 G10-A17 T9-C18
IMI•DNA 6.8± 0.7 4.9± 0.4 4.4± 0.4 6.1± 0.6
IMI•DNAc 4.4± 0.7 5.1± 0.4 4.4± 0.4 4.0± 0.6
Table 3.4: Average values (Å) of minor groove widths calculated between C4’ atoms at
d[TG∗GC]2.
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Figure 3.5: Superimposition
of the IMI•DNA MD-averaged
structures before (green, 1) and
after (orange, 2) 10ns. The
drug moves by 1bp step. The
mean distances between reac-
tive atoms N2G11 and C11Ant
are respectively 3.3± 0.2 Åin 1
and 6.5± 0.5 Åin 2.
ure 3.1). The plot of the average minor groove widths (Figure 3.2) shows the presence
of a large unwinding in this region relative to DNA and ANT-DNA, which is corre-
lated to a flip of the χ glycosidic dihedral at G7 and G19 from anti (−120) to high
anti configuration (−70 - Figure 3.1). The same findings come out from the analy-
sis of helicoidal inter-base-pairs parameters (Figure 3.3). The oligonucleotide after
the sliding (IMI•DNA 2) becomes structurally similar to DNA and the minor groove
narrows, in particular in the central region of the oligonucleotide. The other non-
covalent complex (ANT•DNA) assumes also a conformation differing from those
of DNA and ANT-DNA particularly in its middle (Figures. 3.1, 3.2, 3.3). However,
the minor groove has almost the same width as in DNA, due to the presence of the
OH − 11 group of ANT (Chart I). Summarizing, both the non-covalent complexes
with the drug positioned in front of the reactive site exhibit significant rearrangements
Figure 3.6: Left: Comparison between RMSFs around the average structure at d[TG∗GC]2
in IMI•DNA and IMI•DNAc. Right: Average electrostatic forces acting on the drug in
IMI•DNA (cyan) and IMI•DNAc (orange).
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Figure 3.7: Variations of the non-bonded (electrostatic+LJ) energy of
the drug-d(G7T8T9G10G11)d(C18A17A16C15C14), drug-solvent, and solvent-
d(G7T8T9G10G11)d(C18A17A16C15C14) moieties, upon sliding of anhydro-anthra-mycin
(dashed lines correspond to running averages performed on blocks of 100 steps). The sliding
process is associated to a increase of ∼ 10 kcal/mol in the interaction energy between the
drug and the dodecamer.
in the center of the oligonucleotide with respect to DNA and ANT-DNA. Upon slid-
ing of IMI the conformational parameters recover values close to those of DNA.
Some values of the helical parameters in Figure 3.3, like high twist and rise, and neg-
ative roll, are typical of BII-DNA backbone conformation [50]. BI/BII equilibria can
be influenced by ligands, in order to optimize contacts between partners and to allow
the formation of water-mediated H-bonds [251, 90]. In fact, we find that the binding
of the drug affects these equilibria (data not shown), even if a correlation between
binding and conformational changes of the backbone is not easy to rationalize. For
example, binding either imposes freezing of certain parameters, or allows a major
variability of others. In addition, the presence of a low twist (and rise) at CG steps
(like in C6G7) in MD simulations has been recently correlated to unusual α/γ back-
bones at the adjacent 5’ step [236]. We found indeed along the backbone some flips
of α/γ to stable states other than the canonical g−/g+, but they appear not to be cor-
ANT•DNA IMI•DNA 1 IMI•DNA 2 ANT-DNA
LJ −30± 2 −33± 3 −40± 3 −34± 3
COULOMB −12± 3 −8± 3 −11± 3 −20± 4
Table 3.5: LJ and coulomb interaction energies (kcal/mol) extracted from the non-bonded
terms of the AMBER force field [25, 131].
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ANT-DNA ANT•DNA ANT IMI•DNA 1 IMI•DNA 2 IMI
PROPELLER 31± 7
(37.1)
26± 8 22± 8
(34.4∗)
29± 7 22± 7 26± 9
BUCKLE 13± 6
(17.6)
10± 5 12± 6
(8.2∗)
8± 4 8± 4 9± 5
Table 3.6: Propeller twist and buckle of the drugs (degrees). In parenthesis are reported
available experimental results. Data labelled with the asterisk refers to the O11-methyl ether
of the drug.
related with the low twist at C6G7. The lifetimes of these conformations are supposed
to be larger than typical MD timescales [52], yet our and other simulations do observe
them [236], even if in almost all the cases reverse transitions are absent. The origin
of their appearance has not been enlighted yet, although it might be related to the
force field parametrization. Also the drugs exhibit a slight distortion upon binding, as
shown by the average values of the propeller and twist angles reported in Table 3.6.
Despite the high standard deviations, twist seems to be anti-correlated with the de-
gree of binding, with the only exception of IMI•DNA 2. The buckle instead does not
change significantly upon binding. The energetic analysis has been performed us-
ing the non-bonded terms of the AMBER force field [24,25,131] for an approximate
estimate of the interaction energies. Although the number of drug-DNA H-bonds is
reduced in going from 1 to 2 the overall interaction energy increases by few kcal/mol,
(Figure 3.7). This mirrors a better accommodation of the drug into the DNA minor
groove after the sliding, increasing the hydrophobic contact area by 4% (Table 3.7).
As a result, the twist of the drug decreases (29◦ vs 22◦ in Table 3.6), allowing a better
Figure 3.8: Drug/oligonucleotide H-bonds in ANT-DNA (MD structure).
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IMI ANT GTTGG IMI•CTTGG ANT•GTTGG ANT-GTTGG
SASA 191± 5 161± 5 764± 17 667± 18 (2)
709± 17 (1) 746± 25 739± 21
∆SASA
−288 (30%, 2)
−246 (26%, 1) −179 (19%)
−216 (26%, IMI)
−186 (20%, ANT)
Table 3.7: Calculated hydrophobic SASA’s (Å2). The hydrophobic effect plays a role in the
formation of the complex: a negative value of ∆SASA upon solvation in water corresponds
to a gain in the non-polar part of the solvation free energy.
delocalization of π orbitals on the drug. The entropy change associated to the sliding
process turns out to be very small, as: (i) the first shell of waters surrounding the
drug and the binding site does not change, as shown by a calculation of the radial
distribution function of waters around the binding region (data not shown); (ii) the
conformational entropy of the DNA (calculated with the Schlitter’s formula [252]) is
unchanged. Within the limitations of these simple estimations, we conclude that the
sliding of the drug is mainly due to a gain in non-specific interactions with the DNA
frame, accompanied by a release of the structural stress accumulated by this latter
under the presence of the drug.
Other features of IMI•DNA 2 and ANT•DNA. The LJ interactions account for
∼ 70−80% of the non-bonded energy for both the systems, while electrostatics plays
a minor role (Table 3.5). Note that the LJ (Coulomb) interaction is slightly stronger
(weaker) in IMI•DNA 2 than in ANT•DNA, possibly because of the presence in
the latter of the OH11 group, that prevents the drug to be very close to the DNA
backbone. Consistently, the relative decrease of the hydrophobic SASA [240] upon
formation of the complex is larger in IMI•DNA 2 than in ANT•DNA (Table 3.7),
corresponding to a larger relative gain in the non-polar contribution to the free energy
of solvation. Thus, IMI establishes a more favourable non-bonded interaction with
the DNA frame than ANT. In the covalent complex the electrostatic energies become
comparable to the LJ ones (Table 3.5): in fact, the formation of the covalent bond
shortens the distances between charged groups, inducing a different distribution of
the electronic density on the reactants. Interestingly, the H-bonds between the sol-
vent and IMI, ANT, DNA (calculated only for the atoms at the drug-DNA interface)
are only partially replaced in the non-covalent complexes (Table 3.2). Specifically,
drug-DNA H-bonds are formed between G10, G11, A16 nitrogens, O4′G11, and O9,
O11 and N10 on the drug (Figure 3.8). No water molecules are present between the
reactive guanine G10 and the drugs, as should be expected for extended aromatic sys-
tems making favourable hydrophobic interactions with the DNA backbone. However,
the presence of the OH11 group in ANT•DNA allows the entrance of water(s) in the
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Figure 3.9: Contour plots of the electrostatic potential (Volts) within the QM region, through
the plane defined by atoms N2, N10, C11. The plots report the difference in the electrostatic
potential calculated with and without bioframe. Note that only in IMI•DNA (a) the largest
difference is localized near to the electrophilic carbon, while in ANT•DNA (b) it is spread
in front of the reactive amino group of the guanosine. The N10-C11 arrow indicates the
polarization of the bond, while the arrow between N2 and C11 indicates the gradient in ∆V .
region between the drug and the DNA backbone (Table 3.2). Based on these results
we suggest that the formation of the complexes has an important entropic contribu-
tion, and their stabilization, even in a highly charged system like the minor groove of
DNA, is mainly due to hydrophobic contacts.
3.3.2 Reactant Polarization
DNA is a polyelectrolite and it may produce large electric fields on the reactants.
In this section, we investigate the electrostatic effect of the biomolecular frame on
the electronic structure of the reactants (the drug and its guanosine target) by 3 ps
QM/MM simulations on ANT•DNA and IMI•DNA 1. Within this scheme the drug
and the reactive guanosine are treated at a quantum level, while the rest of the system
is parametrized using AMBER [231, 25, 131] effective potential. Thus the QM/MM
scheme allows to dissect the source of polarization into various contributions, namely
those due to the DNA and the solvent, by switching off their charges. We also evaluate
the amount of reciprocal polarization of the reactants by performing additional QM
calculations in vacuo.
Our QM/MM simulations suggest that the biomolecular frame alters significantly
the electric field of the reactants, in particular the region between the reactive atoms
N2G10 and C11drug (Figure 3.9). The polarizing field created by the environment
turns out to be due almost completely to the DNA frame, since identical results are
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ANT
IMI
GUA
IM
I•
D
N
A
A
N
T•
D
N
A
bioframe no bioframe no solvent vacuo
C11−H11 0.66± 0.01 0.68± 0.04 0.66± 0.01 0.68
C11−N10 0.57± 0.01 0.54± 0.01 0.58± 0.01 0.55
C11−N10 0.58± 0.01 0.55± 0.01 0.59± 0.01 0.56
C11−C11a 0.51± 0.01 0.51± 0.01 0.50± 0.01 0.51
N2−H21 0.57± 0.01 0.59± 0.01 0.57± 0.01 0.59
N2−H22 0.59± 0.01 0.58± 0.01 0.57± 0.01 0.58
N2−C2 0.36± 0.04 0.37± 0.04 0.38± 0.06 0.33
N2 lonepair 0.21± 0.05 0.19± 0.05 0.21± 0.07 0.24
C11−H1 0.66± 0.01 0.68± 0.04 0.66± 0.01 0.67
C11−N10 0.57± 0.01 0.57± 0.01 0.58± 0.01 0.57
C11−C11a 0.50± 0.01 0.50± 0.01 0.50± 0.01 0.51
C11−O11 0.63± 0.01 0.62± 0.01 0.62± 0.01 0.62
N2−H21 0.57± 0.01 0.59± 0.01 0.57± 0.01 0.59
N2−H22 0.58± 0.01 0.58± 0.01 0.59± 0.01 0.58
N2−C2 0.37± 0.04 0.38± 0.04 0.38± 0.04 0.33
N2 lonepair 0.20± 0.05 0.15± 0.06 0.15± 0.06 0.24
Table 3.8: Bond ionicity of X-N2G10 and X-C11drug bonds. Last column refers to cal-
culations in vacuo on the drug or the guanosine. Two rows with the same label indicate a
double bond, while the last row in each system represents the BI associated to the lone pair
of the guanine nitrogen. The figures on the right side depict the BO’s considered for the BI
calculations (see Methods).
obtained in calculations in which the charges of the solvent are switched off (data not
shown). The DNA field is directed from N2G10 to C11drug in IMI•DNA 1. Thus, this
field may assist the alkylation reaction by rendering C11drug more electrophilic, i.e
creating electrostatic conditions very favourable for a nucleophilic attack. Instead, in
ANT•DNA the largest effect occurs in proximity of the amino group of G10. Thus, in
this latter case, the DNA field is expected to enhance the reactivity neither of the drug
nor of the DNA. These findings are in agreement with experimental findings [253,
254], indicating the anhydro form as the most reactive.
A measure of the polarity of chemical bonds is given by bond ionicity indexes
(BI’s). For the bond between atoms A and B, a BI<0.5 (>0.5) indicates shift of the
center of mass of the electronic charge towards A (B) (see Methods). Such analysis
can be extended also to investigate the polarization of electron lone-pairs of a given
atom. In this case, the BI is defined in such a way that larger is the index, stronger
are the polarization effects on the lone-pair. Here we investigate the changes in BI’s,
averaged along the QM/MM trajectory, due to the inclusion of the electric field of the
biomolecular frame. It is worth to notice that also little differences between these val-
ues are significant, because of the restricted range of values of the BO projection onto
the bonds [247]. The N10-C11 π bond is the most polarized by the external elec-
tric field in IMI•DNA 1 (where the drug is located in front of the reactive guanine 1),
1Note that, due to the delocalization of π bonds [247], these results should be taken as an indication.
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whilst in ANT•DNA the largest effect is seen on theN2G10 lone pair (Table3.8). Con-
sistently, a large field is localized on the C11 atom in the first system (Figure 3.9).
Thus, in IMI•DNA 1 the C11 atom is more electron poorer than in vacuo, suggesting
that DNA renders the complex more reactive. These results agree with experiments,
which have shown a marked preference of anthramycin to bind double-stranded DNA
(dsDNA), rather than single nucleobases [98, 255, 99].
3.4 Concluding Remarks
Whilst a large number of ns-scale simulations of non-covalent drug/DNA complexes
have appeared in the literature (see e.g. Refs. [74, 75, 256, 257, 76]), very few MD
studies have been reported on alkylating drug/DNA systems, in spite of their phar-
macological relevance [258, 104, 259]. Here we have investigated by molecular me-
chanics simulations the non-covalent interaction between two forms of anthramycin
present in solution (hydroxy and anhydro) and the 12-mer d[GCCAACGTTGGC]2.
Our MD simulations suggest that the formation of the covalent complex does not af-
fect DNA helical axis, in agreement with experiments [99]. However, local structural
changes are evident in both the DNA and the drug, consistently with the “induced fit
mechanism” of binding proposed by Kizu et al. [221]. The non-covalent complexes
are mainly stabilized by non-specific hydrophobic interactions, consistently with the
modest sequence selectivity shown by these drugs [217,218,260,15]. In this respect, it
is worth to note the remarkable difference observed in dynamical properties of the two
forms of the drug. Hydroxy-anthramycin remains in the same site during the whole
length of our simulation. In contrast, anhydro-anthramycin moves after ∼ 10ns to-
wards an adjacent site, and the system keeps the new configuration for the rest of
the dynamics. Note that similar shuffling of minor groove binders has been already
detected experimentally [248]. To the best of our knowledge, however, this is the first
time that such a behaviour is observed for minor groove alkylating drugs in a MD sim-
ulation. The sliding of the anhydro form is associated with an energetic and structural
relaxation of the non covalent complex, and is seen in a variety of additional simu-
lations of the complex. The DNA conformation of the reactive complexes (i.e. with
the drugs in front of its target guanine) is distorted relative to that assumed in solution
or in the covalent complex. In particular, significant changes are observed in sugar,
backbone, and helical parameters at the central region of the oligonucleotide. These
values are associated with conformations higher in energy than that of canonical B-
DNA. Interestingly, after the sliding of anhydro-anthramycin (non-reactive complex),
the above structural parameters become similar to those of the free DNA. We conclude
therefore that the oligonucleotide in the reactive complex is more distorted than in so-
lution, in the observed non-reactive complex, and in the final product of the reaction.
This requirement of a sizeable structural distortion of the DNA frame and, to a lesser
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extent, that of the drug, could play a role for the experimentally observed slower
reactivity of anthramycin relative to that of other alkylating agents [98]. Classical
simulations are complemented by QM/MM calculations. These show that the dsDNA
electric field polarizes the reactive carbon of anhydro-anthramycin so as to render it
more electrophilic. On the contrary, in the complex with hydroxy-anthramycin, the
DNA field is unable to increase either the drug electrophilicity or the guanine nucle-
ophilicity (although it clearly affects the electronic structure of the reactants). The
field due the water solvent appears instead to play a negligible role in both the com-
plexes. Thus, although the exact role of the electrostatic field of the environment can
be established only if one simulates the entire alkylation reaction, our results suggest
that the DNA frame assists the alkylation reaction by polarizing one of the reactants,
at least in the case of the complex with anhydro-anthramycin. This is consistent with
the experimental observation that the drug is able to covalently bind G-containing
oligonucleotides but not guanine in aqueous solution [98, 255, 99].
Chapter 4
Mechanism and thermodynamics of
drug sliding along the minor groove
4.1 Introduction
The design of sequence-selective anticancer molecules which bind to regions of DNA
involved in replication and transcription processes is a key goal of rational drug de-
sign [261, 262, 263, 264]. In this respect sequence-specific read-out codes have been
deciphered for the class of non-covalent minor groove binders [73, 265]. In contrast,
the important class of DNA-alkylating agents has received less attention, particularly
from a theoretical point of view, probably also due to the paucity of experimentally
determined structural data [19,9]. It is commonly accepted that molecular recognition
and formation of the non-covalent complex by these drugs are driven by non specific
interactions and sequence-specific structural features along the minor groove [19, 9].
Recently, molecular dynamics studies performed in the group [83, 84] have provided
information at the molecular level on the non-covalent interaction between the DNA
and two covalent binders, anthramycin [253,99,254,221] and duocarmycin [107,266].
Anthramycin alkylates guanines, showing a modest sequence selectivity for PuG∗Pu
sequences [221], while duocarmycin binds to adenines and is very selective towards
AT-rich sequences which have to be at least 4 bps long [107, 266]. Both compounds
are powerful cytotoxic agents interfering with transcription and replication processes,
and some of their derivatives have entered clinical test phases [223, 267]. The natu-
ral twist of 35◦ between phenol and pyrrol rings (respectively A and C in Chart I),
gives to anthramycin the ideal shape to fit into the minor groove [99]. In contrast,
the largest duocarmycin is formed by two moieties connected via an amide link and
to fit into the minor groove it needs a 40◦ twist around the amide link relative to its
conformation in water [266].
For the purposes of the present work, we focus on the putative reactive imine form
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of anthramycin [hereafter IMI] [253, 99, 254, 221], and on duocarmycin-SI [hereafter
DSI] [107,266]. Non-covalent complexes of both IMI and DSI with DNA are mainly
stabilized through hydrophobic interactions [83,84]. However, while IMI could form
a relatively strong H-bond network with DNA [84, 99], DSI is able to form one H-
bond only [83, 107]. As seen in the previous Chapter, IMI turned out to slide along
the minor groove of the d[GCCAACGTTGGC]2 duplex, leading to the formation of
a non reactive stable complex. Such a sliding is independent on the initial location
of the drug, occurring when IMI sits either at the end or in the middle of a DNA
duplex. The same kind of displacement has been observed after docking the molecule
to its preferred site, the triplet AGA [221], within a 14-mer duplex (data not shown).
Instead, the complex between DSI and the duplex d[GACTAATTGAC]2 is stable
during the whole dynamics [83].
As the non-covalent recognition of the preferred DNA sequence may involve a
sliding of drugs along the minor groove [248, 249, 268, 269], knowledge of the en-
ergetics of such process may provide useful information on ligand selectivity and
molecular recognition. In this chapter this issue is addressed by investigating quanti-
tatively the mechanism of sliding of IMI and DSI. The free energy is then dissected
at a qualitative level into its enthalpic and entropic contributions, the rank of which
has been shown to depend strongly on the chemical structure of the drug and on the
DNA sequence [270, 271].
It is found that binding of IMI to the reactive site is less favored than at nearby
base-pair, whereas for DSI the non-covalent binding site coincides with the reactive
one, in agreement with previous MD simulations [83, 84]. While the PMF associated
to sliding of IMI can be roughly rationalized through a simple analysis of drug/DNA
enthalpic interactions, solvation effects appear to be much more relevant for DSI, as
a consequence of more stringent requirements for optimal fit of drug into the minor
groove. These findings suggest the need of considering multiple binding pathways in
drug design, and provide a rationale for the modest selectivity of anthramycin relative
to duocarmycin [266, 217].
4.2 Systems and Methods
Free energy profiles have been calculated as a function of the position of the drug
along the minor groove, for the non-covalent complexes of IMI with d[GCCAACGTT-
G∗GC]-d[GCCAACGTTGGC] (hereafter IMI•DNA) and DSI with d[GACTAATTG-
AC]-d[GTCAATTA∗GTC] (hereafter DSI•DNA). These are built starting from ex-
perimental structures [99, 266] by cutting the covalent bond between the carbon of
the drug and the nitrogen of the nucleobase, and manually pulling out the drugs from
the minor groove, until the distance d[C-N] was about 3.3 Å. As DSI moves toward
the nearest end of the duplex upon sliding, test calculations have been to investi-
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ChartI: Schematic view of alkylation of guanine by IMI (left), and adenine by DSI (right).
gate the possible influence of end-effects [84]. To this end, an additional simulation
was performed on the 14-mer d[GACGACTAATTGAC]-d[GTCAATTA∗GTCGTC]
[hereafterDSI•DNAc] in complex with DSI. The drug was placed with its reactive
carbon C13 in front of the base T24 (corresponding to T21 in DSI•DNA). A 7 ns MD
simulation was performed on this system, and analyses were performed on the last
2 ns.
All simulations have been carried out using the GROMACS package [237, 238,
272]. AMBER/gaff force fields [24, 25, 131, 234] were used for the parameteri-
zation of oligonucleotides and drugs [83, 84]. Drug structures were optimized by
means of DFT calculations at B3LYP/6-31G(d,p) [161, 157] level, using the Gaus-
sian03 package [273]. Atomic RESP [134] charges were derived using the resp mod-
ule of AMBER after wavefunction relaxation. Potassium ions, modelled with the
AMBER-adapted Aaqvist potential [233], have been added to achieve charge neu-
trality (22, 20 and 28 in IMI•DNA and DSI•DNA and DSI•DNAc, respectively).
Systems have been solvated with a cubic box of TIP3P water molecules [274] ensur-
ing solvent shell to extend for at least 12 Å around the DNA. Periodic boundary con-
ditions were used, and constant temperature-pressure (T=300 K, P=1 atm) dynamics
have been performed through the Nosé-Hoover [121, 122] and Andersen-Parrinello-
Rahman [123,126] coupling schemes (t = 1 ps). Electrostatic interactions were treated
using the particle mesh Ewald (PME) algorithm [275] with a real space cutoff of 10 Å,
the same as for Van der Waals interactions. The pairlist was updated every 10 steps,
and Lincs constraints [235] were applied to all bonds involving hydrogen atoms, al-
lowing to use a time step of 2 fs. Coordinates were saved each 500 steps, correspond-
ing to 1000 snapshots per ns. DNA minor groove width was defined as the distance
between sugar C4’ atoms, and it was calculated with the program Curves [276, 239].
The potentials of mean force (PMF’s) [277] associated to drug sliding along the
minor groove of IMI•DNA and DSI•DNA were calculated with the Umbrella Sam-
pling method [183]. The distance between the reactive atoms of drug and DNA base
(specifically the C11 atom of IMI to the N2 atom of guanine 10 in the DNA and atom
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C13 of DSI to atom N3 in adenine 19 of the DNA) was chosen as reaction coordinate.
This simple choice is well suited to describe movements of the drugs that are few bps
long, since both compounds cause no appreciable bending of DNA [83, 84]. In order
to sample the various conformations corresponding to different positions of the drug
along the minor groove, we have imposed a harmonic constraint of 15 kcal/(mol·Å2)
to the distance d[C-N], starting from 2.9 Å to 12.1 Å with a step of 0.4 Å. Doing
so the total movement of 9.2 Å (slightly less than 3 bps steps) is partitioned into
23 windows. Initial configurations of each window were generated starting from
the reactive one, and increasing the distance d[C-N] by steps of 0.2 Å, after 70 ps
of equilibration for each d[C-N] value. The Weighted Histogram Analysis Method
(WHAM) [278, 185] method has been used to recombine PMF obtained from differ-
ent windows. As can be seen from insets in Figures 4.1 and 4.2, the error on the
calculated PMFs is almost constant, meaning that the reaction coordinate has been
sampled in a fairly uniform manner.
Extended MD simulations of oligonucleotides in water [62] indicate that some of
the DNA conformational and helicoidal parameters have relaxation times of 0.5 ns.
Thus, at least multi-ns trajectories must be collected to obtain well-converged free
energy profiles [236]. Systems investigated here were equilibrated for ∼4 ns, albeit
the PMF landscape was roughly converged after 2 ns. A further check on the RMSD
of drug•DNA complexes indicates that convergence has been reached for all of the
windows after ∼4 ns.Therefore, 6 ns of MD simulation were performed on each win-
dow (for a total of ∼140 ns), and the last 2 ns were used to estimate the PMF and for
a structural analysis of the complexes.
The PMF has been decomposed as the sum of individual components, each with a
physical meaning, and evaluated via the force field terms. In particular, variations in
the drug-DNA electrostatic and Van der Waals interactions, 1 solute adaptation energy,
solute configurational entropies, and solvation free energies were examined. Solute
vibrational entropies were calculated within the harmonic approximation [279], using
the nmode module of AMBER 9 [280]. As customary [281, 39, 282], a subset of
structures was selected to be analyzed (20 for each relevant configuration, extracted
every 0.1 ns from the last 2 ns). These were minimized in the absence of explicit
solvent, the latter being mimicked by a dielectric constant ǫ = 4r (r is the interatomic
distance in Å). Then, up to 20000 steps of minimization with no cutoff for all the
interactions were performed, of which the first 100 are steepest descent followed by
conjugate gradient, until the RMS of gradient drops below 10−4kcal/(mol·Å). The
estimate of relative solute conformational entropies is not a trivial task [39,282,119],
in particular for very flexible systems such as oligonucleotides. Moreover, it is not
1Van der Waals interactions were roughly estimated by summing the number of hydrophobic con-
tacts for each atom type pair. For each of these, the equilibrium distance d0 of the Lennard-Jones
potential was calculated and contact was counted when d<(d0+0.2 Å).
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possible to guess a priori how the “spreading” of the dynamics among the various
basins of the free energy surface depends on the conformation (i.e. the position of
the drug). Therefore, results on conformational entropies should be taken only as
suggestive.
Solvent contributions to free energy were calculated using the MM-PBSA method-
ology [283]; for each relevant configuration 200 snapshots from the last 2 ns of each
MD were saved. Since ∆Gsolv = Gcomplexsolv − Gdrugsolv − GDNAsolv , and the last two terms
in the right-hand side are the same for each configuration of the complex, ∆Gsolv
is directly proportional to Gcomplexsolv . Based on this proportionality, only this latter
term was evaluated for each relevant configuration of the two complexes. The elec-
trostatic contribution to solvation was evaluated using the Poisson-Boltzmann con-
tinuum method [284], as implemented in the module pbsa [285] of AMBER 9. Di-
electric constants for the internal and external parts were set to 1 and 80 respectively.
Grid dimensions were set as long as twice the tickness of the solute, and a grid spac-
ing of 0.25 Å was used. The dielectric boundary is the molecular surface defined by
a 1.4 Å probe sphere and by spheres centered on each atom with radii taken from the
PARSE [286] parameter set (H=1.0, C=1.7, N=1.5, O=1.4 Å with a value of 2.0 Å for
the phosphorus). The boundary dielectric constants were set as the harmonic sum
of solvent and solute Debye-Hückel values. Salt effects were not included implic-
itly in the continuum model. The hydrophobic component of solvation free energy
is assumed proportional to the change of the solvent accessible surface area (SASA),
∆Gnp = γ∆SASA + b where γ=0.00542 kcal/Å2 and b=0.92 kcal/mol [286]. For
comparison, we performed MM-PBSA calculations also using a second approach
available in the pbsa module of the AMBER 9 package [285,287]. In this method the
non polar contribution is cast into two terms, a repulsive one (cavity), correlated to
the SASA, and an attractive one (dispersion), calculated through a surface-integration
approach [288].
4.3 Results and Discussion
In this section a description of PMF profiles corresponding to the sliding of IMI and
DSI inside the minor groove of oligonucleotides d[GCCAACGTTG∗GC]-d[GCCAA-
CGTTGGC] and d[GACTAATTGAC]-d[GTCAATTA∗GTC] (IMI•DNA and DSI•
DNA respectively), considering d[C-N] as reaction coordinate. Note that the standard
deviation is very small along the entire sampling interval (≈0.2 kcal/mol, see insets
in Figures 4.1, 4.2), which makes the estimation of the free energy quantitatively re-
liable. Then, the solute enthalpic and entropic contributions to the PMF are analyzed,
along with the effects of the solvent. Finally, the relevance of end-effects [84] on the
energetics of the sliding process is assessed.
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Figure 4.1: (a) Potential of Mean Force (PMF) associated to IMI sliding along the DNA mi-
nor groove. Standard deviation is reported in the inset. (b) Schematic view of the complex in
the configuration corresponding to the free energy minimum. (c) Structures of three relevant
conformations of the drug/DNA complex. The second and third structures (from the left) has
been rotated respectively by ∼30◦ and ∼100◦ about the helical axis, to center the drug for
visualization. Molecular surfaces of drug and DNA are depicted in transparent red and blue,
respectively.
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Figure 4.2: (a) PMF associated to DSI sliding along the DNA minor groove. Standard
deviation is reported in the inset. (b) Schematic view of the configuration corresponding to
the free energy minimum. (c) Structures of three relevant conformations of the complex. The
third structure (from the left) has been rotated ∼40◦ about the helical axis to center the drug
for visualization. Molecular surfaces of drug and DNA are depicted in transparent red and
blue, respectively.
4.3.1 PMF profiles
The PMF of IMI•DNA features four minima (I-IV, Figure 4.1). In I, the complex
is in its reactive configuration, i.e. carbon C11@IMI faces N2@G10 (d[C-N]≈3 Å).
As seen in the previous Chapter, I corresponds to the average structure assumed by
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the complex during the first 10 ns of a 20 ns long MD simulation. From I, a small
barrier of 1.5 kcal/mol has to be overcome at transition state I∗ to reach the absolute
minimum II, where d[C-N]≈5.6 Å. In II, C11@IMI sits slightly before the T9 plane
(along the direction 3’→5’), and IMI sits at the same location as in the last 10 ns the
dynamics mentioned above. The barrier from II to I (5.5 kcal/mol) is much larger
than that from I to II, which again is consistent with results from Chapter 3. At larger
d[C-N] distances other two minima are found: III (7.2 Å) and IV (10.1 Å), in which
C11@IMI is located immediately beyond T9 and in front of O2@T8, respectively.
The PMF landscape of DSI•DNA is remarkably different (Figure 4.2). Indeed,
sliding is hindered by a barrier of ∼4 kcal/mol which traps the drug in the reactive
configuration I (corresponding to the absolute minimum in the PMF, along the inves-
tigated path). This minimum is followed by three other ones (higher in energy by
∼4 kcal/mol) virtually isoenergetic among them. In such minima, the reactive group
of the drug (in particular C13@DSI) is in front of G20 (II, a very shallow minimum),
T21 (III), and between T21 and C22 (IV).
The PMF of IMI•DNA appears to be much rougher than that of DSI•DNA; in
particular it features two configurations corresponding to a larger gain in binding free
energy than in the reactive conformation. Results obtained for the two adducts are in
line with those extracted from unbiased MD simulations [84, 83], and help to explain
the higher selectivity of duocarmycins as compared to anthramycins [266, 217]. For
instance, in IMI•DNA the reactive configuration should be markedly less populated
with respect to II (and competitive with III and IV). In contrast, in DSI•DNA there
is a net gain in the binding free energy at the reactive configuration, the PMF being
almost flat elsewhere.
4.3.2 Dissection of the PMF’s
The PMF can be interpreted as the change in binding free energy ∆Gb upon drug
sliding. To identify the relevant contributions to this process, such a changes can be
expressed as a sum of individual terms [263, 37, 289, 290]. Here ∆Gb is decomposed
in a term due to solute conformation and interactions between the two moieties (so-
lute terms), and a second one due to the presence of water and counter ions (solvent
effects):
∆Gb = ∆Gsolute + ∆Gsolv (4.1)
where:
∆Gsolute = ∆Hadapt + ∆Hel + ∆HvdW − T∆Svib − T∆Sr+t (4.2)
∆Gsolv = ∆Gsolv, p + ∆Gsolv, np (4.3)
In eq. 4.2, ∆Hadapt represents the enthalpic term due to DNA and drug structural
deformations upon binding, while ∆Hel and ∆HvdW are contributions from elec-
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d[C-N](Å) ∆Hadapt ∆Hel # Contacts # H-bonds ∆Gsolv,p ∆Gsolv,np
IM
I•
D
N
A
3.2 (I) 0.0(22.7) 0.0(1.6) 15(4) 2.0(0.8) 0.0(34.2) 0.0(2.0)
3.9 (I∗) +9.6(22.3) +3.3(1.3) 12(3) 0.9(0.6) -38.7(50.2) -2.1(2.4)
5.6 (II) -7.0(21.6) -2.4(1.1) 19(3) 1.2(0.6) -8.8(47.3) -4.6(1.8)
6.5 (II∗) -3.8(21.6) -1.0(1.8) 13(3) 0.6(0.5) -17.5(35.4) +2.0(2.2)
7.2 (III) -4.9(22.2) +1.2(1.1) 11(3) 1.0(0.2) +11.4(36.7) +4.2(2.4)
8.2 (III∗) -1.4(21.8) +2.2(1.3) 9(2) 0.5(0.3) -16.4(31.6) +4.8(1.7)
10.1 (IV) -1.5(22.4) -1.4(1.0) 15(3) 0.5(0.5) -1.5(53.2) -2.1(3.0)
D
SI
•D
N
A
3.0 (I) 0.0(18.1) 0.0(1.9) 63(10) 0.5(0.3) 0.0(36.0) 0.0(2.0)
4.3 (I∗) +18.3(18.2) +6.3(2.0) 47(9) 0.0(0.0) -60.2(45.6) +7.4(2.6)
6.0 (II∗) +18.6(18.1) +3.6(1.7) 63(11) 0.0(0.0) -41.3(29.6) +0.3(2.8)
7.0 (II) +17.6(18.2) +2.2(5.2) 53(12) 0.8(0.4) -25.6(35.0) +1.3(2.4)
8.9 (III∗) +19.9(18.5) +3.7(2.4) 56(11) 0.0(0.0) -34.5(40.0) +1.4(2.5)
10.3 (III) +15.7(18.1) -1.2(2.2) 58(10) 0.9(0.6) -44.4(41.4) +3.9(2.0)
11.9 (IV) +14.1(18.5) +5.3(1.5) 54(11) 0.0(0.0) -49.5(39.1) +2.9(2.0)
Table 4.1: Selected values of solute ∆Hadapt (column II), drug/DNA ∆Hel (c. III), number
of hydrophobic contacts (c. IV), average number of H-bonds (c. V), polar (c. VI) and non
polar (c. VII) contributions to ∆Gsolv. Energies are in kcal/mol and referred to configuration
I. Standard deviations are reported in brackets.
trostatic and Van der Waals interactions, respectively. ∆Hadapt and ∆Hel are es-
timated through the terms in the AMBER force field, while ∆HvdW is assumed
to be roughly proportional to the variation in the number of hydrophobic contacts.
T∆Svib and T∆Sr+t are the free energy contributions from vibrational and transla-
tional+rotational entropy changes upon binding. The former was evaluated through
a normal mode analysis [279], while T∆Sr+t was assumed to be sequence indepen-
dent [271] and was thus not calculated. In eq. 4.3. ∆Gsolv,p and ∆Gsolv,np are re-
spectively the polar (electrostatic) and non-polar (hydrophobic) contributions to sol-
vation, evaluated here with the MM-PBSA method. It is worth to point out that whilst
the PMFs are quantitatively reliable, their dissection into enthalpic, entropic, and
solvation terms has been carried out using approximated and/or strongly sampling-
dependent methods. Thus, these contributions have to be considered qualitatively,
and are here used to gain insights into the sources of drug selectivity. In the follow-
ing, all the values refer to the reactive configuration of the respective complex, which
is indicated as I.
Solute terms
The analysis of enthalpic terms in IMI•DNA is summarized in Tab. 4.1 and in Fig-
ures 4.3a, 4.3b, 4.3c for ∆Hadapt, ∆Hel, and number of contacts, respectively. Consis-
tently with previous unbiased dynamics [84], at I the DNA is distorted in the central
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C6G7 tract with respect to its structure in bulk solvent. The adaptation energy fur-
ther increases going from I to the maximum I∗, while drug/DNA interactions weaken.
Both the present and the previous works [84, 83] indicate that the whole structure re-
laxes at II (indeed, the conformation assumed by the oligonucleotide is very close to
that of canonical B-DNA in aqueous solution), whilst electrostatic and Van der Waals
interactions strengthen. Actually, such interactions are the strongest along the inves-
tigated path, while the adaptation expense is the lowest. In contrast, the (average)
number of direct H-bonds decreases. The subsequent increase in free energy at III∗ is
partially due to the steric clash between the drug acrylamide tail and the amino group
of G7. The latter hinders the sliding of the drug, causing a rotation of its principal
axis with respect to the oligonucleotide, and slightly exposing the molecule to the
solvent ( 4.4).Correspondingly, the number of contacts reaches a minimum in III∗,
and the minor groove widens in the tract C6. . . T8 (average width 8 Å with respect to
4 Å at II). Once the guanine amino group has been overcome by the drug, a wide free
energy minimum is reached in proximity of T8 (IV). Here, the drug recovers some
of the contacts with the DNA backbone. The (solute) enthalpic contributions fairly
correlate with the PMF (Figures 4.3a, 4.3b, 4.3c), albeit deviations are present, point-
ing to the role of solute entropic and/or solvation terms. This is particularly evident
at PMF transition states: for example, the sum of the enthalpic terms indicates II∗
to be lower than III∗, whereas in the PMF III∗ is slightly lower than II∗ (Tab. 4.1).
Concerning solute vibrational entropies, the calculated values at minima of the PMF
turn out to differ scarcely,consistently with results of the previous Chapter. Despite
the limitations of the methodology used here [39], these values indicate that solute
entropy is likely to not vary significantly at different configurations.
In DSI•DNA, the free energy absolute minimum I, corresponding to the reactive
configuration, shows the lowest ∆Hadapt (Figure 4.3e and Tab. 4.1) and the largest
number of hydrophobic contacts (Figure 4.3g and Tab. 4.1), while ∆Hel is very sim-
ilar to the values in II and III (Figure 4.3e and Tab. 4.1). The major source of sta-
bilization in I is the extended pattern of hydrophobic contacts formed between the
drug and the DNA, in agreement with experimental suggestions [107,266]. The drug
is significantly distorted when leaving the reactive configuration: the twist between
the two drug moieties increases from ∼20◦ at I to ∼110◦ at I∗, causing a significant
widening of the minor groove ( 4.4). Consequently, the block A, along with the mi-
nor groove floor (see also next section and Figure 4.3), is more solvent exposed, the
electrostatic interactions weaken and the number of drug/DNA hydrophobic contacts
decreases drastically. Additionally, the H-bond which forms discontinuously at the
reactive configuration is here definitively lost. At II∗, both the DNA and the drug are
less distorted than in I∗, and the number of hydrophobic contacts is the same as in I.
Surprisingly, the adaptation cost is essentially the same as in I∗. II is characterized
by a small gain in electrostatic and adaptation energies as compared to II∗ and III∗,
along with the recover of one H-bond. However, it features less hydrophobic contacts
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than II∗ and III∗. Apart from the reactive configuration, III is the lowest enthalpic
minimum; however, its free energy value is almost identical to those at II and IV
(Figure 4.2). In summary, the (solute) enthalpic analysis shows that several points
lack correspondence with the PMF, indicating a key role of entropy and/or solvent
effects for the sliding process of DSI. Nevertheless, enthalpy contributions pinpoint
unambiguously the configuration I as the most stable one, with ∆Hadapt playing a
more important role than in IMI•DNA (max ∆∆Hadapt = 18 and 7 kcal/mol for DSI
and IMI, respectively).
Finally, T∆Svib was evaluated at the minima of the PMF. The calculated values
show a range of variation comparable to that found for IMI•DNA: thus, also in this
case solute entropic contributions to the sliding process are neglected.
Solvent effects
It is well known that solvent is crucial for nucleic acid structure and stability, and
consequently it is important for binding of drugs to DNA. Indeed, the analysis of
∆Gsolute clearly points to the role of solvent for the sliding of the two investigated
drugs, in particular for DSI. The development of reliable implicit solvent models
and fast finite-difference numerical procedures [285,286,287,288] has made feasible
the calculations of solvation free energy via MD simulations. In particular, binding
free energies of ligands to DNA calculated with the MM-PBSA method agree fairly
well with experimental values [75, 37, 282]. Electrostatic ∆Gsolv, p and hydrophobic
∆Gsolv, np contributions to ∆Gsolv, that can be interpreted as the free energy cost for
drug desolvation upon binding, are evaluated using either the “standard” setup [39,
286] and the alternative approach available in AMBER 9 [285, 286, 287, 288] (see
Systems and Methods). It is worth to recall tha that binding is here always associated
to an unfavorable – positive – change in solvation free energy. The profiles of ∆Gsolv
evaluated with the two methodologies are very similar, albeit the second approach
highlights the sequence dependence of non-polar contributions and is thus reported
here (Figures 4.3d, 4.3h)
The changes in ∆Gsolv appears very large as compared to the PMF; large stan-
dard deviations are seen, as already reported by other authors [37, 282]. Neverthe-
less, some interesting differences between IMI and DSI are observed: i) The cost
in desolvation upon formation of the complex, ∆Gsolv, is the highest at the absolute
PMF minimum in DSI•DNA (Figure 4.3h), in agreement with the better fit of the
drug into the minor groove at I. Already at I∗, where drug distortion results in its
enhanced solvation, ∆Gsolv suddenly decreases, and reaches a rough plateau for the
other configurations. This behavior mirrors the PMF landscape, where the minimum
corresponding to the reactive configuration is the lowest; ii) In contrast, ∆Gsolv does
not show any clear correlation with the PMF in IMI•DNA. In particular, the deepest
minimum in the PMF is not associated with the highest value of ∆Gsolv (highest sol-
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a) e)
b) f)
c) g)
d) h)
Figure 4.3: Selected values of: a,e) ∆Hadapt; b,f) ∆Helec; c,g) number of hydrophobic
contacts; d,h) electrostatic (squares, dotted-dashed line), hydrophobic (rhombus, dashed line),
and total (circles, solid line) ∆Gsolv along the reaction coordinate d[C-N], compared to the
PMF (dotted line, and rescaled in c), d), g), h) to allow for an easier comparison with ∆Hsolv
profiles). Data on the left (a-d) refer to IMI•DNA, those on the right (e-h) to DSI•DNA.
Solvation free energies have been obtained using the method of Luo and co-workers.
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Figure 4.4: Water density distributions extracted from the last 2 ns of dynamics at relevant points of the PMF in IMI•DNA (upper
panel) and DSI•DNA (lower panel). Densities are calculated with the gspatial utility of GROMACS, using a 3D grid with step 0.5 Å.
Water densities at values ∼ 3 times larger than that of bulk water are shown as blue wireframes.
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vation cost). Density plots of water (Fig 4.4) exhibit qualitatively the same trend of
the profile of ∆Gsolv. Both IMI•DNA and DSI•DNA I∗ feature more waters inside
the groove with respect to I, and in IMI•DNA III has the largest desolvation cost,
consistently with its very poor hydration. Interestingly, the number of hydrophobic
contacts in III is lower than that of II, indicating that this number does not necessarily
increase with a lower degree of hydration. This might be due, at least in part, to the
“bridging” of the two DNA strands by the drug, which prevents water to access the
groove around the binding region.
Within the limitations of this analysis, it is suggested that solvent effects play a
key role in DSI•DNA, consistently with the finding that ∆Gsolute does not corre-
late with the PMF. Instead, no clear correlation exists between the PMF and ∆Gsolv
in IMI•DNA, which is also consistent with the rough correlation found between
∆Gsolute and the PMF.
4.3.3 Evaluation of end-effects
All simulations reported here have been started with IMI and DSI positioned in
front of their reactive sites [99, 266] (nucleobases G10 and A19 in IMI•DNA and
DSI•DNA respectively).2 When building-up the sliding windows as described in
Systems and Methods, DSI turned out to slide towards the 3’-end of the strand con-
taining A19, while in IMI•DNA the drug moves towards the oligonucleotide center.
As a result, the regions explored by the two drugs are slightly different (although it
should be noticed that they are comparable, as can be seen from Figures 1 and 2),
and diverse influence of “end-effects” might hamper a thorough comparison between
the calculated PMF’s. In this respect, in the previous Chapter it has been already
shown that end-effects play only a minor role on the dynamics of IMI•DNA. Here,
additional MD calculations were performed to assess the possible influence of such
effects on the interaction between DSI and DNA. Specifically, the features of the tract
DSI•d[GACT]2 either embedded in the 11-mer DSI•DNA (DSI•d[G1A2C3T4]2,
see Systems and Methods) or in the 14-mer DSI•DNAc (DSI•d[G4A5C6T7]2 were
compared along the last 2 ns of the respective MD simulations. The structure, the con-
formational flexibility, the hydration of DSI•d[G1A2C3T4]2 and DSI•d[G4A5C6T7]2
turned out to be rather similar, along with the interactions between DSI and the tracts
d[GACT]2. In fact:
1. The structures of DSI•d[G1A2C3T4]2 and DSI•d[G4A5C6T7]2 overlap very
well (Figure 4.5): moreover the widths of minor groove at the binding region
are comparable with or without the presence of three additional nucleobases
2 Indicating such nucleobases with the asterisk the sequence are d[GCCAACGTTG∗GC]-
d[GCCAACGTTGGC] and d[GACTAATTGAC]-d[GTCAATTA∗GTC] for IMI•DNA and
DSI•DNA, respectively.
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a) b)
Figure 4.5: a) Superimposition between structures (averaged over the two last 2ns) of
DSI•DNA (blue) and DSI•DNAc (red). The tracts d[GACT]2 and DSI have a very similar ar-
rangement in the two complexes. In particular, although the terminal base-pair in DSI•DNA
is clearly distorted relative to DSI•DNAc, the position of the drug in the minor groove is
essentially unchanged. The arrow indicates the opening of the minor groove in DSI•DNAc
b) Water density distribution extracted from the last 2ns of dynamics for DSI•DNA (left) and
DSI•DNAc. Densities are calculated with the g_spatial utility of GROMACS, using a discrete
0.5 Å step in a 3D grid. For each frame, the system has been rototranslated to obtain the best
superimposition of DNA onto a reference structure; the density function is then calculated.
Water densities at values 3 times larger than that of bulk water are shown as blue wireframes.
(data not shown). Consistently the calculated RMSD is very low, 0.6 Å. Fur-
thermore, independently of the duplex length, DSI does not fit perfectly into
the minor groove. As a consequence of these structural similarities, in both
DSI•DNA and DSI•DNAc the methoxyl-carbonyl ester of the drug is fully
solvated.
2. The number of hydrophobic contacts and H-bonds between DSI and d[GACT]2
is almost the same (data not shown).
3. The DSI-Owat and DSI-Hwat Radial Distribution Functions (RDFs), which pro-
vide information on the solvation of the drug, are also rather similar. Consis-
tently, the first and second solvation shells around the drug contain virtually
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the same number of waters. This is not unexpected due to the excellent super-
imposition between the two tracts (Figure 4.5) and the comparable hydration
of the DSI methoxyl-carbonyl ester. In particular, O14DSI (Chart I), which in
DSI•DNA is the drug acceptor (pointing to the minor groove) closest to the du-
plex end, forms in both cases one H-bond with similar lifetime. Interestingly,
also tracts d[G1A2]2 and d[G4A5]2 do not show relevant differences in their H-
bond patterns. Finally, density plots of waters extracted from MD simulations
are also rather similar (4.5).
4. The values of the Root Mean Square Fluctiations (RMSF) do not differ signifi-
cantly, apart for the terminal sugar moieties, which are obviously more flexible
in DSI•DNA (data not shown).
5. The electrostatic energy between DSI and tracts d[GACT]2 is exactly the same
in both systems.
Summarizing, end-effects seem to play a minor role on the interactions between the
two drugs and the DNA duplexes, although they do slightly influence the structure of
water within the minor groove. These findings confirm that steric hindrance and op-
timal interactions with the groove have a prominent role in determining the preferred
binding sequence of duocarmycin.
4.4 Concluding Remarks
The PMFs associated to the sliding of IMI and DSI along the DNA minor groove
differ remarkably The reactive configuration is the most favourable for DSI•DNA,
whereas in IMI•DNA significant activation energy is required to reach the reactive
site moving from the absolute PMF minimum (corresponding to a non-reactive con-
figuration). Results are consistent with previous MD simulations of IMI•DNA [84],
showing that the reactive configuration becomes unstable after few ns, and with those
of DSI•DNA [83], in which the drug is stable in the reactive configuration for the
whole dynamics. Moreover, there is an indication that the higher specificity of DSI
compared to IMI correlates with a higher cost for moving the drug from the preferred
site, at least for the sequences considered here. End-effects turn out not to play a
relevant role for the binding.
For both complexes, configurations associated with the absolute minima of the
PMF are those with the smallest adaptation cost and the better packing. This is con-
sistent with the usual assumption of negligible ∆Hadapt upon binding of the drug in
the minor groove to the preferred sequence [263, 37, 271]. Apart from this common
feature, various contributions to the PMF are found to have different relative weights
in the two adducts. In IMI•DNA the changes in enthalpic terms correlate fairly well
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with the PMF, particularly at the four minima, while the ∆Gsolv landscape is ap-
parently unrelated to the free energy profile. In DSI•DNA a rough anti-correlation
between ∆Gsolv and the PMF profile is found instead, whereas enthalpy contribu-
tions do not have an overall correspondence with the free energy profile, except for
the coincidence of absolute minima.
In summary, this work suggest that, also for alkylating agents, shape complemen-
tarity and packing are significant factors in determining the preferred site of non-
covalent binding [37, 289, 290, 291]. In addition, insights are gained on the way
differences in chemical structure, size and flexibility may influence solvation and
molecular recognition along the minor groove. DSI, due to its larger size relative to
IMI, covers more DNA base pairs and needs to rotate around the linkage between
groups A and B to fit in the preferred sequence. The cost of such a rotation (which
has been supposed to be a key factor for reactivity) depends on flexibility and struc-
ture of the target DNA sequence. Furthermore, the lack of optimal docking results
in a larger drug exposure to the solvent, at opposite with findings for IMI•DNA, in
which drug desolvation cost is uncorrelated to sequence selectivity. This is consistent
with the fact that IMI has a natural right-handed conformation allowing for a snug fit
into the minor groove at different sequences (indeed the reactive configuration does
not correspond to a minimum in ∆Hadapt), and features a lower sequence selectivity
as compared to DSI.
Finally, although speculative, different molecular recognition mechanisms can be
proposed for the two drugs investigated here. DSI might firstly bind to DNA at those
sequences characterized by the lowest desolvation cost (the non-preferred ones), and
then easily slide towards the preferred site, corresponding to a funnel in the PMF. In
this scenario, solvent effects could be critical for the molecular recognition of DNA
by duocarmycins. In contrast, recognition of DNA by anthramycin appears to be
more complicated, since no preferred route exists exist according to results reported
here. Moreover, the reactive site can be reached only upon crossing a significant free
energy barrier.
Clearly, calculations of free energy barriers to form non-covalent complexes at
different sequences, also with drugs other than those considered here, are needed to
achieve a general picture of the molecular recognition. However, the findings re-
ported here help to rationalize the higher selectivity of duocarmycins as compared to
anthramycins, and point out clearly the possibility of multiple patterns for molecular
recognition.
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Chapter 5
Unbinding of distamycin and
anthramycin from DNA investigated
by metadynamics
The mode of binding of minor groove (MG) binders to their target DNA sequences has
been well characterized at an atomic-detail level using both experimental biophysical
techniques as well as molecular simulations [292,289,76,265,37,271,15,293,19,263,
84,83,261,262]. In contrast the structural, thermodynamic and kinetic features of the
molecular recognition event are mostly lacking [294, 295, 296, 297, 269, 292, 298],
despite their key role in rational drug design [264, 9]. Recognition goes beyond
the formation of the final adduct: both non covalent [249, 248, 268, 269] and co-
valent [296, 299] binders exploit mechanisms like shuffling sliding within the MG
and translocation among different sites until a preferred sequence is reached. In the
last years the development of novel methods to accelerate rare events [180], along
with the increased reliability of force fields [24, 25, 31, 300, 27, 30] and simulation
protocols [137, 275], allowed to investigate non-equilibrium dynamics of complex
biological systems [301,302,303]. In particular, the recently introduced metadynam-
ics method [189] has been applied to investigate mechanism and thermodynamics of
biologically relevant processes [304, 305, 306], providing insights on aspects of the
molecular recognition events of proteins by small ligands [307, 193].
Here we have used such an approach to investigate the unbinding from DNA of
two ligands, representative of the main classes of non covalent and covalent MG
binders. We focus on the unbinding process because of its importance in selectivity
and molecular recognition [297, 269, 308] and because it can provide insights on the
mechanism ligands interfere with protein/DNA interactions and dynamics [298]. The
prototype of non-covalent binders is distamycin A [108] (hereafter DST, Chart I).
DST is highly selective towards AT-rich tracts [111, 109], its amide nitrogen forming
H-bonds with N3(A) and/or O2(T) of DNA [9, 73, 309, 310]. The alkylating agent
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is the already studies (see previous Chapters) anthramycin [99, 98], here considered
in its most reactive anhydrous form [84, 253] (hereafter IMI, Chart I). In contrast to
DST, anthramycin shows only a modest preference towards PuG∗Pu triplets (the as-
terisk indicating the alkylated guanine) [221]. Both these antibiotics have shown to
exert an antitumoral action by interfering with transcription [15, 9, 311, 312, 313] and
replication [98,314,315] processes, and have been the prototypes for anticancer drugs
which are currently undergoing clinical trials [78,80,316,317]. For both, experimen-
tal structural information is available of the adducts with DNA1 [99, 109, 111]. In
addition, for DST experimental information on the kinetics of the binding and un-
binding events is available in literature [292]; this enables a test on accuracy of the
method used.
From our metadynamics simulation we extract the Lowest Free Energy Path (LFEP)
[210] associated to the unbinding, which is equivalent to an Intrinsic Reaction Path-
way (IRC) at a finite temperature and gives the minimum-cost path of detachment,
making it possible to identify relevant conformations (and associated free energies)
of the process. Our simulations reveal a different mechanism of IMI and DST un-
binding. In the first case only metastable states are observed between the bound and
unbound configurations, and the overall activation free energy is∼12 kcal/mol. The
unbinding occurs through a loss of contacts between the ligand and one DNA strand,
followed by the detachment of the drug head (ring A in Chart I), which leads to the
complete unbinding. In contrast the detachment of DST passes through an interme-
diate which, along the LFEP, is reached after crossing a barrier of ∼18 kcal/mol and
it is characterized by the full hydration of the ligand hydrophobic moiety, with the
charged tail of the drug anchored into the MG. Importantly, from this complex the
rearrangement towards the bound and unbound configurations are equally likely. The
reliability of our computational scheme is assessed by the finding of virtually the same
mechanism of detachment with different choices of the CVs and of the metadynam-
ics parameters. The activation free energies calculated in different simulations are
also within ∼1 kcal/mol in the case of IMI and ∼4 kcal/mol in the case of DST. Fur-
thermore, a good agreement has been found between calculated and experimentally
determined [292] activation free energies of DST.
Our results are consistent with experimental findings on the mechanisms of un-
binding of the Hoechst dye from DNA [269], helping at rationalize results on the
kinetic features of these processes at a molecular level.2 In addition, the characteriza-
tion of the unbinding proposed here could be useful to achieve a deeper understand-
ing of the dynamics between binary ligand/DNA complexes and proteins involved
in vital cellular processes (e.g. topoisomerases [15, 9, 311, 312, 313, 319], or heli-
1DST has been found to bind to DNA as a side-by-side dimer at high drug/DNA ratios [9, 318].
Here we focus exclusively on the monomeric binding mode as to make a direct comparison with the
1:1 IMI/DNA complex.
2Notice that no attempt has been made here to estimate binding free energies (See Methods).
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cases [320, 320, 321, 322]).
5.1 Methods
Systems. The DST·d[5’-CGCATTACGC-3’]2 complex3 was built by taking the lig-
and from the X-ray structure of the adduct with the duplex d[GGCCAATTGG]2 (PDB
CODE 1JTL [111]), while the 10-mer was built using the nucgen module of AM-
BER [231, 280]. The initial structure of IMI·d[5’-CAACGTTGGCCAAC-3’]2 was
extracted from a previous MD simulation [84], where the adduct was built starting
from the X-ray structure of the covalent complex between anthramycin and the 10-
mer d[5’-CCAACGTTG*G-3’]2 (PDB code 274D [99]). Sodium counter-ions (18 in
DST•DNA and 22 in IMI•DNA) were added to achieve system neutrality, and the
structures were solvated in a monoclinic box with 10246 (DST•DNA) and 13611
(IMI•DNA) water molecules. Periodic boundary conditions were applied. The initial
size of the box were 75×80×72 Å3 and 60×84×69 Å3 in IMI•DNA and DST•DNA
respectively. With this choice the distance between the solute and its first image is
larger than 25 Å during the whole unbinding process.
MD calculations. The recently refined AMBER force field [25,31] was used for the
parameterization of the oligonucleotide moieties. The force field parameters for IMI
were taken from Ref. 84; those of DST were calculated in a similar fashion. Structural
parameters were taken from the gaff force field [234] while the charges were calcu-
lated following the RESP procedure [134]: the ligand was firstly optimized at the
HF/6-31G(d) level up to a convergence in energy of 10−5 au. The presence of the sol-
vent, which was required to avoid formation of unphysical intermolecular H-bonds,
was simulated with the CPCM [323] implicit model using the Gaussian03 [273] pack-
age. The electrostatic potential map generated by the optimized structure was then
3Bold bases are those covered by the ligand, while the asterisk indicated the base forming the
covalent bond.
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calculated in vacuo at the same level of theory, and atomic RESP [134] charges were
derived using the antechamber module of AMBER. Sodium and water were mod-
eled with the AMBER-adapted Aqvist [233] and TIP3P [274] potentials, respectively.
Electrostatic interactions were treated using the particle mesh Ewald [137] (PME) al-
gorithm with a real space cutoff of 10 Å, the same as for van der Waals interactions.
The pairlist was updated every 10 steps, and Lincs constraints [235] were applied to
all bonds involving hydrogen atoms, permitting a time step of 2 fs. NPT conditions
were achieved by coupling the systems with a Nosé-Hoover [121, 122] thermostat
(τ = 1 ps) and the Andersen-Parrinello-Rahman [123, 126] barostat (τ = 1 ps).
Systems were equilibrated using the following computational procedure: i) struc-
tural optimization of the solvent, using the conjugate gradient algorithm up to a con-
vergence of 10−4 kcal/mol; ii) energy minimization of the entire system, using the
same convergence criteria as in i); iii) linear heating of the system up to 300 K (in
100 ps) while putting harmonic restraints on the solute (k=5 kcal/Å2); iv) 5 ns of con-
stant temperature-pressure (T=300 K, P=1 atm). Starting structures for metadynamics
were taken from the last ns of MD, selecting those with the lowest RMSD with respect
to the average structure of the solute (calculated also in this last ns). DNA MG width
was defined as the distance between sugar C4’ atoms, and it was calculated with the
program Curves [276, 239]. All simulations have been carried out using a modified
version of the GROMACS [272] package implemented with metadynamics [305].
Metadynamics. This recently introduced method [189] allows to compute free en-
ergies and to accelerate rare events. It is based on a dimensional reduction: a set
of Collective Variables (CVs) si (i = 1, . . . ,NCV), function of the system coordi-
nates x, is evolved with a standard MD supplemented by a history-dependent potential
which prevents the system from visiting conformations already sampled. Namely, the
history-dependent potential is built-up by Gaussians of dimensionality NCV, height w
and widths δsi (i = 1, . . . ,NCV), deposed at time intervals τG along the CVs trajec-
tory. In the limit of a long metadynamics run, the sum of the penalty terms tends to
compensate exactly the underlying FES in the reduced space permitting a reconstruc-
tion of this FES explored up to time t [209]. To investigate the unbinding mechanism
of IMI and DST the following CVs were chosen:
1. The distance dCMs between the centers of mass of the ligand and of the DNA
tracts d[GTTGG]2 and d[CATTAC]2 (for IMI and DST, respectively). A sim-
ilar choice of CV has been applied in Ref. 193. A reflective wall has been
applied at a distance of 20 (IMI) and 22 (DST) Å in order to avoid the sampling
of conformations where the ligand is fully solvated.
2. The number of hydrophobic contacts nhph between non polar carbons of the
ligand and the bases it covers in the starting structure, modeled as a coordination
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number:
nhph =
∑
ij
1− (rij/r0)a
1− (rij/r0)b (5.1)
The parameters a and b have values of 6 and 12, respectively, while r0=6 Å acco-
unts for the typical carbon-carbon distance (4/4.5 Å) and the thermal motions’
amplitude (1.5/2 Å) [307]. A similar CV has been used in Refs. [307, 324].
3. The number nhb of H-bonds between the ligand and the bases it covers in the
starting structure, described also by Eq. 5.1 and values a = 8 and b = 12, and
r0 = 2.5 Å. A similar CV has been chosen in Refs. 304, 305.
Gaussian parameters were w = 0.1 Kj/mol, δsCMs = 0.5 Å, δshph = 8 and δshb = 1
in the case of IMI, w = 0.3 Kj/mol, δsCMs0.5 Å, δshph = 6 and δshb = 3 for DST.
Gaussian widths were selected so as to be almost half of the thermal fluctuations.
The time interval between two successive Gaussian depositions is 0.5 ps in all the
simulations. Ad hoc CVs were further built to avoid “walking” of the ligand in the
solvent after unbinding, forcing the re-binding at the same site of detachment: the an-
gles N1G5-N3T7-C1IMI , C2G9-N1A22-C1IMI in IMI•DNA and C2A4-O2T6-N5DST ,
N3G8-O2T6-N5DST in DST•DNA. Such CVs were kept inactive (i.e. Gaussian width
was set to zero), and only a wall was applied to force |cosα| ≤ 0.3, where α is the
angle selected as CVs [193].
Free energies surfaces were calculated as a function of (dCMs,nhph) and (dCMs,nhb).
In addition, simulations were performed in which the three CVs were kept active. In
every metadynamics run the unbinding event was seen after a few ns (see Results).
Furthermore, the unbinding mechanism of each ligand turned out to be very similar
in all simulations, which means that the relevant slow motions of the systems are cap-
tured by our CVs. However, no attempt was made to estimate binding free energies,
due to the generality of the CVs itself. Indeed, when the ligand exits the groove and
is fully solvated, it assumes different orientations relatively to the duplex before a re-
binding event occurs. As a consequence, an entropic hole is scavenged in the FES by
all those unbound conformations corresponding to very close points in the CVs space
(for example different head to tail orientations of the drug gives very similar num-
ber of hydrophobic contacts). For this reason, we only report here the activation free
energies, which can be extracted reliably by stopping the summation over Gaussians
just after the complete detachment of the drug. For the sake of clarity, we show here
only the free energy profiles as a function of dCMs and nhph in the case of IMI•DNA
and as a function of dCMs and nhb in the case of DST•DNA. On these surfaces the
LFEPs, which allows a precise identification of minima, intermediates and transition
states, were calculated by adapting a program developed by B. Ensing [210].
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Cluster analysis. A cluster analysis [325] has been performed on the ensemble of
conformations corresponding to relevant minima and transition states of LFEP. In
each state a dominant cluster has been found which is larger in size at least one order
of magnitude than the others. Representatives of each principal cluster are shown in
Figures 5.1 and 5.2. A dissection of free energy differences into various energetic
contributions was performed through averaging over each principal cluster.
5.2 Results
In this section we analyse the mechanism of unbinding of IMI and DST from their re-
spective DNA duplexes. For the sake of simplicity, we report here free energy surfaces
G(dCMs, nhph) for IMI•DNA and G(dCMs, nhb) for DST•DNA, along with associ-
ated Lowest Free Energy Paths (LFEPs) and relevant conformations of the complexes
(Figures 5.1 and 5.2). The CVs dCMs, nhph and nhb are respectively the distance be-
tween the centers of mass of the ligand and of the DNA tracts it covers, the number
of hydrophobic contacts and the number of hydrogen bonds (modeled through a co-
ordination number, see Methods). However, virtually the same mechanism has been
found using other collective variables (see methods), although the free energy may
vary up to 4 kcal/mol. Let us start describing the unbinding process of the alkylating
agent IMI to DNA.
5.2.1 IMI
The initial structural model has been taken from the final configuration of a previ-
ous MD simulation [84] of the adduct IMId[5’-CAACGTTG∗GCCAAC-3’]2. In this
configuration the binding site of IMI, located in d[5’-TTG∗-3’]2, does not coincide
with its alkylation site d[5’-TG∗G-3’]2. The free energy surface G(dCMs, nhph) cor-
responding to the unbinding of IMI from the duplex, along with associated LFEP and
relevant conformations of the complex, are shown in Figure 5.1). There are two virtu-
ally isothermic global minima, which are separated by a small barrier of ∼3 kcal/mol
(Table 5.1). In the first (Min1, the absolute one), located at dCMs = 0.54, nhph = 188,
the drug is bound at the tract d[5’-TTG∗-3’]2 and it is stabilized by hydrophobic con-
tacts with both DNA strands and by electrostatic interactions (Table 5.2); on average,
one H-bond is formed, involving bases G7, A21 and the hydroxyl group and N10 of
IMI, in agreement with the results from the unbiased dynamics performed in Ref. 84.
The structure of the complex in this minimum also corresponds to that of Ref. 84
after sliding of IMI from its alkylation site. Min2 differs only for the local deforma-
tion of the DNA duplex in the IMI binding region, not for the relative position of the
drug into the MG (compare Figure 5.3a with Figure 5.5). Correspondingly, these two
minima feature very similar drug/DNA interaction strength and hydration properties
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Figure 5.1: Free energy surface G(dCMs, nhph) associated to the detachment of IMI from
DNA. A Lowest Free Energy Path (LFEP) is also traced connecting relevant minima and
transition states (whose representative structures are shown). Isosurfaces are drawn one per
2 kcal/mol.
Min1 TS1-2 TS1-3 Min2 Min3 TS3-4
dCMs, nhph 0.54, 188 0.61, 186 0.69, 133 0.68, 199 0.86, 117 1.47, 35
∆G 0.0 3.0 6.7 0.7 5.7 12.3
Table 5.1: Free energies (kcal/mol, Min1 taken as reference) associated to relevant con-
figurations in the unbinding of IMI from DNA. These define the Lowest Free Energy Path
(LFEP).
(Tables 5.2, 5.3). A simple visual inspection of Figure 5.1 reveals that is very unlikely
that Min2 could be directly involved in the unbinding: from it the system will evolve
most likely towards Min1. The two minima are separated by a transition state TS1-2
of about 3 kcal/mol. Figure 5.3a shows that in this conformation the MG widens by
∼1 Å in the tract d[5’-TG∗G-3’]2, and the whole width profile virtually overlaps to
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that in Min2, suggesting that this opening is related to the transition from Min1.
The detachment process begins at TS1-3, higher in free energy by ∼7 kcal/mol
with respect to Min1. The region of the MG covered by the drug opens (Figures 5.1
and 5.3a) and a few water molecules enter the region between IMI and the strand
containing the alkylating guanine (hereafter strand1, while strand2 refers to the op-
posite one, Figure 5.6). Consistently, the free energy of hydration ∆Ghyd (calculated
from the Solvent Accessible Surface Area [326] - SASA - relatively to the unbound
complex, Out in Figure 5.1) undergo a change from the common value in Min1,
Min2 and TS1-2 (Table 5.6). In addition, the enhanced hydration causes a weakening
of drug/DNA van der Waals interactions (Table 5.2), which mainly involves strand1
(Figure 5.4a).
After TS1-3 the LFEP leads to the metastable minimum Min3, associated to a ∆G
of ∼6 kcal/mol relative to Min1: more waters enter the same region and the ligand
lays now on strand2 (Figures 5.4a, 5.6). The relief of the steric hindrance due to
the DNA backbone permits a slight relaxation of the ligand, which can be quantified
through the values assumed by dihedral angles between benzene and pyrrol rings and
between the pyrrol and the tail CONH2 (respectively Dihe1 and Dihe2 in Table 5.4).
At dCMs = 1.47, nhph = 35 we reach the highest transition state of the plot (TS3-
4, ∼12 kcal/mol relative to Min1), in which the drug has still a weak contact with the
duplex through its hydrophilic tail while IMI head is completely solvated (Figure 5.1,
Tables 5.2, 5.3). From this transition state the complete unbinding of the ligand takes
place (Out in Figure 5.1).
During the whole unbinding process the profile of the MG width significantly
changes; in particular two subsets can be identified: I, comprising Min1, Min2 and
TS1-2, in which the groove is narrow in the tract d[5’-GTT-3’]2 and wide in the ad-
jacent tract d[5’-G∗GC-3’]2; 2); II, encompassing the remaining conformations, in
which the situation is reversed. Despite these structural rearrangements, the oligonu-
cleotide remains quite close to the canonical B-DNA conformation, and IMI also
undergoes only minor deformations during the whole process(Table 5.4). In conclu-
sion, our results suggest that the detachment process takes place in the following way.
The drug first loses contacts with the strand containing the alkylating guanine G∗, al-
lowing waters to insert in between (Min3); then it experiences a complete detachment
crossing a transition state in which the head of the drug (A, in Chart I) leaves the MG,
while IMI tail keeps small residual interactions with the duplex. In this conformation
the principal axis of the drug is almost perpendicular to the one of the DNA. The
overall calculated barrier for the exit of the drug is ∼12 kcal/mol, and two metastable
states are found along the LFEP (Figure 5.1, Table 5.1).
Importantly, the detachment of the drug occurs with the same mechanism as above
when the active CVs are dCMs and nhb or dCMs,nhph,nhb, and the overall barrier cal-
culated as a ∆G‡(dCMs, nhb) is ∼11 kcal/mol, very similar to that found described
here (Figure 5.7).
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Min1 TS1-2 TS1-3 Min2 Min3 TS3-4 Out
Coulomb -8.4 (2.5) -7.3 (2.4) -4.8 (3.0) -7.9 (2.4) -2.9 (2.3) -2.3 (1.3) -0.1 (0.1)
LJ -38.1 (3.4) -37.7 (4.9) -22.2 (3.5) -38.0 (4.3) -19.4 (2.4) -6.2 (2.2) -0.4 (0.1)
∆Cpa -0.06 (0.13) -0.06 (0.13) -0.04 (0.13) -0.06 (0.12) -0.03 (0.13) 0.00 (0.12) -
T∆Shyd
b 4.5 (9.8) 4.5 (9.8) 4.5 (9.8) 4.5 (9.1) 2.3 (9.8) 0.0 (9.1) -
∆Ghyd
c
-4.8 (10.5) -4.8 (10.5) -3.2 (10.5) -4.8 (9.7) -2.4 (10.5) 0.0 (9.7) -
a. Heat capacity changes are evaluated as ∆Cp = 0.00032∆Anp − 0.00014∆Ap kcal mol−1K−1, where ∆Anp and ∆Ap
are the changes in the hydrophobic (non-polar) and hydrophilic (polar) surface areas, respectively.
b. Evaluated as ∆Cp (T − 295) kcal mol−1.
c. Evaluated as ∆Cp T ln(T/386) kcal mol−1.
Table 5.2: Interaction energies (kcal/mol, calculated between IMI and the tract d[5’-
CGTTGGC-3’]2) and changes in the heat capacity Cp, hydration entropy and hydration free
energy (referred to the unbound system, Out) at minima and TS of the LFEP.
Min1 TS1-2 TS1-3 Min2 Min3 TS3-4
# H-bonds 0.9 (0.6) 0.7 (0.5) 0.5 (0.8) 0.7 (0.5) 0.2 (0.7) 0.0 (0.2)
IMI 9.0 (1.7) 9.1 (1.6) 11.0 (2.3) 8.8 (1.7) 12.4 (2.2) 13.4 (2.4)
d[5’-GTTGG-3’]2 6.6 (1.3) 6.7 (1.1) 7.2 (1.1) 6.7 (1.2) 8.9 (1.2) 10.6 (1.0)
Table 5.3: Average number of IMI·d[5’-GGTTGGC-3’]2 H-bonds and number of waters
within the first hydration shell of IMI and d[5’-GGTTGGC-3’]2, calculated through relevant
configurations of the LFEP.
5.2.2 DST
The initial configuration has been built by manually docking the ligand on the sym-
metric 10-mer d[GCGATTAGCG]2, using as a template the X-ray structure of the
adduct DST·d[GGCCAATTGG]2 (see Methods). Figure 5.2 shows the free energy
surface G(dCMs, nhb) corresponding to the unbinding of DST, along with associated
LFEP and relevant conformations assumed by the complex. The bound conformation
is associated with a single broad minimum (Min1) centred at dCMs = 0.45, nhb = 57.
Here DST makes on average 4 H-bonds with the DNA duplex (Table 5.6), involving
mostly the nitrogen-donors of the ligand and atoms O2 and N3 on the nucleobases.
The complex is further stabilized by Van der Waals interactions between the three
pyrrol rings of DST and the DNA backbone, and by favourable electrostatic interac-
Min1 TS1-2 TS1-3 Min2 Min3 TS3-4 Out
Dihe1 26.8 (6.3) 27.4 (7.1) 30.2 (7.0) 27.2 (6.6) 31.0 (7.1) 28.6 (8.2) 31.1 (6.8)
Dihe2 11.8 (6.6) 12.8 (6.9) 14.5 (7.8) 13.3 (7.2) 15.9 (8.7) 13.2 (7.2) 17.8 (10.8)
Table 5.4: Dihedral angles between benzene and pyrrol rings (Dihe1) and between the pyrrol
and the tail CONH2 (Dihe2) of IMI along the LFEP path.
110
Unbinding of distamycin and anthramycin from DNA investigated by
metadynamics
Figure 5.2: Free energy surface G(dCMs, nhb) associated to the detachment of DST from
DNA. See Figure 5.1 for details.
Min1 TS1-2 Min2 TS2-3 Min3 TS3-4
dCMs, nhb 0.45, 57 0.61, 40 0.69, 40 1.13, 24 1.38, 19 1.84, 5.3
∆G 0.0 5.4 4.5 17.8 10.2 17.2
Table 5.5: LFEP relevant points (kcal/mol, referred to Min1) in the unbinding of DST from
DNA.
tions between the charged amidinium tail and the tract d[5’-AG-3’]2 (Table 5.6). The
free energy of hydration is about -14 kcal/mol with respect to the unbounded config-
uration and is almost entirely entropic in nature, consistently with: i) the presence
of hydrophobic rings in the ligand; ii) the fact that the DST amide protons are all
H-bonded to the nucleobases atoms. The pyrrol rings A and B (Chart I) are slightly
rotated with respect to each other to match the curvature of the groove, while the
amidinium terminal is rotated with respect to the optimized structure of DST in the
solvent in order to maximize contacts with the duplex. To quantify the distortion we
define dihedral angles between pyrrol rings (Dihe1 and Dihe2 for the dihedral angles
between rings A and B and B and C, respectively) and between the amidinium tail
and ring C (Dihe3) (Chart I, Table 5.8). In the bound conformation, Dihe1 and Dihe2
have values of ∼20◦ (in agreement with experimental [111] values observed for the
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Min1 TS1-2 Min2 TS2-3 Min3 TS3-4 Out
Coulomb -35.4 (5.3) -20.6 (2.8) -23.5 (5.6) -20.8 (3.7) -13.9 (5.2) -18.2 (1.2) -0.1 (0.1)
LJ -75.3 (4.6) -59.5 (4.5) -56.1 (2.4) -21.1 (4.0) -12.2 (2.3) -0.9 (2.1) -0.1 (0.2)
∆Cp -0.17 (0.12) -0.15 (0.14) -0.12 (0.11) -0.07 (0.15) -0.04 (0.13) 0.00 (0.06) -
T∆Shyd 12.8 (9.1) 11.3 (10.6) 9.1 (8.3) 5.3 (11.3) 3.0 (9.8) 0.2 (5.4) -
∆Ghyd -13.6 (9.7) -12.0 (11.3) -9.6 (8.9) -5.5 (12.1) -3.1 (10.5) -0.2 (6.3) -
Table 5.6: Interaction energies (kcal/mol, calculated between DST and the and tract d[5’-
CGTAATCG-3’]2) and change in the heat capacity Cp, hydration entropy and hydration free
energy (referred to the unbound system, Out) at minima and TS of the LFEP. See Table 5.2
for details.
adduct DST·d[GGCCAATTGG]2), while Dihe3 changes by∼180◦. Interestingly, we
also found that DST influences asymmetrically the MG width [111], which is larger
at the 3’ end of strand1 (Figure 5.3b), whereas it does not influence the overall struc-
tural parameters of the duplex. The detachment process starts at the transition state
TS1-2 (∆G‡ = 5.4,kcal/mol). Here the drug is significantly distorted with respect
to Min1; in particular the amidinium tail now points outside the MG floor, which is
reflected by changes of 80◦ and 50◦ in Dihe3 and Dihe2, respectively (Table 5.8). The
tail reorientation causes a widening of the MG by ∼4 Å in the neighbouring region
(Figure 5.3b), and the complex gains ∼10 waters within the first ydration shell (Ta-
ble 5.7). Consistently, the average number of DST-DNA H-bonds, the van der Waals
and the electrostatic interactions decrease with respect to Min1 (Table 5.6).
The next relevant conformatin we encounter along the LFEP is a relative mini-
mum, Min2, 4.5 kcal/mol higher in free energy than Min1. Here the values of Dihe1
and Dihe2 are very similar to those found in Min1, while Dihe3 further decreases by
∼20◦ with respect to TS1-2 (Table 5.8). The number of drug/DNA H-bonds as well as
the overall interaction energy is virtually the same as in TS1-2. A few additional wa-
ters enter the hydration shell of the ligand and the duplex; indeed a lower desolvation
free energy is found as compared to Min2.
The successive relevant conformation is associated to the highest state in free en-
ergy, TS2-3, ∼18 kcal/mol relative to Min1. Here DST loose contacts with the MG
Min1 TS1-2 Min2 TS2-3 Min3 TS3-4
# H-bonds 3.9 (1.0) 1.7 (0.8) 1.7 (0.8) 1.5 (0.7) 1.5 (0.7) 1.0 (0.2)
DST 11.4 (1.9) 16.4 (1.9) 18.0 (1.5) 18.9 (3.2) 19.8 (2.5) 22.3 (3.7)
d[5’-CGTAATCG-3’]2 5.4 (0.8) 8.9 (1.6) 12.5 (0.7) 10.7 (1.1) 12.5 (1.1) 15.3 (1.3)
Table 5.7: Average number of DST·d[5’-CGTAATCG-3’]2 H-bonds and number of waters
within the first hydration shell of IMI and d[5’-CGTAATCG-3’]2, calculated through relevant
configurations of the LFEP.
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floor but still bounds to the DNA backbone: as can be seen in Figure 5.2, the lig-
and “follows” the strands of the duplex while its charged tail is still into the groove.
As the main body of DST exits the MG this latter recovers the same overall profile
it has in Min1 (Figure 5.3b). The loss of hydrophobic contacts between the ligand
pyrrole rings and the MG walls in Min3 is mirrored by a significant decrease of van
der Waals interactions, while leaving unaltered the other non-bonded interactions (Ta-
bles 5.6, 5.7) and the number of waters within first hydration shells. As for the ligand
conformation, only Dihe3 features a significant change with respect to Min1.
TS2-3 is followed by the intermediate Min3, in which the main axis of the ligand
is almost perpendicular to that of the duplex. Both the electrostatic and van der Waals
interactions weaken with respect to TS2-3, while the number of H-bonds between
the ligand and the duplex does not change(Tables 5.6, 5.7). As for TS2-3, there is a
significant decrease of the solvation free energy gain with respect to Min2, yet the hy-
dration of the complex is quite similar to that found there. This might be traced back
to two compensating factors: i) the narrowing of the MG (Figure 5.3b), which causes
a decrease of the value of the SASA contrasting the increase due to the unbinding of
the main DST body; ii) the burying of the charged amidinium tail, which compensate
for the complete solvation of DST rings and polar hydrogens. Regarding the structure
of the ligand, the rings are almost planar among them and Dihe3 also recovers a value
very similar to that found in Min1.
From Min3 the ligand exits the MG (configuration Out) passing through TS3-4
(∆G‡∼7 kcal/mol with respect to Min3 and ∼17 kcal/mol relative to Min1, where it
is stabilized by electrostatics interactions with strand1 (Table 5.6, Figure 5.4b). Both
the duplex and DST gain a few water molecules in their hydration shells, and the free
energy of hydration is virtually zero.
On passing from Min1 to Out the DNA remains close to the canonical B-DNA
conformation, and there is a progressive decrease in the hydration free energy, con-
sistently with the largest buried area in Min1 with respect to the other relevant con-
figurations. Summarizing, the unbinding of DST proceeds in three steps i) a partial
rearrangement of amidinium tails occurs, with breaking of ligand/DNA H-bonds; ii)
DST pyrrol rings are solvated, while the positively charged tail anchors the drug to
Min1 TS1-2 Min2 TS2-3 Min3 TS3-4 Out QMa
Dihe1 21 (12) 16 (15) 21 (3) 4 (22) -4 (18) -9 (4) -10 (9) -19
Dihe2 22 (12) -26 (25) 29 (18) 17 (22) -20 (16) -11 (7) -17 (10) 23
Dihe3 89 (27) 9 (22) -16 (14) 26 (42) 108 (35) -71 (21) 81 (24) -86
a. Taken from the structure optimized at the HF/6-31G(d)/CPCM level (see Methods).
Table 5.8: Dihedral angles between rings A and B (Dihe1), B and C (Dihe2), and between
ring C and the amidinium tail of (Dihe3) of DST along the LFEP path.
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a) b)
Figure 5.3: a) Variations of the minor groove width in the region d[5’-CGTTGGCC-3’]2,
calculated along relevant points of the LFEP associated to the detachment of IMI from the
DNA duplex; b) Variations of the minor groove width in the region d-[5’-ATTAC-3’]2, during
detachment of DST.
a) b)
Figure 5.4: a) Interaction energies of IMI with the tracts d[5’-CGTTG∗GC-3’] (strand1) and
d[5’-CGTTG∗GC-3’] (strand2) along relevant points of the LFEP. Arrows indicate configu-
rations where waters enter the region between IMI and strand1, weakening hydrophobic in-
teractions; b) Interaction energies of DST with the tracts d[5’-CGTAATCG-3’] (strand1) and
d[5’-CGTAATCG-3’] (strand2). In contrast to IMI, DST interactions with the two strands are
almost identical in strength during the entire unbinding process.
MG, iii) a complete detachment occurs with the removal of the ligand tail from the
groove. The largest activation free energy we found, ∆G‡ ∼13 kcal/mol, is required
by the transition from Min2 to Min3 through TS2-3. However, considering the neg-
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Figure 5.5: Close view of
the difference between con-
formations Min1 and Min2
in IMI•DNA. The two struc-
tures globally overlap, al-
though the ribose sugar and
the nucleoside G8 are rotated
relatively to each other.
ligible barrier of 1 kcal/mol associated to TS2-1, we can assume an overall activation
free energy for the pyrrol rings detachment of ∼18 kcal/mol. In addition, the free
energy barrier for the complete DST detachment (from Min3 to Min4) is practically
identical to that found for the reverse path from Min3 to Min2 (∆G‡ ∼7 kcal/mol).
As for IMI, the detachment of the drug occurs with the same mechanism described
above when the active CVs are dCMs, dCMs,nhph or dCMs,nhph,nhb (see Figure 5.8).
The largest free energy barrier (∆G‡∼14 kcal/mol) corresponds again to the disrup-
tion of hydrophobic ligand/DNA contacts and to the solvation of the DST main body
(from Point 1 to 7 in Figure 5.8). However, some differences in the free energy sur-
face G(dCMs, nhph) are found with respect to Figure 5.2: the overall barrier in the
latter is higher by ∼4 kcal/mol than that calculated as a function of dCMs,nhb, and the
intermediate is shifted towards lower values of dCMs and less stable than Min3. The
larger discrepancies found in the free energy surfaces as compared to IMI are prob-
ably due to the larger number of internal degrees of freedom in DST. The enhanced
flexibility of the ligand renders free energy profiles obtained trhough a dimensional
reduction (as those calculated here) much more “CVs-sensitive”, despite a very simi-
lar underlying mechanism.
Figure 5.6: View of the MG widening in configurations Min3 (left) and TS1-3 (right) of
IMI•DNA. The opening of the groove enhances the hydration of the region between the drug
and strand1, which appears to be an important pre-requisite for the exit of the compound.
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In this work we have characterized the unbinding of anthramycin and distamycin
starting from the non covalent complexes between the ligands and the DNA. Although
catching the free energy changes in the process by dimensional reduction is a deli-
cate task, especially for ligands featuring internal flexibility as DST, the mechanism
appears to be much less sensitive to the choice of the CVs, at least in this specific
case. DNA duplexes do not experience bending or other global deformations upon
unbinding of both ligands. This is the case also for the quite rigid molecule anthra-
mycin, consistently with previous results indicating that the drug already possesses a
natural conformation to fit into the MG [84, 99]. In contrast, the more flexible DST
undergo some relevant conformational change along the process. The barrier for the
removal of DST, ∼18 kcal/mol, turns out to be significantly larger than that for the
detachment of IMI (∼12 kcal/mol), consistently with the higher molecular weight of
the former. The calculated activation free energy for DST•DNA compares well with
that (16.6 kcal/mol) extracted within the Arrhenius theory from stopped-flow experi-
ments [292].
The primary source of destabilization in DST•DNA is the loss of specific H-
bonds, which in turn causes a weakening of hydrophobic interactions. Disruption
of these latter corresponds to the highest barrier (∼13 kcal/mol) along the LFEP, in
agreement with previous suggestions [9], while electrostatic plays a relevant role in
the last step of detachment. These results indicate that, also for this prototype of
sequence-readers based on H-bond matching [73, 327, 9], the hydrophobic interac-
tions provide the main contribution to DNA affinity [37, 271, 261], while the charged
tail could be the main responsible for the targeting of negative potential AT tracts. Hy-
drophobic interactions give the largest contribution to the affinity also in IMI•DNA,
whereas H-bonds or electrostatics do not play a key role.
Both IMI and DST anchor to the MG via their hydrophilic tails before the com-
plete detachment takes place. However, the strength of this interaction is different
in the two complexes: DST forms an intermediate by interacting with both DNA
strands, because its positively charged amidinium tail complements the negative po-
tential of AT tracts. In contrast, in IMI•DNA such a conformation corresponds to
a transition state because the neutral ligand’s tail is not able to establish such an in-
teraction. A further difference between the two compounds regards the role of DNA
conformational changes and waters in the detachment process. The detachment of
IMI is triggered by a local deformation of the duplex and a corresponding hydration
of the region between the drug and one DNA strand. On the contrary, for DST no
intermediate or metastable states where waters interpose between the ligand and one
DNA strand have been identified in our simulations. Thus, water molecules seem not
able to interfere with the tight packing between DST and DNA and to play an active
role in the unbinding.
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Breusegem et al. have performed kinetic measurements on DNA binding and
unbinding by Hoechst33258 (HST) [297, 269], representative of the class of MG
binders containing benzimidazole groups. The comparison of their data with our
results, along with those of previous MD simulations of anthramycin and duocarmy-
cin [328], seems to suggests the existence of common aspects in the DNA molecular
recognition by MG binders. Indeed they found that dissociation of HST from DNA
is characterized by a rather complex behavior, necessitating an intermediate that re-
quires structural changes with respect to the bound conformation [269]. Thus, two
different states are apparently involved while the drug is bound within the MG, that
can be interpreted either as a sliding of the drug along the MG (as for IMI [84]) or
as the presence of an intermediate (as for DST). In addition, as in the case of DST,
they suggest that rates of binding and unbinding from the intermediate (here Min3)
are very similar, so that the overall dissociation rate is due to the breaking of Van
der Waals contacts and hydrogen bonds in the bound state. Although this discussion
is in part speculative and requires a further thorough analysis, it is still important to
pinpoint common features among the different classes of MG binders.
Limitations of the present calculations. Although appropriate to investigate the de-
tachment, the CVs used here may be too general to distinguish among many different
possible orientations that the drug would assume to enter the groove. Particular at-
tention may be payed in the future to identify CVs well suited to characterize the
binding process. In addition, no evaluation of the error has been performed as we
stop estimating the FES after the complete detachment of the drug (see Methods).
Nevertheless, the accuracy of metadynamics has been shown to depend only on the
height and widths of the CVs and on their intrinsic diffusion coefficient, along with
the deposition time [209]. The choices we made for metadynamics parameters are in
line with previous studies, for which the average error has been shown to be less than
∼2 kcal/mol [304, 307].
5.4 Conclusions
The mechanism of unbinding of IMI and DST from DNA has been here investigated
via metadynamics in the framework of classical molecular dynamics. Our simula-
tions reveal that IMI unbinding occurs via the detachment of the ligand from strand
containing the alkylating guanine, which leads to the exit of the IMI benzodiazepine
head. The process has an overall activation free energy barrier ∼12 kcal/mol, and
groove hydration appears to be relevant to the weakening of ligand/DNA interactions.
Diversely, DST unbinding occurs through three steps: initially the amidinium tail
of the drug rearranges, determining a loss of ligand/DNA H-bonds contacts and in-
creased hydration and MG width; successively, the main body of the drug exits from
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the groove; the charged amidinium tail keeps the last contacts with the DNA before
unbinding. Due to the stronger packing and electrostatic stabilization (associated with
the higher effective contact size within the minor groove) as well as the larger num-
ber of specific H-bonds, the overall activation free energy is larger for DST than for
IMI (∆G‡ ∼18 kcal/mol, in good agreement with the experimental value). The ac-
cordance confirms the reliability of metadynamics, here applied for the first time to
drug/DNA complexes, in the characterization of rare events. The mechanism found
here for DST compares quite well with the one suggested for the dye Hoechst33258
on the basis of kinetics measurements. Furthermore, our study provides interesting
molecular-level features on the unbinding of representatives of two large and pharma-
cologically relevant families of MG binder, unveiling their similarities and peculiari-
ties.
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Figure 5.7: Free energy surface of detachment of IMI from DNA calculated as a function of
dCMs and nhb. Selected minima and transition states are indicated by green points and corre-
sponding free energies are reported in kcal/mol. Isosurfaces are drawn one per 2 kcal/mol.
Figure 5.8: Free energy surface of detachment of DST from DNA calculated as a function of
dCMs and nhph. Selected minima and transition states are indicated by green points and cor-
responding free energies are reported in kcal/mol. Isosurfaces are drawn one per 2 kcal/mol.
Part III
Hydrolysis of Ru-based drugs
Chapter 6
Hydrolysis of anticancer ruthenium
drugs NAMI-A and ICR
6.1 Introduction
Ru-based complexes are today one of the most promising alternatives to platinum-
containing anticancer drugs [329]. Among this class of compounds, (ImH)[trans-
RuCl4(DMSO-S)(Im)] (Im=imidazole, DMSO-S=S-bonded dimethylsulfoxide),
NAMI-A (Chart I), is a powerful antimetastatic agent that already passed phase I clin-
ical trials [330]. Despite its promising pharmacological activity, nature of NAMI-A
chemical species responsible for the antimetastatic activity [331,332] and the mecha-
nism of action [329,116] have not been unveiled. In vitro experiments have shown the
drug to readily undergo hydrolysis at physiological conditions (pH=7.4) [333, 334,
335], suggesting that NAMI-A in vivo may form a mixture of hydrolyzed species,
whose nature strongly depends on pH. NAMI-A disappears after 15-20 min [333,
334, 335] due to both Cl− and DMSO hydrolyses; 45 minutes are required to com-
plete the first hydrolysis step, while the second occurs within 2 hours [334]. Un-
der acidic conditions (pH=3-6), Cl− dissociation is much slower and only a partial
DMSO dissociation occurs [331, 332, 333, 334, 336]. Hydrolysis eventually leads to
formation of polymeric oxo- or hydroxo-bridged species [334, 335], albeit this phe-
nomenon is less likely in vivo due to the bio-ligands availability, e.g., presence of
albumin precludes formation of such polymeric species [337]. NAMI-A metabolites
have shown to bind strongly to several proteins, including integrins, transferrins and
human serum albumin [337, 338, 339, 340, 341, 342]. In contrast to platinum drugs,
NAMI-A binds to DNA weakly [343], indicating that its antimetastatic activity may
be not related to DNA damage. The compound (ImH)[trans-RuCl4(Im)2], ICR (or
KP418), (Chart I) and its indazole analogue KP1019 [116,344,345,346], albeit struc-
turally similar to NAMI-A, have promising anticancer activity against colorectal can-
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Chart I
cers [342, 345, 346], but no relevant antimetastatic effects [344]. ICR reacts with
DNA following a cisplatin-like kinetics, inhibiting its template-primer properties for
nucleic acid synthesis [347]. Experimental data indicate that in vitro ICR undergoes
step-wise hydrolysis of chloride ions [345, 348], but nature and oxidation state of the
active ruthenium metabolites are still unknown. The hydrolysis is supposed to be a
crucial step as only aged ICR solutions how the drug binding to DNA [349].
The biological diversity between NAMI-A and ICR may be partially due to their
different redox properties: reduction potentials Em (vs. normal hydrogen electrode,
NHE) are 0.235 V and -0.275 V, respectively [350, 351]. Such a difference is caused
by the DMSO, which is a moderate π-acceptor and stabilizes RuII [332,333]. Because
of its positive Em, NAMI-A may be easily reduced in vivo by biological reductants,
even before undergoing dissociation. Indeed, the reduced form of NAMI-A and/or its
metabolites have been demonstrated to be of crucial importance [331, 332, 333, 334],
having a robust antimetastatic activity on tumor models [334]. In contrast, ICR
would need stronger reductants which may be more rare in a biological environ-
ment [331, 348, 352]. Consistently, ICR has proved to be more inert than NAMI-A,
and its hydrolysis path is less affected by reductants [353].
Recently, Chen et al. have reported a theoretical investigation on NAMI-A and
ICR hydrolyses [354, 355], focusing on Cl− dissociation. Calculated structural prop-
erties and kinetic constants are in good agreement with the available experimental
data. However, dissociations of DMSO and imidazole have not been studied, despite
the proved biological relevance of DMSO (partial) hydrolysis [333, 334]. Further-
more, the hydrolysis of the reduced compounds has not been considered, even though
it may be important for both drugs due to the high reducing power of solid tumor
tissues [348, 356].
In order to understand the mechanism of action of NAMI-A and ICR at the molec-
ular level, an extensive investigation of the hydrolysis paths in both Ru oxidation
states, along with an evaluation of the reduction potentials of the two drugs and their
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metabolites is needed. In this work we tackle this issue and report a systematic study
of the hydrolyses of the two drugs up to the third aquation, combining DFT calcu-
lations and an implicit description of the solvent through the Conductor-like Polariz-
able Continuum Model (CPCM) [323]. Reduction potentials of NAMI-A, ICR, and
of their most relevant hydrolyzed species were estimated within the same setup, to
explore the effects of biological reductants.
This study is a first attempt to rationalize the large amount of available experimen-
tal findings, that in some cases led to discrepant conclusions [332, 348]. In addition,
it confirms the ability of computational studies to qualitatively predict the hydrolysis
of different substituents from metal-containing compounds.
6.2 Computational Details
The hydrolysis of NAMI-A and ICR in both RuIII and RuII oxidation states was in-
vestigated in the framework of the Density Functional Theory (DFT), employing the
Gaussian03 package [273]. In order to consider all possible hydrolytic paths, disso-
ciation of each ligand (namely Cl−, DMSO-S and Im), was studied in the presence of
one explicit incoming water. To achieve a trade-off between accuracy and computa-
tional costs the following methodology was adopted [357, 358]:
1. Full in vacuo optimization without symmetry constraints of reactants (R), prod-
ucts (P) and transition states (TS) using the B3LYP exchange-correlation func-
tional [157,161], with 6-31G(d,p) and Lanl2DZ [359,360,361] basis sets on N,
S, C, O, H, Cl and Ru atoms, respectively.
2. Harmonic frequency calculations at the same level of theory, i) to confirm that
optimized structures were minima or transition states, ii) to estimate zero-point
vibrational energies, thermal and entropic corrections.
3. Single point calculations with larger basis sets on optimized structures. Namely,
6-311+G(3d) on Cl and S atoms, 6-311+G(d,p) on all the other non-metal
atoms, and Lan2DZ(f) (ζf = 1.235) [362] on Ru were used in order to obtain an
improved value of the internal energy [357, 358].
4. Single point calculations (same set-up as in c) on optimized structures mim-
icking hydration effects via an implicit solvation model (CPCM) [323]. We
are aware that PCM calculations of small ions such as Cl− may be problem-
atic. However, a very good agreement was found between experimental and
theoretical solvation free energies of Cl− calculated here [323, 363] (data not
shown).
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Free energies were then calculated adding to the internal energy the zero-point vibra-
tional energy, the entropic term (using Wertz correction) and the solvation free en-
ergy [364, 365]. Correction for the standard concentration was also considered [354,
355].
Activation free energies are usually calculated as the difference between the free
energy of the transition state (TS) and that of the reaction intermediate RI, i.e. the
stable complex between the reactant and a water molecule (the same terminology is
used also for the product intermediate, indicated by PI). However, Lau et al. have
cast doubts on the physical basis of considering reaction intermediates RI and PI as
reference states for calculating activation and reaction free energies of hydrolysis pro-
cesses [358]. Indeed, they have shown that the free energy of an isolated reactant and
an isolated water molecule (named as R, and P for the reactant and product, respec-
tively) significantly differs from that of RI (and PI). This discrepancy is believed to
arise from the failure of implicit solvent models at reproducing the correct solvation
entropy in bimolecular reactions. To overcome this issue in Ref. [358] the entropy was
corrected by Wertz’s approach [364,365], obtaining almost identical free energies for
RI and R. Unfortunately, the same procedure does not provide consistent results when
applied to the PIs, whose free energies are systematically higher than those of Ps. In
particular, all hydrolysis steps turned out to be endothermic (up to 10 kcal/mol) when
comparing the free energy of PI to that of RI. Considering the free energy differences
between reactants R and products P led to reaction free energies in close agreement
with experiments.
Therefore, we calculated the activation free energies by referring each TS to the
corresponding RI (which are likely to be affected to the same extent by the inaccu-
racy of our computational model), while reaction free energies were calculated by
comparing P with R, as in Ref. [358]. We believe this protocol to be more suitable
to correctly calculate TS barriers, and to minimize the uncertainty when comparing
different hydrolysis products (e.g. those resulting from Cl− or DMSO dissociation).
Notably, this scheme gave results in good agreement with previous theoretical and
experimental results (Tabs. 6.1, 6.3), vide infra [350,354,355,366]. We are thus con-
fident that our set-up may predict thermodynamic and kinetic data, not experimentally
available, and may be useful to rationalize both NAMI-A and ICR hydrolyses.
For the sake of clarity, products of different steps were labeled as PNa,b,c where
a,b,c refers to the ligand exchanged during hydrolysis, N indicating the hydrolysis
step. Similarly, transition state structures were reported as TSNa, where a is the leav-
ing group, N indicating the hydrolysis step. We would like to stress that reactions
involving small groups or atoms are routinely characterized, while those in which
the leaving groups are as large as Im (or DMSO) present many issues. In particu-
lar, due to the large number of degrees of freedom the search for their TS may be
awkward. We indeed found accurate TS structures corresponding to Cl− and DMSO
dissociation. Unfortunately, such a satisfactory accuracy was not achieved for Im dis-
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sociation. Due to these difficulties, we considered as (pseudo) TS for Im dissociation
the structure corresponding to the highest energy while breaking the Ru-NIm bond in
the presence of one explicit water. This should allow a qualitative comparison of the
Im dissociation barrier with activation free energies of Cl− and DMSO. Indeed, our
results suggest, in line with experimental findings [333], that Im dissociation is not
likely under neutral conditions.
A final comment on the reactants concentrations is necessary. It has been shown
that cell chloride ion concentration strongly affects the hydrolysis of other metal-
based drugs, such as cisplatin [367,368,369]. This may be expected to occur also for
NAMI-A and ICR, but our theoretical approach cannot consider such an important
aspect. Nevertheless, Reedijk and co-workers [333] have shown that Cl− concentra-
tion affects both Cl− and DMSO dissociations from NAMI-AIII in a similar manner,
suggesting that also other hydrolysis pathways may be similarly affected in vivo.
All possible hydrolytic paths1 were characterized employing the approach dis-
cussed above, yet, for the sake of clarity, we only reported energetics, along with
selected structural and electronic properties of the most relevant complexes (for more
details, see Supporting Information). Remarkably, structures of NAMI-A and ICR
obtained with our computational set-up are very similar to those reported in pre-
vious theoretical studies [354, 355] and in fair agreement with experimental results
[350, 112] (Tab. 6.1). Discrepancies may be caused by the intrinsic inaccuracy of the
computational approach as well as to crystal packing forces present in the X-ray struc-
tures [354, 355]. To further test our computational set-up, we performed calculations
with larger basis sets with and without the inclusion of solvent during optimization,
finding virtually the same geometries as with the previous setup. Furthermore, struc-
tural and energetic properties of NAMI-AII were calculated at the MP2 level [143],
founding a satisfactory agreement with DFT results.
Molecular properties were calculated using Bader et al.’s theory of Atoms In Mo-
lecules (AIM) [370, 371], in order to analyze the electron density (ρ) at Bond Criti-
cal Points (BCP). Indeed, the electron density at such critical points correlates well
with the strength of chemical bonds and interactions [372, 373, 374, 375]. Topologies
were built using AIMPAC series of programs [376]. Charges were calculated with
the full Natural Bond Orbital (NBO) analysis [377]. Both NBO and AIM analyses
were carried out considering the solvent effects. Following previous works [378,379],
reduction potentials (Em) at standard conditions were estimated from the following
equation:
Em =
∆G
nF
(6.1)
1For example, about 15 geometry optimizations were performed only for the first hydrolysis step
of NAMI-AIII, or more than 400 calculations for describing the entire hydrolysis paths for NAMI-A
and ICR in both oxidation states.
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where F = 96485C (the Faraday constant), Em is the reduction potential and n the
number of electrons involved in the redox process. To compare reduction potentials
with experimental data, Em were referred to the normal hydrogen electrode, NHE.
As suggested by previous benchmark studies [380], to reproduce redox potential is
not a trivial task and medium-large basis sets, zero-point-energy and entropic correc-
tions should be employed to provide a semi-quantitative agreement with experimental
results.
6.3 Results and Discussion
Energetic, structural and electronic properties of the most relevant metabolites of
NAMI-A and ICR in both RuIII and RuII oxidation states (hereafter as NAMI-AIII/II,
ICRIII/II) are reported. As NAMI-A is likely to be reduced in vivo, and NAMI-AII
metabolites have shown antimetastatic effects [331,332,334,345,346,352,380,114],
the chemical behavior of reduced species is crucial to understand the biological ac-
tivity of this drug. Reduction of ICR in biological environments is less likely, but
may take place in cancerous tissues. For these reasons, and since theoretical studies
on NAMI-AIII and ICRIII have recently been reported [354, 355] discussion of RuII
species is more detailed and precedes that of RuIII ones.
6.3.1 Hydrolysis Mechanism of NAMI-A
Fig. 6.1 displays the most likely hydrolysis paths of NAMI-A in both Ruthenium
oxidation states, up to the third hydrolysis step. At the end of the Chapter is also
reported a complete thermodynamic characterization of all the hydrolysis steps in-
vestigated here (Figs. 6.4, 6.5, 6.6 6.7). Dissociation of Im typically requires an
activation free energy (∆G‡) larger than that of Cl− and DMSO, and products of Im
hydrolysis have the largest endothermic character. Therefore, Im-water exchange is
unlikely under neutral conditions in both Ru oxidation states, in agreement with ex-
perimental results [116]. This may be partly due to the strength of their coordination
bonds, e.g., the Ru-N bond of NAMI-AII is somewhat stronger than the Ru–S bond
(dRu−N = 2.10 Å and ρRu−N = 0.0701 au, dRu−S = 2.32 Å and ρRu−S = 0.0576 au,
where ρ is the density at the critical point, Tab. 6.1). Thus, the following discussion
is limited to Cl− and DMSO hydrolyses.
NAMI-AII
Step I. In line with previous theoretical studies [354] and experimental findings [332]
our data suggest that Cl− dissociation is the most favorable process. The activation
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Figure 6.1: a) Proposed reaction paths for the hydrolysis of NAMI-A. Calculated and experi-
mental (in brackets) reduction potentials vs NHE are shown. b) Free energy profile associated
to the most likely hydrolysis path of NAMI-AII, up to the third substitution. The most favor-
able transition states and products are represented by solid lines, while dotted lines are used
for unlikely transition state and intermediates. Activation energies (kcal/mol) are displayed in
the squares along the reaction path. Reaction free energies are calculated with respect to R.
c) Free energy profile associated to the most likely hydrolysis path of NAMI-AIII. Black and
red lines correspond to Cl− and DMSO hydrolysis paths.
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free energies of DMSO and Cl− dissociations are comparable (Fig. 6.4), but thermo-
dynamics largely favors chloride ion hydrolysis (PICl is virtually isothermic to R,
whilst PIDMSO is endothermic by 10.7 kcal/mol). Indeed, the NBO analysis con-
firmed that after DMSO dissociation, the drug will maintain the overall -2 charge,
losing a large group on which the electron density may delocalize. In contrast, the
leaving Cl− has partial charge of about -0.9 au, i.e., the overall negative charge on
the metal complex is reduced to -1, promoting the reaction. The larger stability
of PICl as compared to PIDMSO may be partly caused by an intra-molecular O-
H· · ·ODMSO H-bond between the coordinated water molecule and the DMSO oxygen
(dH···O=1.96 Å and ρ=0.0189 au), as well as an intra-molecular O-H· · ·Cl H-bond,
(dH···Cl=2.30,Å and ρH···Cl=0.0148 au). We verified that the isomer in which the Ru-
OH2 bond is rotated by 180◦ (no H-bonding) is less stable by ∼6 kcal/mol, i.e. PICl
should be preferred over PIDMSO also in case the intra-molecular H-bond to DMSO-
S is broken. Thus, both kinetic and thermodynamic features suggest that chloride ion
hydrolysis is the most favored at the first step.
Step II. Reaction proceeds faster from step I to II, as the activation free energy of
the second Cl−-water exchange decreases by ∼6-8 kcal/mol. As in previous step,
this dissociation is kinetically competitive with that of DMSO, yet relative products
stability favors dissociation of a second Cl−. Indeed, the product of DMSO hydrolysis
is endothermic by 10.4 kcal/mol, while PIIcis2Cl and PII trans2Cl sit respectively at -2.6
and -3.1 kcal/mol with respect to R. This would rule out the possibility of DMSO
dissociation at the second step, in line with in vitro studies at neutral pH [332, 335].
In addition, our calculations suggest formation of a mixture of cis and trans diaqua
isomers, supporting experimental hypotheses [332].
Step III. The analysis of the third hydrolysis reveals intriguing features. In particu-
lar, DMSO dissociation becomes kinetically unlikely with respect to that of Cl−, yet
NAMI-AII ICRII NAMI-AIII ICRIII
d ρ d ρ d ρ d ρ
Ru-Cl 2.55 0.0604 2.58 0.0529 2.43(2.34) 0.0627 2.44(2.36) 0.0609
Ru-S 2.32 0.0576 - - 2.40(2.30) 0.0520 - -
Ru-N 2.10 0.0701 2.10 0.0772 2.10(2.08) 0.0854 2.10(2.08) 0.0761
Table 6.1: Selected bond lengths (d, Å) and electron densities (ρ, au) of NAMI-A and ICR in
both oxidation states. Experimental values (in brackets) of NAMI [330, 331] (the analogous
sodium salt of NAMI-A) and ICR [332,335] bond lengths are displayed (Ru-Cl is reported as
average).
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the free energy difference between PIII3Cl and PIII2Cl,DMSO reduces as compared
to the first and second steps. A simple electrostatic analysis may provide a rationale
for this behavior. During the first two hydrolysis steps, the metal complex bears an
overall negative charge of -2 and -1, respectively, i.e. dissociation of the negatively
charged chloride is favored with respect to neutral DMSO-S ligand. After the second
Cl− dissociation, PII2Cl is neutral, with DMSO dissociation becoming more favor-
able. Thus, the hydrolysis of NAMI-AII mainly consists of a stepwise Cl−-water ex-
change: all Cl− dissociations are exothermic with decreasing activation free energy
barriers as the reaction proceeds. Findings of the first, second and third hydrolysis
steps are in qualitative agreement with experiments by Alessio and co-workers, who
extensively characterized the hydrolytic behavior of NAMI-AII at pH=7 [332, 351].
NAMI-AIII vs. NAMI-AII hydrolysis
At the first hydrolysis step, the activation free energy of Cl− dissociation is larger
(by ∼6 kcal/mol) than that of DMSO (Fig. 6.1). Notably, the calculated barrier
for Cl− dissociation (∆G‡=24.5 kcal/mol) is in good agreement with experimental
measurements (∆G‡=22.8 kcal/mol) and recent, more accurate and computationally
expensive, theoretical predictions (∆G‡=23.2 kcal/mol) [350, 354]. Since PICl and
PIDMSO are virtually isothermic, DMSO substitution, thermodynamically hindered
for NAMI-AII, is very likely to take place during NAMI-AIII hydrolysis. Indeed,
geometrical properties and electron density analysis confirm that the Ru-S bond is
stronger in NAMI-AII than in NAMI-AIII , i.e. DMSO-S is a moderate π-acceptor
and the π component of the RuII-S bond is expected to be stronger when the complex
has a negative charge [334] (see Tab. 6.1). Consistently with these results, experi-
ments by Sava et al. showed that a slow DMSO hydrolysis occurs [334]. This is also
in line with NMR, spectroscopic and X-ray data, which indicate that DMSO-S binds
more strongly to RuII than to RuIII [350, 331].
Irrespective of the path followed, the product of the second hydrolysis step is
PIICl,DMSO: the most likely leaving group from PICl is DMSO, with a ∆G‡=17.9
kcal/mol, while, the release of Cl− from PIDMSO occurs with a kinetic barrier of
18.9 kcal/mol. This scenario is compatible with experimental findings of a partial
DMSO dissociation occurring simultaneously to Cl− hydrolysis [333]. The loss of a
further Cl− from PIICl,DMSO is kinetically more favored in cis than in trans, with
the entire process being slightly endothermic.
These results suggest that reduction significantly affects the hydrolysis of NAMI-
A: NAMI-AII hydrolysis is overall exothermic with slightly lower activation free en-
ergies barriers compared to those of NAMI-AIII, this difference increasing as the hy-
drolysis proceeds. Importantly, our data suggest that neither NAMI-A reduction nor
DMSO dissociation can be neglected a priori, since they may both play a fundamental
role for NAMI-A antimetastatic activity.
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6.3.2 Hydrolysis Mechanism of ICR
In order to identify those features responsible for the different pharmacological ac-
tivity of NAMI-A and ICR, a broad analysis of the ICR hydrolysis mechanism is
proposed. In agreement with experimental studies [333] we find that imidazole dis-
sociation is typically unlikely in both oxidation states.
ICRII
The most likely group to dissociate from ICR is Cl− (Figs. 6.2b, 6.6) with ∆G‡=23.2
kcal/mol, PICl being virtually isothermic to R. Interestingly, the activation free en-
ergy is similar to that of 24.8 kcal/mol estimated for TSICl of NAMI-AII , suggest-
ing that kinetics of the first Cl− dissociation are virtually unaffected by the pres-
ence of DMSO-S or Im ligands. At the second hydrolysis step PII trans2Cl and PIIcis2Cl
may originate with the following energetics: ∆G‡ = 21.6 and ∆G = 0.7 kcal/mol,
∆G‡ = 16.1 and ∆G = −1.8 kcal/mol respectively. Importantly, our calculations
strongly suggest that formation of cis diaqua complexes is kinetically preferred to
that of trans isomers. This may be due to an intricate interplay of several factors,
including trans influence and H-bonding. Firstly, as consequence of the trans influ-
ence, Ru-Cl in trans to water is the strongest in PICl, and Cltrans therefore is the
least likely to leave (dtransRu−Cl=2.46 Å and ρtransRu−Cl = 0.0666 au, as compared to dcisRu−Cl
=2.56 Å and ρcisRu−Cl=0.0560 au, averaged over the other two Ru-Cl bonds).
Because of a strong H-bonding (Tab. 6.2), both entering water and leaving Cl−
interact more strongly with the metal center compared to TSII transCl . These effects
may provide the extra stabilisation of the transition state that leads to the cis diaqua
isomer. The kinetic preference for PIIcis2Cl with respect to PII trans2Cl is remarkable as
may be related to different pharmacological activity of NAMI-A and ICR. Yet, calcu-
lations that include dynamical properties of explicit solvent molecules are needed to
confirm this point beyond doubt. Nevertheless, we would like to remark that strong
intramolecular H-bonds should be less affected by the presence of explicit water mo-
lecules [373, 381]. In agreement with experimental findings [349], thermodynamics
of cis and trans diaqua complexes are virtually equivalent i.e., on a long time scale
both complexes are formed. Similarly to NAMI-AII hydrolysis, the third Cl− substi-
tution is exothermic and most likely to take place from TSII transCl .
ICRIII vs. ICRII hydrolysis
As suggested by the experiments of Mestroni et al. [353], a change in Ru oxidation
state affects ICR hydrolysis to a minor extent (Figs. 6.2c, 6.6). Indeed, the ICRIII
hydrolysis consists of a stepwise Cl−-water exchange with Im dissociation being un-
likely at every step. The activation free energy relative to the first hydrolysis is virtu-
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Figure 6.2: a) Proposed reaction paths for the hydrolysis of ICR. Calculated and experimen-
tal (in brackets) reduction potentials vs NHE are shown. b) Free energy profile associated
to the most likely hydrolysis path of ICRII, up to the third substitution. The most favorable
transition states and products are represented by solid lines, while dotted lines are used for
unlikely transition states and reaction intermediates. Activation energies (kcal/mol) are dis-
played in the squares along the reaction path. Free energies are calculated with respect to R.
c) Free energy profile associated to the most likely hydrolysis path of ICRIII. Only cis diaqua
complexes are shown to remark the ICR kinetic preference for these isomers.
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O∗-H · · · Cl‡ Ru-O-H · · · Cl‡ Ru · · · Cl‡ Ru · · · ∗OH2
PIIcis2Cl 2.12(0.0300) 1.95(0.0437) 3.20(0.0173) 2.84(0.0189)
PIItrans2Cl 2.05(0.0347) - - 3.28(0.0135) 2.91(0.0144)
∗ entering water molecule; ‡ leaving Cl ion.
Table 6.2: Selected geometrical (Å) and electron density (in brackets, au) properties of TS
leading to PIIcis2Cl and PIItrans2Cl products of ICR hydrolysis.
ally insensitive to the Ru oxidation state, but the process is thermodynamically more
favored. Calculated activation free energy (∆G‡=22.7 kcal/mol) is in good agreement
with that recently found by a theoretical investigation based on more computationally
demanding calculations (24.0 kcal/mol) [355] and to that measured experimentally
(24.1 kcal/mol) [366].
As for the first step, Ru oxidation state hardly affects the second hydrolysis. In-
deed, chloride ion dissociation is the most likely event, kinetically preferred (by
4 kcal/mol) in cis rather than in trans. The activation free energies, ∆G‡=20.8 and
24.8 kcal/mol for TSIIcisCl and TSII transCl , respectively, are in good agreement with
the values of 20.0 and 25.4 kcal/mol reported recently [355]. By contrast, thermody-
namics of cis and trans diaqua complexes are similar, suggesting that as for reduced
species, both products may be found in solution [349]. The third hydrolysis step has
a similar barrier to that of previous aquations, but, unlike ICRII, reaction is endother-
mic.
6.4 Estimation of Reduction Potentials
As the electrochemical behavior of NAMI-A and ICR is crucial for their biological
activity [331, 334, 348], reduction potentials of these drugs as well as those of their
most relevant hydrolysis products were estimated (Tab. 6.3). Calculated and experi-
mentally measured reduction potentials of NAMI-A and ICR are in good agreement,
as they differ by ∼0.08 V on average. Thus, the estimated difference between re-
duction potentials of NAMI-A and ICR was found to be close to the experimental
value, ∆∆Em ∼ 350mV vs. ∆∆Eexpm ∼ 500mV. Unfortunately, data about re-
dox potentials of their hydrolysis products are not available in literature. However
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NAMI-A ICR
Calc. Expt. Calc. Expt.
R 0.17 0.235a -0.18 -0.275b
PICl 0.34 0.337a,c -0.01
PIDMSO(Im) -0.13 -0.13
PIIcis2Cl 0.67 0.12
PII trans2Cl 0.57 0.07
PIICl,DMSO(Im) -0.17 -0.17
PIII3Cl 1.02 0.53
PIII2Cl,DMSO(Im) 0.09 0.09
a: from Ref. [350]; b: from Ref. [331]; c: experimental reduction potential
refers to mer-RuCl3(DMSO)2(Im), see text for further details.
Table 6.3: Calculated and experimental reduction potentials (Em, vs. NHE - V) of NAMI-A
and ICR metabolites.
electrochemical measurements on mer-RuCl3(DMSO)2(Im), which contains a Ru-
ODMSO bond similar to Ru-Owater of the first hydrolysis product of NAMI-A, are
available [350]. Indeed, the experimental reduction potential (Em=0.337 V, vs NHE),
compares very well with our calculated value (0.34 V). These data confirm the re-
liability of our computational set-up, allowing us to predict reduction potentials for
NAMI-A and ICR metabolites possibly with a similar accuracy.
As the hydrolysis of Cl− proceeds to PI , PII and PIII , reduction potentials
increase to ∼0.3, ∼0.7 and ∼1.0 V and to ∼0.0, ∼0.1 and ∼0.5 V for products of
NAMI-A and ICR, respectively (Fig. 6.3). This is in qualitative agreement with ex-
perimental findings showing that for each Cl−-water exchange a constant increase of
the reduction potential occurs [352, 382]. In contrast, reduction potential decreases
upon dissociation of DMSO (or Im for ICR), to -0.13 V and -0.17 V for PIDMSO(Im)
and PIICl,DMSO(Im) (Tab. 6.3). This suggests that DMSO dissociation may preclude
NAMI-A reduction, slowing down the hydrolysis and possibly the formation of the
active metabolites, confirming the crucial role played by DMSO for NAMI-A phar-
macological activity [331, 334].
Reduction of ICR in vivo is unlikely as reduction potential is negative, yet this
may occur in specific regions where strong biological reductants are available, such
as proliferating cells [348]. Alternatively, as the hydrolysis proceeds, Em increases
and the products of the second aquation have a positive reduction potential. Thus,
reduction may easily occur in particular for PIIcis2Cl, which has a similar reduction
potential to NAMI-A. These results highlight the role of reduction in driving the hy-
drolysis of NAMI-A and ICR towards different chemical routes.
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Figure 6.3: Estimated reduction potentials Em (vs. NHE, V) of NAMI-A, ICR and the prod-
ucts of Cl− dissociation. Experimental reduction potentials from Ref. [350] and Ref. [332].
See text for further details.
6.5 ICR vs. NAMI-A: Biological Implications
The analysis of activation and reaction free energies combined with the estimation
of reduction potentials reveals intriguing features of NAMI-A and ICR hydrolyses
(Fig. 6.1a, 6.2a).
Under neutral conditions, NAMI-AIII hydrolysis leads to the formation of com-
pounds with one DMSO and one Cl− exchanged by water molecules. In presence of
biological reductants, reduction does not take place for the products of DMSO disso-
ciation. On the other hand, NAMI-A and PICl have positive reduction potentials and
undergo reduction more easily. Therefore, the most abundant NAMI-A metabolites
are expected to be the RuII-diaqua and triaqua complexes bearing the DMSO-S lig-
and. However, we cannot exclude that monoaqua complexes may play a role for its
biological activity. Moreover, in vitro experiments have shown that poly-oxo species
are rapidly formed already during second hydrolysis, whereas in vivo the interaction
with N- and S- biological donors would prevent polymerization [331]. Either way,
products of the third hydrolysis should be less relevant for the biological activity of
NAMI-A. Thus, our data stress the relevance of the oxidation state for the hydroly-
sis path, and support the hypothesis that reduced form of NAMI-A or its hydrolytic
products are relevant for the antimetastatic activity [331,334,340,352]. Furthermore,
from the analysis of reduction potentials clearly emerged the crucial role of DMSO
as it stabilizes RuII species, promoting NAMI-A reduction.
Reduction of ICR is less likely than that of NAMI-A, unless strong biological
reductants are available [348]. However, as the hydrolysis proceeds, reduction poten-
tial of metabolites increases, i.e. the products of the second hydrolysis have positive
reduction potentials. Thus, reduction may require a relatively long time, perhaps
long enough for ICRIII to undergo hydrolysis, with the most likely products being a
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mixture of mono and diaqua complexes (Fig. 6.2a). Once these species are formed,
reduction may easily occur, particularly for the cis isomer. If reduction occurs, the
most abundant metabolites are PIIcis2Cl and PIII3Cl, holding for the latter similar
considerations as for NAMI-A. All these findings are compatible with experimental
results, suggesting that ICR binding to biological targets occurs in hours and that only
aged ICR solutions can bind to DNA [349].
In addition, the analysis of the second hydrolysis kinetics reveals important dif-
ferences between ICR and NAMI-A. In particular, ICR (in both RuIII and RuII oxi-
dation states) shows a strong kinetic preference for cis diaqua complexes, while both
NAMI-A isomers have similar kinetics and thermodynamics. In vivo such a kinetic
preference may affect the way of binding and also lead the drugs to different biolog-
ical targets, DNA for ICR and proteins or receptors, for NAMI-A (see for example
Ref. [383] and references therein).
6.6 Conclusions
Extensive DFT calculations, with estimation of solvation and entropic effects, were
performed to investigate the hydrolysis mechanisms of two promising anticancer
drugs, NAMI-A and ICR.
The computational set up has been validated by comparing available experimental
and theoretical data with our findings. Predicted and measured reduction potentials
of NAMI-A and ICR differ by ∼0.08 V on average, while calculated activation free
energies for the first hydrolysis are within 2 kcal/mol from those determined experi-
mentally. A broad qualitative agreement with experimental findings of NAMI-A and
ICR hydrolysis at physiological conditions was achieved.
Our calculations confirmed that NAMI-A is easily reduced in vivo and showed
that reduction strongly affects the hydrolysis. We suggest cis and trans RuII-diaqua
metabolites to be the most abundant and perhaps the most relevant for the biological
activity of NAMI-A. However, we cannot exclude that monoaqua complexes may
also be involved.
Reduction of ICR is less likely than that of NAMI-A, yet if occurring would hardly
affect the hydrolytic path. Indeed, the most abundant metabolites are the mono and
diaqua complexes, with a kinetic preference for cis isomer in both oxidation states.
Nevertheless, reduction may occur for the products of the second hydrolysis step since
reduction potentials increase as the hydrolysis proceeds.
The most relevant NAMI-A and ICR metabolites would retain the main structural
and chemical differences of parent compounds, the DMSO-S ligand for the former
and Im ligand for the latter. In addition, the kinetic preference for the cis diaqua ICR
compounds may affect the binding to biomolecules and lead to a different biological
behavior. Such features may be of primary importance in determining the diverse
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pharmacological activity of NAMI-A and ICR anticancer drugs.
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Figure 6.4: (continue on the next page) Free energy profiles of Cl− and DMSO hydrolyses in NAMI-AII: a) first hydrolysis; b) second
hydrolysis; c) third hydrolysis starting from PIItrans2Cl ; d) third hydrolysis starting from PIIcis2Cl. Black and red lines correspond to Cl−
and DMSO dissociations, respectively, and metabolites without DMSO are indicated by a red line. The most favorable transition states
and products are represented by solid lines, while dotted lines are used for the less likely intermediates and TS structures. Activation
free energies (kcal/mol) are displayed in the squares along the reaction path. Energies reported on the lines are referred to R.
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Figure 6.4: (continued) Free energy profiles for the third Cl− hydrolysis starting from PIItrans2Cl NAMI-AII.
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Figure 6.5: (continue on the next page) Free energy profiles of Cl− and DMSO hydrolyses in NAMI-AIII: a) first hydrolysis; b) second
hydrolysis from PII2Cl; b’) second hydrolysis from PIIDMSO. For further details see Fig. 6.4.
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Figure 6.5: (continued) Free energy profiles of Cl− and DMSO hydrolyses in NAMI-AIII: c) third hydrolysis from PII2Cl,DMSO; c’)
third hydrolysis from PIIcis2Cl; third hydrolysis PIItrans2Cl .For further details see Fig. 6.4.
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Figure 6.6: Free energy profiles of Cl− and Im hydrolyses in ICRII: a) first hydrolysis; b) second hydrolysis; c) third hydrolysis
starting from PIItrans2Cl ; d) third hydrolysis starting from PIIcis2Cl. For further details see Fig. 6.4. * Im pseudo transition states: see
Computational Details.
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Figure 6.7: Free energy profiles of Cl− and Im hydrolyses in ICRIII: a) first hydrolysis; b) second hydrolysis; c) third hydrolysis
starting from PIItrans2Cl ; d) third hydrolysis starting from PIIcis2Cl. For further details see Fig. 6.4. * Im pseudo transition states: see
Computational Details.
Part IV
Conclusions and Perspectives
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In the first part of my thesis work I investigated chemical, thermodynamic and
kinetic aspects of drug/DNA molecular recognition and hydrolysis. First, I have fo-
cused on the the interaction between DNA and the alkylating agents anthramycin and
duocarmycin by classical MD and hybrid Car-Parrinello QM/MM simulations. The
electrostatic field due to DNA catalyzes the alkylation reaction by anthramycin, while
the solvent plays a minor role in polarizing reactants. Moreover, QM/MM studies al-
lowed to connect this catalytic effect to identification of the most reactive form of
this drug. Based on classical MD, it can be suggested that the formation of both the
non covalent and covalent drug/DNA adducts does not alter the main structural de-
terminants of oligonucleotide and ligand structures. However, the most reactive form
of anthramycin slides by one base-pair step to the site adjacent the reactive guanine.
This result prompted for further structural and thermodynamic characterization of the
sliding process by umbrella sampling simulations. This is an important step of DNA
molecular recognition by small ligands, which can not be restricted to the forma-
tion of the final adduct only, but also involves shuffling within the minor groove and
translocation between different sites. According to the calculated free energy profile
and consistently with results from unbiased simulations, the site adjacent to the reac-
tive one is more stable by a few kcal/mol, and the free energy barrier associated to
the sliding of the drug is also very small (∼ 2 kcal/mol). Furthermore, free energies
corresponding to conformations in which the drug covers other sequences are similar
to that associated to the reactive one.
To address the role of the sliding process in recognition and sequence-selectivity,
I compared the mechanism exploited by anthramycin to that of the indole derivative
of duocarmycin, which is highly selective towards AT-rich tracts. At odd with anthra-
mycin, the alkylation site of duocarmycin is the most stable also in the non covalent
adduct, and drug sliding far from it requires to overcome a barrier of ∼ 4 kcal/mol.
Interestingly, far from the preferred sequence the free energy profile is virtually flat,
and the funnel in the free energy landscape mirrors the obtained profile of the solva-
tion free energy. The results allow to speculate about a different molecular recogni-
tion mechanisms for the two drugs. Duocarmycin might first bind to DNA at those
sequences characterized by the lowest desolvation cost (the non preferred ones) and
then easily slide towards the alkylation site. In contrast, recognition of DNA by an-
thramycin appears to be more complicated as no preferred route exists on the one-
dimensional sliding path. Moreover, the reactive site can be reached only upon cross-
ing a significant free energy barrier.
Next, I addressed the unbinding of ligands from DNA. To gain insights into this
mechanism, I compared one of the covalent binders previously investigated (anthra-
mycin) to a representative of the main class of non covalent minor groove binders,
distamycin A. Free energy calculations using metadynamics pointed out that the de-
tachment of anthramycin from the minor groove involves an active role of waters and
a local widening of the minor groove. No stable intermediates are detected during
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the simulated unbinding. In contrast, distamycin unbinding involves the formation
of an intermediate in which the positively charged tail of the compound lays within
the minor groove while its body is solvated. The detachment starts with the disrup-
tion of specific ligand/DNA H-bonds and does not involve significant opening of the
minor groove or an active role of waters. The calculated activation free energy of
detachment of distamycin compares very well with the available experimental data,
assessing the reliability of the setup used. In perspective, the natural continuation
of this and the previous work involves: i) performing similar simulations at different
ionic strength to assess its influence on the calculated free energies; ii the study of the
sliding along different sequences, to assess the effect of sequence-dependent features
on the process; the study of the sliding by non covalent binders. iii) the study of the
binding process (for which different collective variables are needed); iv) the study of
the way ligands interfere with biological process, starting with the inhibition of he-
licases by some minor groove binders (the structure of a DNA/helicase complex has
been released in june 2007 [384]).
The second part of my thesis concerned the hydrolysis of two anticancer ruthe-
nium compounds, NAMI-A and ICR, the first active against metastases and the other
against the primary tumour. Calculations confirmed the experimental fact that the
ruthenium center in NAMI-A is easily reduced in vivo from oxidation state III to II,
with reduction strongly affecting the hydrolysis. The most abundant (and perhaps rel-
evant) hydrolitic products are found to be cis and trans RuII-diaqua metabolites. Re-
duction of ICR is less likely than that of NAMI-A, yet if occurring would hardly affect
the hydrolytic path. Indeed, the most abundant metabolites are the mono- and diaqua
complexes, with a kinetic preference for cis isomer in both oxidation states. Never-
theless, reduction may occur for the products of the second hydrolysis step since re-
duction potentials increase as the hydrolysis proceeds. Importantly, the structural and
chemical differences between NAMI-A and ICR, which are at the basis of their differ-
ent pharmacological activity, are conserved during the hydrolysis steps according to
results shown. In addition, the kinetic preference for the cis diaqua ICR compounds
may affect the binding to biomolecules and lead to a different biological behavior.
Such features may be of primary importance in determining the diverse pharmaco-
logical activity of NAMI-A and ICR anticancer drugs. A future perspective of this
work is the study of the binding of NAMI-A and ICR to their targets [385, 338]. In
particular, the interaction between NAMI-A and integrins will be addressed, as these
latter have been supposed to be crucial for the development of metastases [339, 386].
Appendix A
The structure of DNA
The structure of DNA fibers was crystallized in the early fifties by Franklin and
Wilkins, who discovered that the phosphate-ribose backbone lies at the outside of the
DNA and resolved the basic helical structure of the macromolecule. This knowledge
was a fundamental key in the breakthrough of DNA structure elucidation by Watson
and Crick [387]. Another piece in the jigsaw puzzle was Chargaff’s 1:1 relationship
between the adenine-thymine and guanine-cytosine content, which resulted to be of
general validity in all organisms [388]. Crick realized that this quantitave relation-
ship could be caused by complementary base-pairing between adenine and thymine
or guanine and cytosine, respectively and he envoked the hydrogen bonding pattern
now known as Watson-Crick hydrogen bonds (Figure A.1). Based on this informa-
tion, Watson and Crick proposed a well-known model of a right-handed, antiparallel
double helix, in which the phosphate-ribose backbone lied at the outside of the helix
and the bases pointed towards the center of the helix, held together by these specific
hydrogen bonds. This structure lead to the following observations:
• The charged phosphate groups are solvent exposed and can therefore easily be
neutralized.
• The base-pairing rule offers a simple copying mechanism: One strand serves as
a template, and the missing strand can be reconstructed thanks to the recogni-
tion of the complentary base by hydrogen bonding.
The structure proposed by Watson and Crick is now known as B-DNA. In ideal B-
DNA, the base-pairs are perpendicular to the helix axis and twisted by ∼ 36o with
respect to each other. Therefore 10 base pairs realize an entire turn of the double
helix. The two strands of the double helix are separated by two distinct grooves:
the minor groove and the major groove (Figures A.1 and A.2). The narrow minor
groove contains ordered water molecules, which form a characteristic hydration pat-
tern, either a spine (A-tracts) or a ribbon of hydration (normal DNA-sequences). The
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Figure A.1: Watson-Crick base pairing. Left: Adenine (A) with Thymine (T); right: Guanine
(G) with Cytosine (C).
bases per turn twist per bp [o] rise per bp [Å] sugar pucker
B-DNA 10 36 3.3-3.4 C2’-endo
A-DNA 11 33 2.9 C3’-endo
Minor groove Major groove
width [Å] depth [Å] width [Å] depth [Å]
B-DNA 5.7 7.5 11.7 8.8
A-DNA 11.0 2.8 2.7 13.5
Table A.1: Selected DNA parameters in A and B forms..
correctness of the model was ultimately prooved by X-ray crystallography. In 1952,
Franklin and Wilkins discovered by the same technique different forms of DNA, the
dry and the wet form, now known as A-DNA and B-DNA (Figure A.2). The dry
A-DNA is a right-handed double helix in which hydrophobic stacking interactions
between base-pairs are optimized by a ∼ 19o inclination of the base-pair plane with
respect to the helix axis. This leads to a wider minor groove, which lacks a spine of
hydration and a very deep major groove (Table A.1). The conformational change from
C2’-endo in B-DNA to C3’-endo in A-DNA distances the phosphate groups in a way
to avoid autocatalysis. Other DNA forms have been detected since such as the left
handed Z-DNA (Figure A.2). DNA structure has proven to be extremely flexible, and
its conformation significantly depends on environmental effects such as the degree of
hydration, salt content and the exact composition of the solution. With the advance
of experimental techniques, such as X-ray crystallography, NMR spectroscopy, gel-
electrophoresis and electron microscopy, deviations from the ideal A and B-DNA
structures were detected. There was growing evidence that these deviations were at
least partially sequence dependent, indicating a possible way of sequence specific
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Figure A.2: Schematic drawing of A-DNA (left), B-DNA (middle) and Z-DNA (rigth).
DNA recognition by proteins and drugs [18, 389]. It also became clear that a uni-
versal set of structural parameters was mandatory in order to describe precisely and
unequivocally the structural features of a given DNA molecule. In the early 70’s
an effort has been made to elaborate a nomenclature of general validity for nucleic
acids, which is now recommended by IUPAC, the Joint Commission on Biochem-
ical Nomenclature [390] and in the following I will give the definitions which are
most relevant to the discussion that follows. The nucleobases can be divided into the
purines adenine (A) and guanine (G) and the pyrimidines cytosine (C) and thymine
(T) or uracyl in RNA (U). The numbering of the atoms in the nucleobases is given in
Figure A.3. A nucleobase covalently bound to C1’ of a deoxyribose (ribose in RNA)
is called a nucleoside, and a nucleoside with one or more phosphate groups attached
at C5’ is called a nucleotide. The atoms in the phosphate-ribose backbone are distin-
guished from the ones in the bases by a prime. The sugar ring is attached to the N9
position in purines and to the N1 position in pyrimidines via a glycosylic C-N bond.
The torsional angle around the glycosylic bond is denoted χ and defines the orienta-
tion of the nucleobase with respect to the sugar ring, which can be eiter syn or anti.
In standard B-DNA the bases are usually in the anti-conformation, which is sterically
more favorable. The sugar ring is not planar but can adopt different conformations, in
which one or two atoms are displaced from the plane described by the other atoms. If
the “out-of-plane” atom lies on the same side as C5’ it is called endo, if it lies on the
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Figure A.3: Structure elements of the most common nucleotides (numbering according to
IUPAC). Image from “http://en.wikipedia.org/wiki/Nucleotide”.
other side it is called exo. The most common conformations are C2’-endo, present in
canonical B-DNA, and C3’-endo, which is usually met in A-DNA (Figure A.4). A
more complete picture is given by the pseudorotation cycle as described for example
in [19]. Further torsional angles along the phosphoester bonds are called α, β, γ, δ, ǫ
and ζ (Figure A.5). The orientation of the bases and base-pairs with respect to each
other is described by the helical parameters (Figure A.6), which can be divided into
groups according to the geometrical features they describe:
• Parameters describing the relative orientation of two bases in the same basepair:
Shear, Stretch, Stagger, Propeller twist, Buckle and Opening.
• Parameters, which consider the relative orientation of two adjacent base-pairs:
Roll and Tilt angle, Shift, Slide and Rise as well as helical Twist angle.
• Parameters which describe the orientation of a base-pair to a primarily defined
global helix-axis: X-and Y displacement, Inclination and Tip.
The measurement of these structural parameters require the definition of a refer-
ence system for each base and base-pair as well as the determination of a global helix
axis. This task is solved by several analysis programs but usually the determination of
the local and global reference frames is not unequivocal, leading to slightly different
results concerning the above parameters. In particular, the determination of a global
axis requires special attention since large distortions in the double helix can lead to
diculties in the determination of a straight helix axis. In the work exposed in this
thesis I used the program Curves, written by Lavery and Sklenar [276, 239]. In this
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Figure A.4: Sugar puckering in ideal B-DNA (C2’-endo, South) and A-DNA (C3’-endo,
North). Taken from “http://www.imb-jena.de/ImgLibDoc/nana/IMAGE_NANA.htm”.
Figure A.5: Atomic numbering scheme and definitions of torsional angles in phospate-
sugar moiety in RNA ( valid also for DNA, after replacing O2’ with H2’). Image from
“http://www.imb-jena.de/ImgLibDoc/nana/IMAGE_NANA.htm”.
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Figure A.6: Schematic drawing of distortion between bases and base-pairs described by
helical parameters. Positive values of the designed parameters are shown. Image from
“http://rutchem.rutgers.edu/ xiangjun/3DNA/examples.html”.
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program, an optimal curvilinear axis is determined by optimizing a suited geomet-
rical function containing four variables for each base, namely the X-displacement,
Y-displacement, Inclination and Tip. Changes in the structural parameters of DNA
are often correlated, due to geometrical restrictions of the sugar/phosphate backbone.
This becomes for example evident in case of a large helical twist, which stretches the
backbone. The stretch is partially relieved by bringing the base-pairs closer together,
lowering thus the rise. This correlation has been quanted by Yanagi et al [391] in
the profile sum. In case of large twist and low rise one is in the region of High Twist
Profile (HTP) and in case of low twist and large rise one is in the region of Low Twist
Profile (LTP). Finally, minor and major groove width and depth are useful parameters
to look at, specially in relation to interactions with minor groove binders. The width
can be measured between different atoms, P, O4’ or C4’ atoms being the most used.
Since the phosphate groups being closest together are usually separated by several
nucleotides in sequence, the assignment is not always unambiguous. The Curves al-
gorithm solves the problem by projecting the minor groove width on the global helix.
In Table 1 are reported some standard parameters of canonical A and B-DNA [392].
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Appendix B
Statistical Mechanics of
non-Hamiltonian systems
Consider a general non-Hamiltonian system whose dynamics is described by the set
of equations of motions (e.g. those described by Nosé)
x˙i = θi(x, t) (B.1)
subject to initial conditions x0 = (x10, ..., xdN0 ), which have solution
i
t = x
i
t(t;x
1
0, ..., x
dN
0 ) (B.2)
where N is the number of particles and d the dimensionality. This equation can
be seen as a coordinate transformation on the phase space from the initial coordinates
at time 0 to those at time t. If we consider a set of trajectories located within the
hyphervolume dx0 at t = 0, at time t these will be within dxt. The variation of the
measure with time is given by
dxt = J(xt;x0)dx0 (B.3)
where J(xt, x0) =
∣∣∣∂x1t ,...,xdNt
∂x10,...,x
dN
0
∣∣∣ is the Jacobian of the transformation, i.e. the de-
terminant of the matrix T with entries Tij = ∂x
i
t
∂xj0
. Taking the time derivative of J and
using the Jacobi’s formula we can write
dJ
dt
= Tr(adjT
dT
dt
) (B.4)
where adjT is the adjugate of T , which entries are (adjT )ij = (−1)i+jMji, Mij
being the ij-th minor of matrix T . As the dynamics is time-reversable, T will be
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invertible, and adjT = JT−1. Thus:
dJ
dt
= J Tr(T−1
dT
dt
) = J
dN∑
i,j=1
T−1ij
dTij
dt
= J
dN∑
i,j=1
∂xi0
∂xjt
∂x˙it
∂xj0
= J
dN∑
i,j,k=1
∂xi0
∂xjt
∂x˙jt
∂xkt
∂xkt
∂xi0
(B.5)
where relations T−1ij = ∂xi0/∂x
j
t , dTij/dt = ∂x˙
j
t/∂x
i
0 and the chain rule for the
derivative ∂x˙jt/∂xi0 have been used. Performing the sum over i we get:
dN∑
i=1
∂xi0
∂xjt
∂xkt
∂xi0
=
dN∑
i=1
T−1ij Tkj =
dN∑
i=1
Tki T
−1
ij = (TT
−1)kj = δkj (B.6)
and finally
dJ
dt
= J
dN∑
j,k=1
δjk
∂x˙jt
∂xkt
= J
dN∑
j=1
∂x˙jt
∂xjt
= J∇x · x˙ = Jκ(x, t) (B.7)
which has to be solved subject to the initial condition J(x0;x0) = 1. The quantity
κ(x, t) = ∇x · x˙ = ∇x · θ(x, t) is called phase space compressibility. Knowledge of
the compressibility allows to derive an invariant measure. In the case where κ does
not explicitly depends on t, the Jacobian is given by
J(xt;x0) = exp[
∫ t
0
κ(xs) ds] (B.8)
By introducing the variable ω(x) = ln J , which gives the variation in time of the
compressibility, ω˙ = κ, the above equation can be rewritten as:
J(xt;x0) = exp[ω(xt)− ω(x0)] (B.9)
Thus, the following conservation law holds:
e−ω(xt)dxt = e−ω(x0)dx0 (B.10)
This is a generalized version of the Liouville theorem of incompressibility of the
phase space. It can be shown that the above formalism holds also if κ depends explic-
itly on time. Thus, the measure e−ω(xt,t)dxt is conserved by the dynamics, not simply
dxt. The exponential e−ω(xt,t) can be viewed as a metric factor
√
g(x, t), satisfing the
metric transformation rule√
g(x0, 0) = J(xt;x0)
√
g(xt, t) (B.11)
The existence of an invariant measure means that time and ensemble averages are
still equivalent for a non-Hamiltonian dynamics (under the assumption of ergodicity),
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with the proper metric taken into account when evaluating integrals. Furthermore, a
generalized Liouville equation holds:
∂f
√
g
∂t
+∇x · (f√gx˙) = 0 (B.12)
which, noting that d
√
g(x, t)/dt ≡ ∂√g/∂t + ∇√g · x˙ = −κ√g, gives the
conservation law for f equivalent to the Hamiltonian case:
∂f(x, t)
∂t
+∇x · x˙ f(x, t) ≡ df
dt
= 0 (B.13)
Finally, this equation is combined with the conservation law for the measure, we
obtain a general statement of Liouville’s theorem:
f(x0, 0)
√
g(xt, t)dx0 = f(xt, t)
√
g(xt, t)dxt (B.14)
In the absence of external and explicitly time-dependent forces, a non-Hamiltonian
microcanonical ensemble can be defined on the basis of the existence of the invari-
ant measure. If the dynamical system has a set of M conserved quantities Kλ(x) =
K¯λ, λ = 1, ...,M , the microcanonical distribution function f can be expressed as:
f(x) = ΠMλ=1 δ(Kλ(x)− K¯λ) (B.15)
and the corresponding partition function is
Ω(N, V, K¯1, ..., K¯M) =
∫
dx
√
g(x)ΠMλ=1 δ(Kλ(x)− K¯λ) (B.16)
Statistical averages can be thus computed with respect to coordinates x at any
time:
〈A〉t =
∫
dx
√
g(x, t)A(x)f(x, t)∫
dx
√
g(x, t)f(x, t)
(B.17)
Consider now the non-Hamiltonian Nosé equations of motion. The compressibil-
ity is given by
κ = ∇x · x˙ =
dN∑
i=1
∂p˙i
∂pi
= −dNη˙ (B.18)
so that
ω =
∫ t
0
κ(s) ds = −dN
∫ t
0
η˙(s) ds = −dNη (B.19)
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and the metric factor is
√
g = edNη (B.20)
Thus, the conserved measure in the phase space of Nosé dynamics is
dµ = ddNr ddNp dη dpη e
dNη (B.21)
For further details and generalization to Nosé-Hoover chains, see e.g. Refs. [393,
394, 395].
Appendix C
Ewald sum method
Consider a neutral system composed ofN positively and negatively particles of charge
qi and placed at ri, enclosed in a volume V . Within pbc each particle interacts with all
the other N − 1 particles into the simulation box and with all the N particle images
in an infinite 3D array of periodic cells. The electrostatic potential energy UCoul of
the infinite system, therefore, takes the form:
UCoul =
1
2
N∑
i=1
qiφ(ri) =
1
2
∑
n=0
′
N∑
ij
qiqj
|rij + nL| (C.1)
where L = V −1/3 is the length of the periodic box (assumed cubic for simplicity)
and n are the direct lattice vectors. The prime on the summation indicates that the
sum is over all the images n, and i 6= j if n = 0. The convergence of this series is
conditional, its value depending on the way the cluster of simulation boxes is built
to fill the space, i. e. from its shape, and the boundary conditions (vacuum or dielec-
tric [135]) The slow convergence of the series requires a very large number of images
to achieve a reliable estimate of UCoul. The idea behind the Ewald method is to sur-
round every charge qi with a density cloud ̺− of opposite sign and total charge −qi.
In this way an efficient screening is realized, so that interactions rapidly go to 0 and
direct summation is possible. Then, a cancellation charge density ̺+ of total charge
qi centered at ri is also added to recover the original distribution. In order to exclude
self-interactions the contributions of these three charge densities should be not eval-
uated in ri. However, it is convenient to keep self-interactions due to the cancelling
charge distribution ̺+, since ̺+ is in this way periodic and can be represented as a
rapidly converging Fourier sum. The spurios self-interaction can be easily subtracted
separetely. In the original formulation [136] Ewald choose two Gaussian charge dis-
tributions, ̺G−(r) and ̺G+(r) of width
√
2/α and total charge −qi and qi, respectively.
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Thus, the total charge distribution of the system ̺(r) may be rewritten as:
̺(r) = ̺(r) + ̺G−(r) + ̺
G
+(r)
=
∑
n
[(
N∑
i=1
qiδ(r− (ri + nL)) +
N∑
i=1
(−qi)
(α
π
) 3
2
e−α|r−(ri+nL)|
2
)
+
N∑
i=1
qi
(α
π
) 3
2
e−α|r−(ri+nL)|
2
] (C.2)
At this point, ̺ + ̺G− and ̺G+ contributions to the total charge distribution can be
considered separately. From the first term one gets a potential energy Udir rapidly
going to 0 at large r, due only to the fraction of qi unscreened by ̺G−. From ̺G+
the long-range interaction energy U rec comes, that can be evaluated in the reciprocal
space. To this aim, we derive the electrostatic potential in this space through Poisson’s
equation ∇2φ(r) = −4π̺(r). Fourier transforming the members of this equation
gives:
∇2rφ(r) =
1
V
∑
k
φ˜(k)∇2reik·r = −
1
V
∑
k
k2φ˜(k)eik·r (C.3)
̺(r) =
1
V
∑
k
˜̺(k)eik·r (C.4)
where
f˜(k) =
∫
V
drf(r)e−ik·r (C.5)
and k = (2π/L)l, l being reciprocal lattice vectors. The Poisson’s equation takes
the particularly simple form:
k2φ˜(k) = 4π ˜̺(k) (C.6)
Substituting the expression for ̺G+(r) in eq. C.5 we have:
˜̺G+(k) =
∫
V
dre−ik·r
∑
n
∑
j
(α
π
)3/2
qje
−α|r−(rj+nL)|2
=
∑
j
(α
π
)3/2
qj
∫
V
dre−ik·r
∑
n
e−α|r−(rj+nL)|
2
=
∫
allspace
dr
∑
j
(α
π
)3/2
qje
−ik·re−α|r−rj |
2
(C.7)
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where the relation
∑
n
∫ a
−a f(x+na) =
∫ ∞
−∞ f(x) for periodic functions has been
used. With the change of variables r → r′ = r − rj we obtain finally the expression
for ˜̺G+ in the reciprocal space:
˜̺G+(k) =
∑
j
qje
−ik·rj
[(α
π
)3/2 ∫
allspace
dr′e−ik·r
′
e−αr
′2
]
=
∑
j
qje
−ik·rje−k
2/4α = ˜̺P (k)γ˜(k)
(C.8)
where ˜̺P (k) =
∑
j qje
−ik·rj and γ˜(k) = e−k2/4α are the Fourier transform of a
point charges set and of the smearing Gaussian, respectively 1
Inserting in Poisson’s equation the potential takes the form:
φ˜G+(k) = g˜(k)˜̺P (k)γ˜(k) (C.9)
where g˜(k) = 4π
k2
is the Green’s function. Note that φ˜G+(k) is defined only for
k 6= 0. This arises from the conditional convergenge of the series and is related
to the assumption that the surrounding of our periodic system is an ideal conductor
1 This is a property of the Fourier transform of a convolution (⋆). If a(x) = b(x) ⋆ c(x) ≡∫
dx′b(x′)c(x − x′), the Fourier transform a˜ is simply the product of the Fourier transform b˜ and c˜.
The charge density ˜̺G+(k) is the Fourier transform of
˜̺G+(r) =
∑
j
qje
−α|r−rj |
2
=
∫
dr′
γ(r′)︷ ︸︸ ︷
e−αr
′2
̺P (r−r
′)︷ ︸︸ ︷∑
j
qjδ (r
′ − (r− rj)) = γ(r) ⋆ ̺P (r)
Thus
˜̺G+(k) = ˜̺P (k)γ˜(k) .
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(ε = ∞)2. Antitrasforming the potential gives the electrostatic energy:
U rec =
1
2
∑
i
qiφ
G
+(ri) =
1
2
∑
i
qi
[
1
V
∑
k 6=0
φ˜G+(k)
]
=
2π
V
∑
k 6=0
∑
ij
e−k
2/4α
k2
qiqje
−ik·(ri−rj) =
1
2V
∑
k 6=0
g˜(k)
∣∣ ˜̺G+(k)∣∣2 e−k2/4α
(C.10)
As mentioned above, this term contains the self-interaction of each charge qi with
a Gaussian distribution ̺self+ = qi(α/π)2e−α|r−ri|
2
. The potential due to this cloud is
obtained solving the Poisson’s equation in spherical coordinates (x ≡ |r− ri|):
1
x
=
∂xφself+
∂x2
= 4π̺self+ → φself+ =
qi
x
(
2√
π
) ∫ √αx
0
e−x
′2
dx′ =
qi
x
erf(
√
αx)
(C.11)
where erf(x) = (2/
√
(π))
∫ x
0
exp(−u2)du. Finally, we get:
U self =
(α
π
) 1
2
N∑
i=1
q2i (C.12)
The advantage of this scheme are now clear: the self-contribution energy is simply
a constant, independent on system configuration, and does not enter in the calculation
of the forces. Using the result for φself it is easy to calculate the short-range inter-
action energy Udir. Indeed, this energy arises from a potential generated by charge
densities qi − ̺G−(r) centered at ri, which thus is given at any point r by:
φdir(r) =
∑
n
∑
j
qj
|r− (rj + nL)|erfc
(√
α |r− (rj + nL)|
) (C.13)
2In the case where the system is surrounded by a medium of finite dielectric constant εs dipoles
will be present on its surface. A formula has been derived relating the energy UCoul we are calculating
here to that corresponding to a finite εs:
U(∞) = U(εs)− Upol = U(εs)− 2π
(2εs + 1)V
∣∣∣∣∣∑
i
qiri
∣∣∣∣∣
The term Upol corresponds to the neglected k 6= 0 contribution. For further details on this point
see [119] and Refs. therein.
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The total electrostatic interaction energy can be finally expressed as:
UCoulE w =
1
2
∑
i
qiφ
tot(ri)
= Udir − U self + U rec = 1
2
∑
i
qi
[
φdir(ri) + φ
rec(ri)− φself (ri)
]
=
1
2
∑
n
′
N∑
ij
qiqj
|rij + nL|erfc
(√
α |rij + nL|
)
+
2π
V
∑
k 6=0
∑
ij
e−k
2/4α
k2
qiqje
−ik·(r−rj)
−
(α
π
) 1
2
N∑
i=1
q2i
(C.14)
Convergence and Accuracy. It is important to remind that, whereas φ depends
linearly on the charge density ̺, the electrostatic energy does not. Thus, Udir and
U rec − U self are not the electrostatic energies due to ̺ + ̺G− and ̺G+, as the potential
these charge distribution generate is evaluated on the original ̺. Consistently, they
have been called real and Fourier space contributions to UCoul, and their sum is would
not give the energy of the original charge density ̺. The accuracy of the method,
defined as the difference ǫ = UCoulEw − UCoul, is related to the optimal choice of the
parameters α, width of the Gaussian distribution, and of the two cutoffs rc and kc
in real and reciprocal space, respectively. It can be shown that ǫ for both the real
and reciprocal space terms is proportional to exp(−s2)/s2 [119], where s ≡ rcα and
s ≡ πnc/αL, respectively. Here nc is a positive integer used to define the cutoff in the
reciprocal space vectors as kc = 2π/Lnc, so that the number of Fourier components
within this cutoff is (4π/3)n3c . If one requires the same accuracy on the evaluation of
Udir and U rec the value of s is fixed, and the choice of α determines both the number
of Fourier components required to calculateU rec and the cutoff rc. The optimal choice
of α is obtained minimizing the total computational time
τ = τ dirNdir + τ recN rec (C.15)
where τ dir is the time needed to evaluate the interaction between a couple of
particles, τ rec that needed to evaluate the interaction per k vector and per particle,
Ndir and N rec are the number of cycles per MD step needed for the evaluation of
Udir and U rec, respectively. For a homogeneous system of density D = N/L3 we
have
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Ndir =
4
3
π
(rc
L
)3
N2 =
4
3
π
( s
αL
)3
N2 (C.16)
N rec =
4
3
πn3cN =
4
3
π
(
sαL
π
)3
N (C.17)
which gives for α and τ the values:
α =
(
τ dirπ3N
τ recL6
)1/6
∼ N−1/6 (C.18)
τ =
8
√
τ dirτ recN3/2s3
3
√
π
= O(N3/2) (C.19)
C.1 Particle-Mesh Approaches
The computational cost for solving eq. C.14 thus scales asO(N3/2). In general, rc can
be safely set to a value < L/2, restricting the calculation of Udir to the original box
only (|n| = 0). However, for convenience rc is sometimes set equal to the cut-off for
short-range interactions, and in this case α does not need to have its optimum value.
This implies that, although the real part of the Ewald sum goes as O(N ), the Fourier
part goes as O(N2). To see this, simply substitute s = αrc in eqs. C.16, C.17 and re-
call that N = DL−3 and Nc ∼ Dr−3c , where Nc is the number of particles within the
sphere of radius rc. Either or noth α takes its optimum value, the computational cost
of the Ewald sum becomes prohibitive for large (N > 104). To cope with this prob-
lem the so-called Particle-Mesh Approaches have been developed [119], in which the
point charges are spread on a space grid. This leads to a Poisson equation expressed
through Discrete Fourier Transform (DFT), which is solved using the Fast Fourier
Transforms (FFT) [139], scaling as O(M log2 M ), where M is the number of grid
points or Discrete Fourier Components (in practice ∼ N?). Since the FFT is a grid
transformation, there are obvious discretization problems to be solved (in primis those
of charge assignement and calculation of forces from grid points back to atoms) and
corresponding discretization errors to be minimized. In this sense an improvement in
the accuracy has been made by further splitting interactions in the reciprocal space
into a short and long range term, and evaluating the first directly as particle-particle
and the second through the use of a mesh ( Particle-Particle Particle-Mesh, PPPM or
P3M [138]). For excellent discussions and comparisons among various Particle-Mesh
approaches the reader can refer to the book by Frenkel and Smit [119] and the two
articles by Deserno and Holm [396,397]. What should be kept in mind is that Particle-
Mesh approaches have been introduced as the allow to implement Ewald summation
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using the FFT, not for reasons of accuracy. Without their advent, however, computer
simulations would have never found spread use in biological problems.
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